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GeneRaL InTRoDUCTIon anD oUTLIne oF TheSIS
Background
Although important scientific advances have shed some light onto the substrate and 
mechanisms of ventricular arrhythmias in patients with structural heart disease, many 
aspects remain incompletely understood. Meanwhile, a pragmatic approach has been 
adopted, employing implantable cardioverter defibrillators (ICDs) to reduce sudden 
cardiac death in patients who survived cardiac arrest due to sustained ventricular tachy-
cardia (VT) or ventricular fibrillation (VF),1-3 and in selected patients who are considered 
to be at high risk for sudden cardiac death.4-6  ICDs can usually effectively terminate ven-
tricular arrhythmias and have thus saved numerous lives, but it is important to realize 
that they do not prevent the occurrence of arrhythmias. ICD shocks are associated with 
significant morbidity and even with increased mortality,7 although there may not be a 
causal relation with the latter.8,9 Therapies to control recurring ventricular arrhythmias 
and ICD shocks, such as anti-arrhythmic drugs and endocardial or epicardial catheter 
ablation, have thus become even more important and indispensable in the era of ICDs.
In the past, catheter ablation was only applied in patients with hemodynamically 
stable VT.10 The development of substrate and pace mapping has allowed catheter abla-
tion of hemodynamically unstable VTs,11 which are inducible in the majority of patients 
with prior myocardial infarction12 or nonischemic cardiomyopathy (NICM).13 Catheter 
ablation is typically performed in patients with recurrent VT despite anti-arrhythmic 
drugs, but is also recommended in patients who do not prefer or tolerate anti-arrhythmic 
drugs14 and may even be applied after a first episode of VT in patients after myocardial 
infarction, as a direct adjunct to ICD implantation for secondary prevention to prevent 
future appropriate ICD shocks.15,16 Despite these recommendations and potential ap-
plications, the vast majority of clinicians restrict VT ablation to patients who experience 
multiple ICD shocks or electrical storm,17 suggesting that ‘there is a need to catch up with 
current recommendations’.18 One potential reason for the poor implementation rate of 
VT ablation may be the disappointing long-term outcomes, with 6 month recurrence 
rates of 47% in one large multicenter study in patients with VT after myocardial infarc-
tion,12 and 12-month recurrence rates of 43% and 59% in patients after infarction and 
with NICM, respectively, in a large tertiary care facility.19 Notably, although VT ablation 
may not completely prevent VT recurrence in around 50% of patients, the 6-month VT 
burden is reduced by ≥75% in approximately 67% of patients.12 It is unclear whether, 
and to what extent, the high VT recurrence rates are attributable to not identified or not 
reachable substrates, imperfect ablation, lesion recovery, arrhythmogenic substrates 
that evolve over time, progressive heart failure, or other factors.
The key to more effective primary and secondary preventive therapies for ventricular 
arrhythmias may be improved understanding of different types of ventricular arrhyth-
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mias, and of its underlying substrate and mechanisms. Improved understanding may 
lead both to more accurate risk stratification and to development of more effective, 
individualized and substrate-based therapies.
Myocardial Fibrosis and Monomorphic Ventricular Tachycardia
In patients with prior myocardial infarction and other causes of replacement fibrosis 
(e.g., laminopathy20, myocarditis21,22), surviving bundles of myocytes may be located 
within regions of fibrosis, resulting in slow conduction.23,24 Classically, slow conduction 
in fibrotic regions has been attributed to increased path length (so-called zig-zag course 
of activation23), but there is  also emerging evidence for functional components, which 
may be unmasked by premature stimulation.25 The presence of inexcitable barriers, 
slow conduction and unidirectional conduction block may allow for stable re-entrant 
activation through a central slow-conducting critical isthmus, which manifests as VT. For 
hemodynamically stable VTs, activation and entrainment mapping can be performed 
to identify the slow-conducting critical isthmus during ongoing arrhythmia, so that the 
arrhythmia can be slowed and terminated by ablation.26-28 In case of hemodynamically 
unstable VT, substrate mapping and ablation are typically performed to localize and 
eliminate the slow-conducting isthmuses during stable rhythm, thereby preventing VT 
recurrence.11,29-31
Nonischemic scars are different from post-infarct scars as they exhibit less late poten-
tials32 and are frequently located intramurally or subepicardially,32 limiting the efficacy 
of endocardial VT ablation. Epicardial mapping and ablation may therefore be required 
to abolish VT.33,34 Substrate mapping may however be hampered at the epicardium by 
interposed epicardial adipose tissue, which is typically not only present in the atrioven-
tricular and interventricular grooves, but also at the acute margin and in other areas.35,36 
In patients undergoing catheter ablation for ventricular arrhythmias, on average 25% 
of the epicardial surface is covered by >4 mm of fat.36 The integration of CT-derived 
fat thickness during VT ablation procedures has demonstrated that fat reduces bipolar 
electrogram amplitudes,35,36 thereby preventing accurate delineation of scar regions. 
The combined integration of both CT and LGE-MRI may compensate for this limitation, 
allowing distinguishing between scar, viable myocardium and epicardial fat.
Although the ‘grass may appear greener’ on the opposite (i.e., epicardial) side of the 
wall during endocardial mapping (Tung et al.37), not all patients with NICM have VTs 
originating from the epicardium34 and as a consequence, pericardial puncture and its 
associated risks (including RV perforation, severe pericardial bleeding, coronary steno-
sis and occlusion, and liver injury38) are not required in all patients with NICM. Also, even 
if the arrhythmogenic substrate is located subepicardially, it may not be amenable to 
epicardial ablation because of overlying coronary arteries and/or epicardial fat.36 Pa-
tients with isolated septal substrates are unlikely to  benefit from epicardial ablation.39 
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Pre-procedural imaging studies, scar patterns, and associated VT morphologies may be 
very helpful to identify patients who are not expected to benefit from epicardial VT 
ablation.
During VT ablation procedures, the slow-conducting critical isthmuses that cause VT 
are typically located in or adjacent to regions with low bipolar voltage based on electro-
anatomical mapping studies,11,29-34,40,41 and in or adjacent to regions with late gadolinium 
enhancement (LGE) on MRI based on image integration studies,42-46 which are both 
considered to be indicative of focal myocardial fibrosis, based on histological correlation 
studies.47-49 There is however limited data on more specific features of the area harboring 
critical isthmuses of VT. Some evidence suggests that fibrosis density may play a role,50 
and that higher scar transmurality is related to slow conduction.43,50,51 Improved insights 
into LGE characteristics at critical isthmuses may improve our understanding of VT 
and the integration of LGE-MRI-derived data may be of significant added value during 
catheter ablation procedures if MRI-derived features can lead to critical isthmus sites, in 
particular in the setting of hemodynamically unstable VT,12 inducibility of multiple VTs,12 
intramural re-entry circuits52,53 and epicardial fat overlying the area of interest.35,36 Finally, 
LGE-MRI characteristics at critical isthmus sites may facilitate improved risk stratification 
for VT in broader populations and in particular in patients with non-myocardial infarc-
tion scars in the future. The potential benefits of image integration during VT ablation 
are discussed in more detail in Chapter 2.
From Substrate and VT Features to Therapy and outcome
The 12-lead ECG of epicardial VTs has been reported to exhibit specific features that may 
be useful for identification of VTs with an epicardial origin,54-59 and for guidance of the 
procedural strategy (i.e., endocardial, epicardial, or both). Based on these ECG features, 
specific criteria have been developed, which all indicate either the  initial direction of the 
activation wave front from epicardium to endocardium (e.g., initial Q-waves in the infe-
rior leads in VTs with a superior axis), or a delayed and slurred onset of the QRS-complex 
in the precordial leads consistent with late activation of the endocardially located con-
duction system (e.g. pseudodelta wave, intrinsicoid deflection time in lead V2).54-59 The 
ECG criteria have however previously only been analyzed during pacing and in induced 
VTs, using electronic calipers at a sweep speed of 200 mm/second on electrophysiology 
recording systems. To guide the procedural strategy and to select patients that need an 
epicardial approach, the criteria should be derived from regular 25 mm/second ECGs of 
clinically documented VTs. The accuracy of the criteria in this setting is unclear.
If epicardial mapping and ablation are performed, post-procedural pericarditic chest 
pain,38,60 atrial fibrillation61 and adhesions62 may occur. Animal experiments demon-
strated that intrapericardial installation of triamcinolone can reduce the development of 
adhesions.62 In humans, the effects of intrapericardial triamcinolone or systemic steroids 
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on pericarditic chest pain and on ECG changes after epicardial mapping has never been 
investigated.
After VT ablation, programmed electrical stimulation is typically performed to assess 
for inducibility of clinical and non-clinical VTs. The value of programmed electrical 
stimulation (PES) after ablation as a procedural endpoint is however unclear in patients 
with NICM; it has mainly been analyzed in patients after myocardial infarction.63,64 Pa-
tients after infarction do however have a different substrate, higher acute success rates 
and lower VT recurrence rates.32,63 Moreover, even in patients after infarction data are 
inconsistent, possibly due to differences in induction protocols, incomplete application 
of protocols but also changes in VT ablation populations over time.12,25,63-65 The predic-
tive value of PES as a procedural endpoint in NICM has only been analyzed in two small 
studies.32,66 Also, VT ablation is now more frequently performed in patients without an 
ICD and off amiodarone, and fast hemodynamically unstable VTs are typically induc-
ible, with uncertain clinical significance. Novel substrate-based endpoints have been 
proposed as an alternative to post-ablation PES,25,67 but are arbitrarily defined and to 
date, their independent predictive value for long-term outcomes has not been reported.
Post-infarct scar features such as transmurality are known to be influenced by reperfu-
sion therapy,68 which may have important implications for VT. In patients undergoing 
VT ablation, it has recently been demonstrated that reperfused patients had non-
transmural, patchy scars that were associated with faster VTs, whereas non-reperfused 
patients typically had more transmural, confluent scars that were associated with slower 
VTs.69 The effect of reperfusion therapy on VT characteristics has not yet been analyzed 
in a broader population of patients at risk for VT after myocardial infarction.
Ventricular arrhythmias: are all the Same?
Importantly, patients with prior infarction and NICM are not only at risk for monomorphic 
VT, but also for potentially fatal polymorphic VT and VF.70,71 Myocardial scar on LGE-MRI 
has been identified as an important novel predictor of sudden cardiac death, appropri-
ate ICD therapy and combined arrhythmic endpoints in patients after infarction and in 
NICM.72-78 In the setting of NICM, the absence of LGE on MRI has been associated with 
(very) low arrhythmic event rates,73,75,77 which has led to questions regarding the benefit 
of ICD implantation in these patients. However, none of these studies has analyzed the 
predictive value of LGE for monomorphic VT and polymorphic VT/VF separately. Based 
on LGE-MRI studies in patients with and without inducible VT,79 and on LGE-MRI inte-
gration during VT ablation procedures,42 monomorphic VT is expected to be related to 
regions of LGE on MRI. It is unclear whether LGE on MRI also contributes to the initiation 
and/or maintenance of polymorphic VT/VF.
Polymorphic VT and VF have been attributed to different causes, such as conduction 
and repolarization abnormalities and electrolyte imbalances.80-83 For example, progres-
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sive activation delay after premature stimulation was associated with a history of VF in 
the setting of various nonischemic heart diseases.83 More specifically, the increase in 
RV intracardiac electrogram duration was larger in patients with prior VF than in those 
without VF, and the premature stimulus coupling intervals at which the electrogram 
durations started to increase were longer. There are limited data on the underlying sub-
strate and mechanisms of this electrophysiological phenomenon. An in vitro study has 
found tissue discontinuities as a cause for abnormal conduction velocity restitution,84 
studies in Langendorff-perfused mouse hearts have demonstrated that reduced sodium 
channel expression and severely reduced Cx43 expression can affect conduction veloc-
ity restitution,85 and finally, two studies in 5-6 explanted hearts from patients with end-
stage heart failure have demonstrated conduction abnormalities to occur in regions 
with long fibrotic strands.82,86 The underlying substrate and mechanisms of activation 
delay after premature stimulation have however never been studied in humans with 
NICM before end-stage heart failure developed.
aIM anD oUTLIne oF TheSIS
The present thesis aims to contribute to an improved understanding of different types of 
ventricular arrhythmias, in both ischemic and nonischemic heart disease. An improved 
understanding is mandatory for the development of  novel, more effective, individual-
ized and substrate-based therapies in the future.
In part I, it is demonstrated how image integration strategies can provide insights 
into the substrate for monomorphic VT in patients with ischemic and nonischemic heart 
disease. Chapter 2 provides a detailed overview of the current literature on this topic. 
Computed tomography-derived epicardial fat thickness and MRI-derived scars are inte-
grated with epicardial substrate maps in chapter 3 in order to obtain insights into the 
effects of scar, viable myocardium and epicardial fat on bipolar and unipolar voltages and 
on electrogram characteristics during epicardial substrate mapping. Chapter 4 analyzes 
typical MRI-derived scar patterns in patients with nonischemic cardiomyopathy, the 
associated 12-lead ECG morphologies of VTs, and their potential use to assess the need 
for epicardial VT ablation. Specific MRI-derived scar characteristics at electroanatomical 
mapping-based critical isthmus sites of monomorphic VTs are analyzed in chapter 5. 
These scar characteristics may be used to restrict VT substrate mapping and ablation to 
limited MRI-identified areas  that are likely to contain the critical isthmus for VT.
In part II, additional strategies are used to improve our understanding of sustained 
monomorphic VT and of polymorphic VT and VF. Previously proposed 12-lead ECG cri-
teria to identify an epicardial origin of VTs in nonischemic cardiomyopathy are analyzed 
in chapter 6. The study focuses on the effect of amiodarone and VT cycle length on the 
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reliability of ECG criteria, and more importantly, on its value in clinical practice. If epicar-
dial substrate mapping and VT ablation are performed, patients may experience post-
procedural pericarditic chest pain and pericarditic ECG changes. Chapter 7 analyzes the 
effects of systemic and intrapericardial steroids on these adverse procedural effects. The 
outcomes of VT ablation and the predictive value of post-ablation programmed electri-
cal stimulation are analyzed in chapter 8, with a special emphasis on the predictive 
value of persistent inducibility of non-clinical VTs for VT recurrence during follow-up. 
In chapter 9, it is demonstrated how early reperfusion therapy may have an important 
impact on monomorphic VTs late after myocardial infarction. The last two chapters will 
focus on distinct substrates for different types of arrhythmias in nonischemic cardio-
myopathy. In chapter 10, the predictive value of the presence and extent of MRI-based 
myocardial scar for monomorphic VT and for polymorphic VT and VF is analyzed. Several 
mechanisms have been proposed as potential causes for polymorphic VT and VF. In 
chapter 11, it is demonstrated how activation delay after premature stimulation can be 
quantified simply by measuring the QRS duration during a standard electrophysiologi-
cal study, and how it relates to inducible polymorphic VT and to underlying fibrosis in 
endomyocardial biopsy specimens. Finally, a summary, conclusions and future perspec-
tives are provided in chapter 12.
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aBSTRaCT
Over the past decades important advances have been made in the field of ventricu-
lar tachycardia (VT) ablation and as a result, VT ablation is now more widely being 
performed. The identification of ablation target sites still relies on electroanatomical 
substrate mapping, which is time-consuming, hampered by the intramural location of 
some scars and limited by epicardial fat. The potential of various imaging modalities 
to overcome these limitations have stimulated clinical electrophysiologists to perform 
studies on image integration during VT ablation. Imaging guidance has been used to 
identify, delineate and characterize the substrate for VT, to provide detailed anatomical 
information, to avoid ablation on coronary arteries, to delineate epicardial fat tissue 
and to assess ablation lesions. In this review reported applications and the potential 
advantages and limitations of different imaging modalities are discussed.
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InTRoDUCTIon
Over the last 20 years ventricular tachycardia (VT) ablation has evolved from a treatment 
modality for selected patients with recurrent hemodynamically tolerated VT (which can 
be mapped during ongoing arrhythmia), to a therapeutic option for patients with toler-
ated and untolerated VT using substrate-based ablation strategies.1 The substrate for VT 
after myocardial infarction (MI) consists of areas of myocardial fibrosis interspersed with 
viable myocytes creating slow conduction through the scar.2 The latter is an important 
precondition for re-entry, the most common underlying mechanism of scar-related 
VT. Inhomogeneous scars also occur in other diseases such as nonischemic cardiomy-
opathy (NICM), sarcoidosis and repaired congenital heart disease.3-5 Substrate-based 
VT ablation procedures currently depend on extensive electroanatomical mapping 
(EAM) to delineate bipolar1,6 and unipolar7,8 low voltage areas and to identify abnormal 
electrograms such as fragmented electrograms and late potentials.4,9-11 The limitations 
of EAM (time-consuming, inaccurate delineation of intramural scars, attenuation of 
electrograms by epicardial fat) on the one hand, and the availability of different imaging 
modalities (providing detailed anatomical information12-15, characterizing myocardial 
scars12,16-22, delineating epicardial fat15,23) as well as the progress in imaging acquisition 
and processing on the other hand, have stimulated clinical electrophysiologists to study 
image integration during VT ablation procedures. Various imaging modalities such as 
multidetector computed tomography (MDCT), contrast-enhanced magnetic resonance 
imaging (CE-MRI), intracardiac echocardiography (ICE) and nuclear imaging modalities 
have been applied, however, most available data are derived from MDCT and CE-MRI 
studies conducted in the post-MI patients; MDCT because of the higher spatial resolu-
tion if compared to CE-MRI and nuclear imaging modalities, and CE-MRI as current gold 
standard to visualize fibrosis. Image integration has been used to identify and delineate 
the substrate for VT during the procedure12,16-22, to avoid ablation in the vicinity of coro-
nary arteries15,23, to delineate epicardial fat tissue15,21 and to assess ablation lesions.24,25 
In this review reported applications and the potential advantages and limitations of the 
different imaging modalities are discussed.
Image registration
An important prerequisite for the use of image integration to guide mapping and abla-
tion is the accurate registration of EAM and imaging data. Of note, image registration 
has mainly been performed during stable sinus or paced rhythm, and may be less reli-
able during VT activation mapping due to potential differences in cardiac morphology. 
An overview of studies on integration of imaging data with ventricular EAM and the 
reported registration accuracy is provided in Table 1. It is important to realize that a 
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not necessarily imply good registration accuracy. Automated surface registration tools 
which are provided by commercially available 3D mapping systems13,15,22,25-30 typically 
minimize this distance by translation movements and circumferential and axial rotation. 
These registration algorithms may result in signifi cant rotation errors in particular if 
only the symmetrically shaped LV is mapped and low resolution imaging modalities are 
used.31 Indeed, the registration accuracy of MRI images with left ventricular (LV) EAM has 
been evaluated using diff erent registration models and it could be demonstrated that 
the best correlation between bipolar voltage and scar transmurality could be achieved 
by avoiding any circumferential or axial rotation during the registration process.32 Map-
ping of well-defi ned anatomical structures such as the ostium of the left main artery 
or additional chambers can improve the registration accuracy. In a phantom model 
incorporation of EAM of the aorta in the registration process resulted in substantial im-
provement, as assessed visually and by the EAM-to-MRI surface distance of both LV and 
aorta.31 Several clinical studies have used the aorta and the ostia of the coronary arteries, 
which correct position can be confi rmed by contrast injection if an open irrigated-tip 
catheter is used (Figure 1, panel A),15,21,22 or a coronary sinus catheter12,13 to improve 
registration accuracy or to monitor the registration stability throughout the procedure.
Lessons learned from Integration of pre-acquired MRI images
The feasibility of MRI integration during EAM of the LV was fi rst demonstrated by Reddy 
et al. in phantom and animal models in 2004.31 To evaluate the registration accuracy iron 








B – Endo bipolar voltage 
Figure 1. Integration of MRI-derived scar and MDCT-derived coronary artery anatomy and epicardial 
fat with electroanatomical maps in a patient with a scar in the epicardial RVoT.
The coronary artery anatomy is derived from the MDCT scan using special software (Medis medical imag-
ing systems BV, Leiden, the Netherlands), allowing visualization of small branches (panel A). During the 
procedure the position of the left main coronary artery (confi rmed by contrast injection, circle in panel A), 
was tagged on the map to integrate the MDCT-derived coronary artery anatomy and MRI-derived scar (dis-
played in black) with the endocardial EAM (panel B). Subsequent epicardial EAM revealed low voltage areas 
around the atrioventricular groove, interventricular groove and acute margin which are consistent with 
MDCT-derived epicardial fat (panels C and D), but also a low voltage area at the epicardial right ventricular 
outfl ow tract corresponding with the location of the MRI-derived scar. Fragmented electrograms were ob-
served in this area, supporting the presence of scar. LAD indicates left anterior descending coronary artery; 
RA, right atrium; RCA, right coronary artery.
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oxide injections were performed in 5 pigs before MRI acquisition. Their position was 
marked on the integrated MRI image and subsequently targeted for radiofrequency (RF) 
catheter ablation. At gross pathology the ablation lesions were localized close (mean 
distance 1.8±0.5 mm) to the iron oxide targets, suggesting that MRI integration may 
allow imaging-guided ablation of MRI-derived target sites.
In humans off -line comparison of EAM data and CE-MRI-derived scar data could 
demonstrate a good overall correlation between the MRI-reconstructed post-MI scar 
surface and low bipolar voltage areas. However, CE-MRI allowed even improved iden-
tifi cation of scar areas not suffi  ciently delineated by EAM, thereby paving the way for 
true MRI guidance during the VT ablation procedure.18,33 The fi rst study on real-time 
integration of MRI-derived scar distribution during VT ablation could demonstrate that 
the integrated scar information facilitated substrate mapping and could be used as a 
guide to VT isthmus sites in 15 post-MI patients.22 These fi ndings were confi rmed in a 
second series of 13 patients with frequent PVCs and 10 patients with VT after MI.28 Of 
importance, although scars due to MI are predominantly localized subendocardially, 
in particular non-transmural parts of the scar remain undetected by bipolar voltage 
mapping (example in Figure 2).22 These parts of the scar may however contain critical 
parts of the VT re-entry circuits, and can be visualized during real-time integration of the 










Figure 2. MRI-derived 3D scar reconstruction integrated with eaM
The endocardial bipolar voltage map (panel A) shows only a limited low voltage area, smaller than the MRI-
based non-transmural scar (panels C and D). The unipolar voltage map (panel B) reveals a larger low voltage 
area which is more consistent with the true size of the scar area. The MRI-derived scar is integrated with the 
electroanatomical maps based on the left main (LM) landmark (panel E).
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The limitation of electroanatomical voltage mapping to fully delineate the 3D 
geometry of scar has also been reported in patients with NICM, in whom scars are 
typically localized intramurally or subepicardially.17,21,34 Intraprocedural registration of 
MRI-derived scars in patients with NICM has demonstrated that critical components 
of ventricular arrhythmias are confined to scar tissue,17 and it has been reported that 
MRI integration in patients presenting with VT can reveal scars not identified by EAM, 
which may have important diagnostic and therapeutic consequences.25 In a small series 
of NICM patients the distribution of contrast enhancement, which was classified as 
endocardial, intramural or epicardial, corresponded with the location (endocardium or 
epicardium) containing critical components of the VT circuit. This finding suggests an 
important role for MRI in choosing the appropriate procedural strategy which can be 
either endocardial, epicardial or both.17 Notably, half of the patients had predominantly 
endocardial scar in this study,17 which is reported to be less common in patients with 
NICM.35 Further studies are required before MRI-derived scar distribution can be used to 
guide preprocedural planning.
Not only the presence of enhanced regions, but also MRI-derived scar characteristics 
have been correlated with VT-related sites and local electrophysiological findings 
in patients with prior MI and NICM. Isolated potentials and critical sites of re-entrant 
VT (based on pace and entrainment mapping) were associated with high infarct scar 
transmurality.30 In another study, also conducted in post-MI patients, 71% of VT isthmus 
sites were localized within the infarct core (defined as signal intensity [SI] >3 standard 
deviations above remote myocardium), while the remaining isthmus sites were localized 
in transmural border zone with SI slightly lower than this cutoff.33 Electrogram character-
istics consistent with slow conduction such as prolonged duration, late potentials and 
fractionated electrograms were also related to higher scar transmurality in patients with 
NICM.21 The association between MRI-derived scar characteristics and EAM-based elec-
trophysiological parameters has recently been used to create non-invasive 3D substrate 
maps in post-MI patients. These MRI-derived substrate maps showed a remarkably high 
resemblance to the endocardial electroanatomical substrate maps.30
Similar to the method that adapts bipolar voltage thresholds of EAM to display 
channels of relatively higher voltages within low voltage regions,36 some investigators 
have attempted to identify relatively low SI channels within higher SI post-MI scars on 
MRI.16,20,37 Using variable SI and voltage thresholds a good correlation regarding the 
location (segments) and orientation (perpendicular or parallel to the mitral annulus) of 
relatively low SI channels and relatively high voltage channels has been reported.20 In a 
recent paper a favorable association between lower SI channels within high SI regions 
based on “pixel SI scanning” (i.e. modifying the thresholds to 60±5% and 40±5%37) and 
channels of slow conduction identified by high density endocardial activation mapping 
during sinus rhythm has been reported (example in Figure 3). Of importance, 17 of these 
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45 identified SI channels were related to VT based on pace mapping and entrainment 
mapping, and on  localization within the same AHA segment with the same orientation 
(parallel or perpendicular to the mitral annulus or intermediate).37 The validation of 3D 
lower SI channels within high density scars is limited by the lack of a gold standard, 
which would be histological 3D scar reconstruction. Application of different scar 
identification methods and cut-off values impede the comparison of reported data. 
Considering the known limited field of view of bipolar mapping,38 simply correlating the 
3D CE-MRI-derived SI channels with 2D bipolar voltage channels or with progressively 
delayed low voltage electrogram channels cannot overcome these limitations.7 In addi-
tion, advanced imaging techniques providing relatively high spatial resolution CE-MRI 
Figure 3. MRI-based border zone channel identification
Subendocardial (10%) pixel signal intensity map and endocardial bipolar voltage map, with an extensive 
area of scar in the anterior wall. A border zone channel is shown in the 10% shell, consistent with the con-
duction channel identified on the voltage map (white arrows). The 12-lead electrocardiogram on the left 
shows the induced monomorphic ventricular tachycardia. Electrocardiogram on the right shows pace map 
from the middle of the conduction channel (yellow asterisk in both maps). Pacing from the channel repro-
duces the induced VT morphology with a long stimulus-to-QRS delay, as expected by the location of the 
stimulus delivery on the channel. Additionally, there is a late potential channel in the EAM (blue dots) not 
visible on the cardiac magnetic resonance. EAM indicates electroanatomic map; PM, pace mapping; VT, ven-
tricular tachycardia. Derived from Fernández-Armenta J et al. Circ Arrhythm Electrophysiol 2013;6:528-537.
Imaging-guided VT Ablation 35
2
(1.4 x 1.4 x 1.4 mm in a recent paper37) are still unlikely to delineate channels at a micro-
scopic level2, which produce very low amplitude late potentials during sinus rhythm4 
and diastolic potentials during VT.39 Despite all current limitations the integration of 
high resolution CE-MRI-derived 3D scar characteristics with EAM is exciting. Additional 
studies are however required to determine the intraobserver and interobserver vari-
ability of the channel identification process, both on MRI images and on EAM (including 
different applied scar detection methods and cut-off values for SI). Ideally, the identified 
channels should be compared to histology, and the clinical relevance of the channels 
needs to be determined by assessing the impact of ablation of CE-MRI-derived channels 
on procedural outcome.
Compared to other imaging modalities, the advantages of MRI integration include a 
higher resolution for detection and localization of non-transmural scar areas, and the 
possibility of tissue characterization (T1-weighted sequences after gadolinium adminis-
tration to assess for extracellular matrix, T2-weighted sequences to assess for myocardial 
edema). However, currently MRI integration requires extensive and time-consuming (± 
1 hour) image pre-processing by specialists experienced in CE-MRI, which restrict its 
wide applicability. The most important limitation of MRI is its use in device recipients, 
as the majority of patients undergoing VT ablation have an implantable cardioverter 
defibrillator (ICD). Although ICDs may not necessarily preclude MRI if appropriate safety 
measures are taken, detailed evaluation of important parts of the LV (in particular the 
anterior segments) is hampered by artifacts due to the pulse generator.19,30 However, 
also based on the results of 2 recently published randomized controlled trials conducted 
in post-MI patients,40,41 early VT ablation may be considered in an increasing number 
of patients before ICD implantation, suggesting that CE-MRI integration may play an 
increasing role in the future.
Ce-MRI as a gold standard
Although considered a gold standard, the technique of CE-MRI to delineate 3D scar 
geometry still has limitations. First, contrast enhancement is not specific for fibrosis; 
T2-weighted sequences should therefore also be performed to assess for myocardial 
oedema.42 Second, the delineation of scars and in particular border zones is hampered 
by the partial volume effect (i.e. the averaging that occurs between high and low SI 
regions) which may cause overestimation of the scar size.43 Third, current scar identifica-
tion methods vary between studies (e.g. full-width half-maximum method, standard 
deviation of remote region based methods) and although scar characteristics predict 
ventricular tachyarrhythmias in patients after MI independent of the scar identifica-
tion method used, the size of the border zone varies by a factor five depending on the 
method.44 Finally, the present scar identification methods are based on the SI of scar 
and/or remote myocardium in a look-locker sequence, which depend on the amount 
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of diffuse fibrosis in remote myocardium, and on the maximum density of fibrosis in 
the scar area, the heart rate, contrast dose, glomerular filtration rate, hematocrit, and 
other variables;45 scars are therefore not directly comparable between patients. Novel 
techniques are required to allow more accurate and objective characterization of scars. 
A general disadvantage of integrating pre-acquired imaging data during VT ablation is 
the potential change that may occur between scan and procedure (e.g. volume, orienta-
tion of the heart) – a logical next step would therefore be on-site MRI.
on-site MRI guidance
On-site MRI may provide an all-in-one solution during VT ablation, allowing catheter 
tracking without fluoroscopy, anatomical guidance, substrate delineation (including 
intramural and subepicardial scars), MRI-based identification of ablation target sites, 
and evaluation of ablation lesions. In 2008 the feasibility of real-time MRI-based catheter 
tracking to perform an electrophysiology study was first demonstrated in 10 mongrel 
dogs and 2 humans.46 In another study in pigs, a real-time MRI-tracked mapping cath-
eter could be visualized on pre-acquired magnetic resonance angiography (MRA) and 
CE-MRI images. Real-time MRI based tracking could be used to construct an EAM of the 
LV, which matched well with the pathological specimen.47 Although in both studies RF 
filters were applied to remove MRI-induced artifacts, significant artifacts remained inter-
fering with both the surface electrocardiogram (ECG) and the intracardiac electrograms, 
which is an important current limitation. Although the use of CE-MRI has been reported 
to allow evaluation of ablation lesions hours to months after RF energy application,24,29 
no study has analyzed the value of MRI to characterize and assess acute lesion formation 
during VT ablation yet. The required continuous gadolinium contrast infusion is only one 
of the problems that need to be solved. However, despite these hurdles, direct evalua-
tion of lesion formation would be desirable to assess completeness of linear lesion but 
also to monitor substrate-based ablation targeting intramural scar, or scar covered by 
epicardial fat.
Integration of pre-acquired MDCT images
The high resolution of current MDCT images allows the detailed anatomic reconstruc-
tion of the heart, including the cardiac chambers, aortic sinus cusps, coronary vessels, 
epicardial fat thickness and the atrial appendages.15 The feasibility of MDCT-guided 
catheter manipulation was first reported in a porcine model in 2003,48 and the accuracy 
of MDCT-guided RF applications was demonstrated in 9 mongrel dogs with a 2.1±1.1 
mm position accuracy of RF lesions with respect to the targeted MDCT markers.26 In 
humans, integration of the anatomic reconstruction of the coronary artery anatomy 
has been used to avoid RF energy applications at, or in close proximity to coronary 
arteries, thereby potentially preventing complications of epicardial ablation (example 
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in Figure 4). The registration accuracy was confirmed by coronary angiograms in various 
angulations in a case report23 and in a study in 28 patients.15 The high accuracy which 
can be evaluated by a single coronary injection is important as coronary angiography 
in some (in particular caudal) angulations can be precluded by the location pad of the 
EAM system, hampering accurate estimation of the distance to coronary arteries by 
angiography. The integration of MDCT images can also facilitate catheter ablation in 
patients with complex anatomy due to congenital heart disease.49
Apart from the coronary arteries an important limitation for epicardial mapping 
and ablation is the presence of epicardial fat.15,50,51 Epicardial fat can be delineated by 
MDCT with high spatial resolution and has been shown to cover significant parts of the 
Figure 4. Integration of MDCT-derived images to assess the proximity of coronary arteries at abla-
tion target sites
The distance between the catheter tip and coronary arteries on integrated MDCT images and coronary an-
giography is shown in a right anterior oblique (RAO) view (left) and left anterior oblique (LAO) view (right) 
in 2 patients. In one, limited activation mapping identified a target site located on the left coronary artery 
(LCA) on both MDCT and angiography (upper panels). In another, the target site (based on pace mapping) 
was located < 7 mm from the right coronary artery (RCA) confirmed by angiography (lower panels). LM 
indicates left main; LV, left ventricle; PA, pulmonary artery; RV, right ventricle. Reproduced from reference 
15 with permission.
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ventricles, with on average 25% of surface being covered with > 4mm fat in patients 
undergoing epicardial PVC or VT ablation.15 In particular the acute margin, anterior right 
ventricular (RV) free wall, interventricular groove and atrioventricular groove may be 
covered by significant fat layers (example in Figure 1).15,52 Importantly, not only scar but 
also epicardial fat attenuates bipolar electrogram amplitudes, thereby limiting the accu-
racy of epicardial substrate mapping.15,21,51 In addition, epicardial RF energy applications 
may be ineffective in the presence of >7 mm fat.15,51 The integration of MDCT-derived 
fat thickness can therefore be very helpful to classify low voltage areas (due to fat or 
true scar in the absence of fat, Figure 1) and to predict and explain ineffective RF energy 
applications during epicardial VT ablation.
In patients with epicardial idiopathic ventricular arrhythmias the approximate site of 
origin can often be estimated based on electroanatomical activation mapping of the 
endocardial RV, LV, aortic cusps and coronary sinus, if appropriate. The integration of 
MDCT images with EAM data may predict epicardial ablation failure in selected patients, 
which can be due to the close proximity of coronary arteries and/or a thick epicardial fat 
layer at the predicted epicardial site of origin (example in Figure 5), thereby potentially 
preventing unnecessary pericardial puncture and its associated risks.15
Detailed contrast-enhanced MDCT scans can provide important anatomic (wall thick-
ness, example in Figure 6), dynamic (wall thickening) and perfusion (hypoenhancement) 
information, which may guide to MI areas during VT ablation.14 However, in a small series 
of 13 post-MI patients, 87% of abnormal electrograms, but only 46% of termination sites 
Figure 5. Prediction of an epicardial target site and the proximity of coronary arteries and epicardial 
fat
Endocardial electroanatomical activation maps of the LV, right ventricle outflow tract (RVOT), aorta (Ao), 
and great cardiac vein (GCV) (panel A). Similar activation time of the LV, RVOT, and GCV was observed. The 
white triangle demonstrates the predicted epicardial target area in the vicinity of the LAD, covered by >4 
mm of fat. The final fusion image was registered with the endocardial maps, using the left main coronary 
artery (LM) landmark. Limited epicardial activation mapping confirmed the earliest activation within the 
predicted area not suitable for ablation (panel B). Reproduced from reference 15 with permission.
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were localized within 5mm of MDCT-derived wall thinning areas, perhaps suggesting a 
limited value of MDCT-derived wall thinning for identification of the VT substrate.13 Data 
on the use of MDCT for detection of the arrhythmogenic substrate in patients with NICM 
are remarkably sparse, with only 3 patients being included in one study.12
Compared to other imaging modalities the main advantage of MDCT integration 
during VT ablation is its superior spatial resolution. Furthermore, MDCT can be per-
formed without precautions in patients with implantable devices, and with only minor 
lead artifacts. Pre-processing of MDCT images is relatively easy when segmentation 
is performed on the CARTO system (± 15-30 minutes), but may be time-consuming if 
advanced coronary artery and epicardial fat images are required (± 2 hours). As a main 
limitation, contrast-enhanced MDCT is associated with significant radiation exposure 
(currently ±2 to 12 mSv depending on acquisitions14,53).
Figure 6. MDCT-derived wall thinning areas and the electroanatomical substrate in a patient with 
nonischemic dilated cardiomyopathy.
Correlation between voltage and wall thinning at MDCT in a patient with nonischemic dilated cardiomy-
opathy. Myocardial wall thinning is seen in the lateral wall of the left ventricle on 4 chambers (panel A), 3 
chambers (panel B), and short axis (panel C) reconstructions of the contrast-enhanced MDCT volume. No 
delayed enhancement was seen at MRI. Areas of wall thickness <5mm are mapped on the epicardial surface 
and integrated in the NavX system (panel D). The epicardial voltage map is registered to the imaging model, 
demonstrating a match between wall thinning and low voltage (panel E). Brown dots indicate sites of local 
abnormal ventricular activities targeted by ablation. A high-frequency fragmented signal occurring during 
the far field ventricular electrogram is seen (yellow frame), indicating the presence of persisting local elec-
trical activity within scar. Please note that these high-frequency signals are fractionated but not late as they 
are recorded within the QRS. Reproduced from reference 12 with permission.
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Intracardiac echocardiography
Intracardiac echocardiography (ICE) provides real-time anatomical information and 
allows monitoring of catheter-tissue contact, lesion formation and potential complica-
tions without radiation exposure.54-58 The anatomical information provided by ICE has 
been shown to be useful to guide catheter ablation of the papillary muscles,54,55 or to 
avoid RF delivery near the coronary artery ostia and on the aortic leaflets, as has been 
demonstrated in one series of 5 patients.58 An experimental study in 7 pigs after left 
anterior descending infarction demonstrated a close correlation between ICE-derived 
infarct size and low voltage (≤ 2 mV) areas.59 Akinetic and thinned areas on ICE cor-
responded with the electroanatomic scar during VT ablation in one study in 18 humans 
(15/18 post-MI).54 In a series of 18 patients with NICM and abnormal echogenicity on ICE 
imaging it could be demonstrated that the areas of increased echogenicity in the lateral 
wall corresponded with the endocardial and/or epicardial electroanatomical substrate.56 
In these studies ICE images were visually interpreted, and data on interobserver and 
intraobserver variability are not available. Whether ICE-derived reconstruction of scar 
areas in post-MI patients and patients with NICM provides complementary substrate 
information to EAM data requires further investigation. Important limitations of ICE 
include the two-dimensional nature of ICE images, the considerable costs and the time 
required to acquire and interpret ICE images.
nuclear image guidance
Nuclear imaging has the advantage of not being limited by the presence of implantable 
devices. Three studies have analyzed the value of hybrid positron emission tomography 
(PET)/CT imaging, combining low-resolution metabolic activity information from PET 
scans with high-resolution anatomic information from MDCT scans.27,60,61 Although areas 
with low metabolic activity corresponded well with low voltage areas, the net benefit of 
PET integration during VT ablation may be limited due to the inferior resolution of PET 
(currently 4-7 mm62), significant radiation exposure, high costs, and the time required to 
create mapping system-compatible images from the PET data.63 Notably, the value of 
PET for identification of intramural and subepicardial scars, which are common in NICM, 
remains unclear as only 2 of the 41 patients in these studies had NICM.27,60,61 PET scanning 
is limited by the high costs of cyclotrons, which are required to produce radionuclides. 
Single-photon emission computed tomography (SPECT) images are more widely avail-
able but have an even lower resolution (±12 mm64). SPECT-derived scar images were 
integrated with EAM in a small series of 10 patients, demonstrating that all successful 
ablation sites were located within 1 cm of the SPECT-derived scar area.64 Similar to PET, 
the added value of SPECT integration to EAM during VT ablation may be limited due to 
its poor resolution.
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Bimodality or multimodality image integration
Different imaging modalities can provide complementary information, which may be 
important during complex ablation procedures as has been illustrated in several case 
reports.49,65 In a study conducted in 10 patients with NICM, MDCT-derived fat images and 
MRI-derived scar images were integrated with the epicardial EAM during VT ablation 
and provided important insights in the complex interplay between scar, viable myo-
cardium and epicardial fat. It could be demonstrated that in the presence of > 2.8 mm 
fat neither bipolar nor unipolar voltage mapping can distinguish scar from fat. Specific 
electrogram morphologies were not affected by fat, but identified only 25% of all scar 
sites.21 In a second series, MDCT and MRI-derived images were fused and integrated 
during VT ablation procedures in 9 patients with various underlying diseases to provide 
detailed anatomical information (e.g., coronary artery anatomy during epicardial VT 
ablation) and to guide to the arrhythmogenic substrate (using MRI-derived scar areas 
and MDCT-derived wall thinning areas).12 These data illustrate the potential clinical ap-
plications of advanced bimodality image integration.12,21
Future perspectives
Currently integration of MDCT, MRI and nuclear images requires pre-processing of 
imaging data, which is time-consuming (typically 1-2 hours based on one study12 and 
our own experience15,21,22) and requires experienced observers and special software. 
Development of advanced software to allow more efficient or even automated analysis 
of imaging data would therefore be of interest, and would also make advanced image 
integration techniques available to electrophysiologists who do not have supporting 
imaging specialists.
Integration of MRI-derived images has been shown to accurately delineate ventricular 
scar without time-consuming EAM. Real-time image integration would be even more 
valuable if more specific scar features that are related to VT could be identified and dis-
played. In the future, MRI-based identification of critical re-entry circuit sites may then 
allow MRI-guided delivery of RF energy applications and thereby true imaging-guided 
VT ablation, which has already been demonstrated feasible and accurate in an animal 
model.31
Although image integration has provided important insights into the substrate for VT, 
to date it has not been demonstrated that the integration of MDCT, MRI or nuclear im-
aging data is cost-effective, improves preprocedural planning, total radiation exposure 
(including both imaging-related radiation and intraprocedural fluoroscopy), EAM time 
and, most importantly, the outcome of VT ablation. Prospective randomized studies 
comparing imaging-guided VT ablation to standard VT ablation in the setting of differ-
ent diseases are required to determine whether the promising technology translates 
into improved acute and long-term outcome.
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Epicardial substrate mapping for ventricular 
tachycardia ablation in patients with 
nonischemic cardiomyopathy
A new algorithm to differentiate between scar and viable 
myocardium developed by simultaneous integration of 
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During epicardial electroanatomical mapping (EAM) it is difficult to differentiate be-
tween fibrosis and fat, as both exhibit attenuated bipolar voltage (BV). The purpose of 
this study was to assess whether unipolar voltage (UV), BV and electrogram characteris-
tics (EC) can distinguish fibrosis from viable myocardium and fat during epicardial EAM 
for ventricular tachycardia (VT) ablation in nonischemic cardiomyopathy (NICM).
Methods and Results
Ten NICM patients (7 males, 56±13 years) with VT underwent epicardial EAM with real-
time integration of CT-derived epicardial fat and contrast-enhanced MRI-derived scar. 
BV (filtered 30-400Hz), UV (filtered 1-240Hz) and EC (duration and morphology) were 
correlated with the presence of fat and scar. At sites devoid of fat, the optimal cutoff 
values to differentiate between scar and myocardium were 1.81mV for BV and 7.95mV 
for UV. BV, UV and electrogram duration >50ms distinguished scar from myocardium 
in areas covered with <2.8mm fat (all p<0.001), but not ≥2.8mm fat. In contrast, elec-
trogram morphology-characteristics could also detect scar covered with ≥2.8mm fat 
(p=0.001). A newly developed 3-step algorithm combining electrogram morphology, 
duration and UV could correctly identify scar with a sensitivity of 75%. UV but not BV 
could detect intramural scar in the absence of fat.
Conclusions
Both BV≤1.81mV and UV≤7.95mV are useful for detection of scar during epicardial EAM, 
in the absence of ≥2.8mm fat. However, EC can be used to detect scar covered with fat. 
A newly developed algorithm combining UV and EC can differentiate between scar and 
viable myocardium. UV but not BV could detect intramural scar.
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InTRoDUCTIon
The substrate for ventricular tachycardia (VT) in patients with left ventricular (LV) 
nonischemic cardiomyopathy (NICM) is frequently located intramurally or epicardially 
and may require an epicardial ablation approach.1,2 Since the majority of induced VTs 
are hemodynamically unstable,3 substrate mapping is indispensable for successful 
ablation. Epicardial substrate mapping is however challenging. Firstly, it may be difficult 
to differentiate between scar and epicardial fat, since both exhibit attenuated bipolar 
electrogram amplitudes.4,5 Secondly, even in the absence of epicardial fat, scar may be 
difficult to detect if located intramural.
Electrogram characteristics have been proposed to distinguish scar from epicardial fat4 
since long electrogram duration, fragmented electrograms and late potentials indicate 
slow conduction typical for inhomogeneous scar.6 However, subtle bipolar electrogram 
abnormalities such as low-amplitude late potentials may be reduced to noise level by 
the interposition of epicardial fat. Unipolar voltage has been demonstrated to have a 
larger field of view,7 which may allow detection of scar covered by fat and intramural 
scar.
Computed tomography (CT) and contrast-enhanced magnetic resonance imaging 
(CE-MRI) are considered gold standards for delineation of fat and fibrosis. Prior studies 
have demonstrated the feasibility and accuracy of integration of CT-derived epicardial 
fat5 and CE-MRI-derived fibrosis8,9 with electroanatomical maps (EAM). By integrating 
both CT- and CE-MRI-derived data during substrate mapping, gold standards for the 
presence of fat and fibrosis become available.
The purpose of this study was to (1) establish bipolar and unipolar voltage cutoff 
values for scar detection during epicardial EAM, (2) assess whether voltages and electro-
gram characteristics can distinguish scar from viable myocardium in the presence of fat, 
(3) develop an algorithm that differentiates between scar and viable myocardium and 
(4) to determine whether the epicardial area of interest containing ablation target sites 
can be delineated using voltage or electrogram characteristics.
MeThoDS
Patients
The study population consisted of 10 out of 11 consecutive patients with NICM referred 
for combined endocardial and epicardial VT ablation, with integration of both CT-
derived epicardial fat and CE-MRI-derived scar information. One patient was excluded 
because of imaging artifacts causing non-interpretable CE-MRI image data. Coronary 
artery disease was excluded by coronary angiography in all patients. Seven patients 
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underwent combined endocardial and epicardial VT ablation after endocardial ablation 
failure which was presumed to be due to an epicardial VT exit site based on the lack of 
early endocardial activation during VT and/or an endocardial substrate for VT. In the 
remaining 3 patients, an epicardial VT exit site was suspected based on the 12-lead ECG 
morphology of the clinical VT.10
Six patients with idiopathic ventricular arrhythmias (VA) who underwent endocardial 
and epicardial EAM with CT integration served as controls for voltages and electrogram 
characteristics. Structural heart disease was excluded by echocardiography and CT in 6 
patients (100%), by coronary angiography in 5 patients (83%) and by MRI in 4 patients 
(67%). All 6 patients underwent combined endocardial and epicardial ablation after 
endocardial ablation failure and an endocardial activation pattern consistent with an 
epicardial site of origin.
All patients were treated according to the clinical protocol and provided informed 
consent.
CT acquisition and processing
Before the procedure, electrocardiogram-gated cardiac CT imaging was performed 
with intravenous iodinated contrast agent either on a 64-detector row helical scanner 
or a 320-detector row volumetric scanner (Toshiba Medical Systems, Otawara, Japan). 
Using in-house developed software (Mass, V2009-EXP LKEB, Leiden, The Netherlands) 
the endocardial, epicardial and pericardial contours were manually traced on short-axis 
reformatted CT slices (0.5x0.5mm resolution, 2mm thickness, 2mm inter-slice gap) to 
create 3D meshes (Figure 1). Fat thickness was computed by calculating the distance 
between epicardial and pericardial contours and the vertices of the epicardial 3D mesh 
were color-coded for fat thickness. Subsequently, the original CT data and the meshes 
were imported into the mapping system (CARTO XPTM, Biosense Webster Inc, Diamond 
Bar, CA, USA). Using CARTOMerge (IPE) software, which enables integration of multiple 
datasets, the ventricles, aorta and coronary arteries were segmented and merged with 
the 3D meshes.
Ce-MRI acquisition and processing
Contrast-enhanced MRI was performed on a 1.5 T Gyroscan ACS-NT/Intera MR system 
(Philips Medical Systems, Best, The Netherlands). A standardized protocol was followed, 
including a black-blood turbo spin-echo sequence for the proximal aorta.9 Contrast- 
enhanced images were acquired 15min after bolus injection of gadolinium. The heart 
was imaged in one breath-hold with 20–24 imaging levels (dependent on heart size) in 
short-axis views.
The images were post-processed as described previously.9 The centerline of the proxi-
mal coronary arteries was manually defined in the black-blood spin-echo image data 
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Figure 1. Processing and integration of CT and contrast-enhanced MRI
Step 1. Epicardial fat meshes and 3D scar reconstructions were created from the short-axis CT and CE-
MRI slices. Step 2. Before the procedure, the CT was segmented and all meshes were imported into the 
mapping system. Step 3. During the procedure, CT- and CE-MRI-derived images were integrated with the 
electroanatomical map (displayed as a mesh to better visualize the scar distribution [right]) Step 4. After the 
procedure, points were projected on the corresponding short-axis CT slices and the 3D scar reconstruction 
to determine fat thickness and the presence of underlying scar.
CE-MRI denotes contrast-enhanced MRI; LAD, left anterior descending; LM, left main; LV, left ventricle; RCA, 
right coronary artery; RV, right ventricle.
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and the aortic, endocardial and epicardial contours were semi-automatically detected 
on the short axis views. The contours were converted into 3D meshes (Mass research 
software, Figure 1). Myocardial tissue with ≥35% of maximal signal intensity was con-
sidered scar. The vertices of the LV endocardial and epicardial meshes were color-coded 
with scar transmurality for the inner and outer half of the wall, respectively. All meshes 
were imported into the CARTO system using CARTOMerge (IPE) software.
electrophysiological evaluation
Anti-arrhythmic drugs were discontinued for ≥5 half-lives with the exception of amioda-
rone (n=1). Programmed electrical stimulation was performed under conscious sedation 
(3 drive cycle lengths [600, 500 and 400ms], 1-3 ventricular extrastimuli [≥200ms] from 
2 right ventricular (RV) sites and burst pacing (CL≥200ms), repeated with isoproterenol 
(2-10µg/min) when necessary). A positive endpoint for stimulation was the induction of 
sustained monomorphic VT lasting >30s or requiring termination because of hemody-
namic compromise.
electroanatomical mapping, real-time image integration and ablation
Pericardial access was obtained through a subxyphoid puncture followed by intrave-
nous heparin administration. Electroanatomical mapping was performed using a 3.5mm 
irrigated-tip catheter with a 2mm ring electrode and a 1mm interelectrode spacing 
(NaviStar ThermoCool, Biosense Webster Inc, Diamond Bar, CA, USA) and the CARTOXP 
system. Electrograms were filtered at 30-400Hz (bipolar) and 1-240Hz (unipolar). Lim-
ited EAM of the aortic root was performed and the left main coronary artery position, 
confirmed by undiluted contrast injection through the mapping catheter, was tagged 
on the map. Secondly, an endocardial map of the LV was created using a retrograde 
approach via the aorta. An RV map was created if indicated. CT-derived images were 
visually aligned with the EAM using the left main landmark to overcome rotation errors. 
The LV surfaces were automatically aligned using CARTOMerge software and the mean 
surface registration error was calculated.
CE-MRI-derived images were visually aligned with the EAM using the left main land-
mark. Then, the LV surfaces were aligned with the translation tool until the lowest mean 
surface registration error was reached.
After image registration, epicardial EAM of the target area was performed. Endocardial 
and epicardial ablation target sites were identified based on activation mapping and 
entrainment mapping for stable VT, and substrate mapping (electrogram characteristics 
and pace-mapping) for unstable VT. Radiofrequency energy was applied at 30-45W 
(maximum temperature 45ºC, flow 20-30ml/min, 60s) for endocardial sites and up to 
50W (flow 20ml/min) for epicardial sites.
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electrogram analysis
All bipolar electrograms were displayed at the same gain (reference caliper 0.20mV, Fig-
ure 2) and categorized as normal (≤4 sharp spikes) or abnormal (>4 sharp spikes).11 The 
latter were subdivided into the following morphologies: double potentials (amplitude 
ratio ≤1.5), continuously fragmented electrograms (amplitude/duration [mV/msec] ratio 
≤0.05), late potentials (inscribing after QRS and separated by an isoelectric segment 
>20ms) or other abnormal morphologies (>4 spikes but none of the previous; Figure 2). 
In addition, electrogram duration was measured from the first to the last sharp spike11 
and categorized into 4 predefined categories: ≤50ms, 51-60ms, 61-70ms or >70ms.
Post-procedural reverse registration of electroanatomical maps with both CT 
and Ce-MRI
After the procedure, all points were superimposed on the corresponding short-axis CT 
slice using the reversed registration matrix and point coordinates (Mass research software). 
The epicardial fat thickness was calculated for each point and categorized as 0.0mm, 0.1-
2.7mm or ≥2.8mm. Sites with 0.0mm fat were analyzed separately to assess the impact of 
scar on electroanatomical mapping parameters in the absence of fat. The 2.8mm cutoff 
has been demonstrated to separate low (<1.5mV) from normal bipolar voltage.5
All points were also superimposed on a 3D reconstruction of the CE-MRI, which was 
created using the short-axis slices (MATLAB software, version 2009b). Centered around 
each mapping point that was projected on the LV epicardial surface, a 5mm-diameter 
transmural cylinder was created and divided into three layers of equal thickness. Points 
with late enhancement (LE) in the endocardial 1/3 or 2/3 were categorized as endocar-
dial scar, those with LE only in the intramural layer as intramural scar, those with LE in 
the epicardial 1/3 or 2/3 as epicardial scar and points with LE in all 3 layers as transmural 
Figure 2. electrogram morphology categories.
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scar. All LV epicardial ablation target sites with a ≥11/12 pacemap were evaluated for 
voltages, electrogram characteristics and the presence of LE.
endomyocardial biopsy
After ablation, when indicated by current guidelines12 endomyocardial biopsy was per-
formed (6 patients, interventricular septum [n=4] and/or apicolateral LV [n=3]). Tissue 
was fixed in 4% formaldehyde. After embedding the tissue in paraffin, cross-sections 
were cut at 4µm and stained for collagen content by Picro-sirius Red staining. Nuclei 
were counterstained with Mayer’s hematoxylin. High resolution images were taken by 
microscopy and collagen content was quantified as a percentage of the total biopsy sur-
face using dedicated software (ImageJ, National Institutes of Health, USA). The amount 
and pattern of fibrosis (compact and/or interstitial) were compared with CE-MRI and 
EAM findings.
Statistical analysis
Categorical variables are displayed as number (percentage) and continuous variables as 
mean±SD or median (interquartile range). Data were analyzed using the χ2 test, Fisher’s 
exact test, Mann-Whitney U test or Kruskal-Wallis test when appropriate. Receiver-oper-
ating characteristic curve analysis was performed to determine the optimal cutoff values 
of bipolar and unipolar voltage for detection of scar, which were defined as the values 
maximizing the sum of sensitivity and specificity. The area under the curve (AUC) was 
calculated to evaluate the accuracy of the mapping parameters. To create an algorithm 
for differentiation between scar and viable myocardium, independent predictors of scar 
were identified using multivariable logistic regression analysis and backward stepwise 
selection (inclusion p<0.10, exclusion p>0.20). The algorithm outcome was positive 
for scar if any of the incorporated parameters was abnormal. McNemar’s test was used 
to compare the sensitivity and specificity for the different steps of the algorithm. All 
analyses were performed with SPSS v18.0 (SPSS Inc., Chicago, Illinois). All p-values were 
two-sided and a p-value of <0.05 was considered significant.
ReSULTS
Patients
Ten patients with NICM (7 males, 56±13 years) and 6 patients with idiopathic VA (5 males, 
55±19 years) were studied. Baseline characteristics are summarized in Table 1. Mapping 
of the LV (NICM mean 110±66 points [median 102, min 33 – max 254], idiopathic mean 
50±27 points [median 50, min 21 – max 90]) and epicardium (NICM mean 137±78 points 
[median 138, min 55 – max 247], idiopathic mean 80±51 points [median 81, min 28 – 
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max 164]) was performed focusing on the area of interest based on the 12-lead ECG of 
spontaneous and induced VA.
Image integration was successfully performed in all patients (CT surface registration 
error 2.0±0.3mm in NICM patients and 3.5±1.8mm in patients with idiopathic VA; CE-MRI 
surface registration error 3.2±0.4mm) (figure 3).
Fat and epicardial voltages
Of 1374 epicardial mapping points acquired in patients with NICM, 476 (35%) points 
were projected on the RV and excluded. Epicardial fat thickness was 0.0mm at 423 (47%) 
epicardial LV sites, 0.1-2.7mm at 296 (33%) sites and ≥2.8mm at 179 (20%) sites. LE on 
MRI was present at 558 (62%) points and no LE at 340 (38%). In patients with idiopathic 
VA, 268 points were analyzed. Epicardial fat thickness was 0.0mm fat at 37 (14%) epicar-
dial LV sites, 0.1-2.7mm at 48 (18%) sites and ≥2.8mm at 183 (68%) sites. Both bipolar 
and unipolar electrogram amplitudes at sites without LE were attenuated by fat in NICM 
(p<0.001, Figure 4A-B) and controls (p<0.001, data not shown).
Bipolar and unipolar voltages: scar vs. viable myocardium
Bipolar and unipolar voltages in areas without scar on CE-MRI or fat on CT were similar 
in NICM patients and controls (Figure 4A-B). In patients with NICM, cutoff values of 
1.81mV for bipolar voltage (AUC 0.73, sensitivity 59% and specificity 78%) and 7.95mV 
for unipolar voltage (AUC 0.79, sensitivity 80% and specificity 72%) could best differenti-
ate between the absence and presence of scar in areas devoid of fat. In areas covered 
by ≥2.8mm fat neither bipolar nor unipolar voltage could differentiate between the 





Male gender (%) 7 (70%) 5 (83%)
Age, years 56±13 55±19
Body mass index, kg/m² 25±4 28±5
LV ejection fraction, % 39±13 56±7
LV end-diastolic volume, mL 243±99 112±33
Hypertension (%) 3 (30%) 3 (30%)
Diabetes Mellitus (%) 1 (10%) 3 (50%)
Creatinin clearance < 60 mL/min 2 (20%) 2 (33%)
Atrial flutter / fibrillation (%) 1 (10%) 0
PVC (%) 0 5 (83%)
VT (%) 10 (100%) 2 (33%)
LV = left ventricular, NICM = nonischemic cardiomyopathy, PVC = premature ventricular contraction, SHD = 
structural heart disease, VT = ventricular tachycardia
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Figure 3. example of simultaneous CT and contrast-enhanced MRI integration during epicardial elec-
troanatomical mapping.
Substrate mapping demonstrates low voltage areas consistent with epicardial fat, scar or both. Late po-
tentials were detected at the basal LV low voltage area, while an apparently healthy but attenuated elec-
trogram was found at the interventricular groove. Integrated CT-derived fat meshes demonstrate that the 
interventricular groove and the RV are covered by thick fat layers, possibly explaining the attenuated elec-
trogram amplitudes. The late potentials were caused by a basal scar, which was identified by the integrated 
CE-MRI-derived scar mesh. RVOT=RV outflow tract. Other abbreviations as in Figure 1.
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absence or presence of scar. A summary of the value of EAM parameters for identifica-
tion of scar is provided in Table 2.
electrogram characteristics: scar vs. viable myocardium
In NICM patients electrograms were prolonged (>50ms) at 263 (47%) sites with scar, 
as compared to only 45 (13%) sites without evidence of scar on CE-MRI (p<0.001). 
Electrograms at scar sites with <2.8mm fat were more often prolonged (>50ms) than 
electrograms at scar sites with ≥2.8mm fat (50% vs. 36%, p=0.02, Figure 5A-B).
The electrogram morphology at sites with scar was categorized as normal in 173 
(31%), double-equal in 61 (11%), fragmented in 57 (10%), late potential in 22 (4%) and 
other abnormal morphologies in 245 (44%) points. The double-equal, fragmented and 
late potential morphologies were unaffected by fat thickness (p=0.90), while the other 
abnormal electrogram morphologies were affected by fat thickness (p<0.001, Figure 
5A-B, Table 2).
algorithm for differentiation between scar and viable myocardium
The variables that were independently associated with scar by multivariable logistic 
regression analysis were electrogram morphology, electrogram duration and unipolar 
voltage, but not bipolar voltage. The 3 independently associated variables were used to 
create a 3-step algorithm, which is displayed in Figure 6.
Table 2. Diagnostic performance of electroanatomical mapping parameters to detect scar for areas 
with <2.8mm fat and ≥2.8mm fat.
Fat thickness (mm)
aUC* PPV nPV Sensitivity Specificity
<2.8 ≥2.8 <2.8 ≥2.8 <2.8 ≥2.8 <2.8 ≥2.8 <2.8 ≥2.8
Mapping parameters
Bipolar voltage ≤1.8mV 0.73 0.57 78% 58% 53% 48% 65% 69% 68% 35%
Unipolar voltage ≤7.95mV 0.78 0.58 80% 60% 64% 52% 79% 71% 66% 39%
Electrogram duration >50ms 0.70 0.58 89% 69% 50% 50% 50% 36% 89% 80%
Electrogram morphology - any abnormal - - 80% 69% 58% 55% 72% 56% 68% 68%
algorithm
STeP 1: Electrogram morphology - only 
double, fragmented, late potential
- - 91% 92% 42% 50% 25% 24% 96% 98%
STeP 1+2: As above, OR
duration >50ms †
- - 88% 70% 54% 51% 58% 42% 86% 77%
STeP 1+2+3: As above, OR unipolar 
voltage ≤7.95mV †
- - 78% 70% 66% 51% 83% 42% 60% 77%
* Parameters are analyzed as a continuous variable.
† Overall sensitivity and specificity compared to previous step by McNemar’s test, p<0.001.
AUC denotes area under the curve; NPV, negative predictive value; PPV, positive predictive value.
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The complete algorithm had an overall sensitivity of 75%. The sensitivity was 83% in 
areas covered with <2.8mm fat, which decreased to 42% in the presence of ≥2.8mm fat 
(Table 2). However, in contrast to bipolar and unipolar voltage, the algorithm maintained 
a high specificity in areas covered with ≥2.8mm fat.
Using the complete algorithm 84% of transmural, 73% of epicardial and 64% of intra-
mural scar sites could be identified, as compared to only 36% of endocardial scar sites.
Bipolar & unipolar voltage, electrogram characteristics and scar type
To determine the accuracy of bipolar and unipolar voltage for detection of different 
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Figure 4. Scar, fat and bipolar & unipolar voltages.
Median and interquartile range of bipolar and unipolar voltage at scar and non-scar sites for different fat 
thicknesses (Panel A-B) and scar types (Panel C-D).
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voltage were reduced in the presence of 
epicardial and transmural scar (all p<0.001, 
Figure 4C-D), but only unipolar voltage was 
affected by intramural scar (p<0.001). Sites 
with transmural scar more often had pro-
longed (>50ms) and morphologically abnor-
mal electrograms than sites with epicardial, 
intramural or endocardial scar (all p<0.001, 
Figure 5C-D). Epicardial scar in turn resulted 
in more prolonged (>50ms) electrograms 
than intramural (p=0.007) or endocardial 
scar (p=0.046). Late potentials were only ob-

































































































































































































































































































Figure 5. Scar, fat and electrogram characteristics.
Electrogram duration and electrogram morphology at scar and non-scar sites for different fat thicknesses 
in nonischemic cardiomyopathy (Panel A-B) and for different scar types in nonischemic cardiomyopathy 
and controls (Panel C-D).
Figure 6. algorithm for differentiation be-
tween scar and viable myocardium.
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ablation target sites
A total of 40 VTs was induced (cycle length 310±77ms). A ≥11/12 pacemap could be pro-
duced for 17 VTs (43%). At 9 of these 17 sites (53%), diastolic potentials were identified 
during VT and at 4 (24%) VT slowed and terminated during ablation. Eight (47%) target 
sites were located at the LV epicardium, 3 (18%) in the LV, 3 (18%) in the aortic root, 2 
(12%) at the epicardial RV outflow tract and 1 (6%) at the RV side of the interventricular 
septum. At all LV epicardial target sites bipolar voltage was ≤1.81mV, unipolar voltage 
≤7.95mV, electrogram duration >50ms and electrogram morphology abnormal (5 late 
potential, 1 fragmented, 2 other abnormal). Late enhancement was present at all LV 
epicardial target sites (6 transmural, 1 subepicardial, 1 intramural). Six of 8 VTs (75%) 
were not inducible after ablation. One VT could not be abolished presumably due to 
a deep intramural circuit (intramural LE on MRI) and another due to interposition of a 
coronary artery and >10mm epicardial fat.
histology
Endomyocardial biopsy from the interventricular septum was performed in 4 patients 
(3 specimens each) distant from areas with LE on MRI. In 3 patients, voltages and elec-
trograms were normal at the biopsy site, although both interstitial and limited compact 
fibrosis was identified in 2 of 3 patients (both 8% of surface, supplemental Figure). In 
the fourth patient, bipolar voltage was 1.40mV, unipolar voltage 4.46mV, electrogram 
duration 65ms and electrogram morphology ’other abnormal’. Histology revealed more 
severe compact and interstitial fibrosis (46% of surface).
Endomyocardial biopsy from the apicolateral LV was performed in 3 patients (3 
specimens each). Voltages and electrograms were normal at the biopsy site, while both 
interstitial and limited compact fibrosis were found in all 3 patients (2, 13 and 16% of 
surface). None of the biopsy sites corresponded to an area of LE.
DISCUSSIon
The present study is the first to compare voltage maps, electrogram characteristics, fat 
and scar by integration of both CT and CE-MRI with epicardial EAM. In addition, the 
distribution and amount of fibrosis as identified by histology, were also compared with 
EAM and CE-MRI. The main findings can be summarized as follows: (1) bipolar voltage 
≤1.81mV and unipolar voltage ≤7.95mV are the optimal cutoff values for identification 
of scar during epicardial EAM of areas devoid of fat, (2) electrogram characteristics, 
but not bipolar or unipolar voltages, can detect scar covered by fat, (3) the proposed 
algorithm can be applied to differentiate between scar and viable myocardium and (4) 
unipolar voltage can be used to identify intramural scar.
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Bipolar and unipolar voltage, scar and fat
In the current study, epicardial bipolar and unipolar cutoff values for detection of scar 
were determined based on CT and CE-MRI. In a prior study by Cano et al.2, normal epi-
cardial bipolar voltage values were assessed by excluding a 1.5cm wide area along the 
course of the coronary arteries and the atrioventricular groove. Thick fat layers often 
found in other areas13 may explain the reported lower bipolar voltage cutoff value of 
1.0mV. In another study, CT-derived fat was integrated with EAM, but a gold standard 
for the presence of scar was lacking.5 The currently presented cutoff values of 1.81mV 
for bipolar voltage and 7.95mV for unipolar voltage are likely to be more accurate since 
detailed information on fat and scar was available.
It has been postulated that having a larger ‘field of view‘, unipolar voltage could detect 
scar covered by fat, thereby compensating for the limitation of bipolar voltage mapping. 
However, in the NICM population unipolar voltage could not differentiate between pres-
ence or absence of scar at sites with ≥2.8mm fat, suggesting a limited field of view.
electrogram characteristics, scar and fat
Prolonged bipolar electrograms with an abnormal morphology are likely to indicate slow 
conduction in inhomogeneous scar, perhaps related to VT. Since bipolar electrogram 
amplitudes are attenuated by epicardial fat, low amplitude components such as late 
potentials may be reduced to noise level. In this study, both CT-derived fat and CE-MRI-
derived scar information were integrated, which for the first time allowed evaluation of 
the value of different EAM parameters. Electrograms were prolonged at only 47% of sites 
with LE, suggesting that CE-MRI and EAM may provide complementary information, with 
CE-MRI more accurately delineating (intramural) fibrosis and EAM providing functional 
information. Importantly, double-equal, fragmented and late potentials were not af-
fected by fat and almost exclusively detected in scar areas, whereas other (more subtle) 
abnormal electrogram morphologies were affected by fat and also frequently found in 
non-scar areas. Subtle electrogram abnormalities may be caused by small amounts of 
fibrosis not detected by CE-MRI, as was found in the biopsy specimens. Late potentials 
may indicate the presence of slow conduction caused by large amounts of scar, which is 
supported by the presence of transmural scar at all sites with late potentials.
algorithm
If CE-MRI is not available, the proposed easy-to-apply 3-step algorithm may be used to 
improve the accuracy of scar delineation during epicardial EAM. In areas with ≥2.8mm 
fat (as delineated by CT, which can be acquired irrespective of prior device implantation) 
only the first and second step should be used to maintain specificity, whereas the third 
step may be used for sites with <2.8mm fat (on average 80% of mapping sites). When 
CT scans are not available, step 1 and 2 of the algorithm can be used, although with 
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lower sensitivity. When only the electrogram morphology (any abnormal) is applied, the 
sensitivity is acceptable and the specificity is unaffected by fat thickness.
Voltage mapping and scar type
In the current study, for the first time it is demonstrated that epicardial unipolar volt-
age can be used to identify intramural scar. However, due to the limited field of view 
unipolar voltages cannot be used to detect subendocardial scar. Previously, Hutchinson 
et al. demonstrated that 61% of endocardial low unipolar voltage areas (≤8.27mV) over-
lapped with epicardial low bipolar voltage areas.7 This may however also be explained 
by epicardial scar extending towards the endocardium. Further studies are needed to 
assess the exact ‘field of view’.
ablation target sites
Since extensive epicardial EAM is time-consuming, it may be preferable to map the area 
of interest only. Importantly, all target sites were projected on areas with transmural 
LE on MRI, suggesting that CE-MRI may be used to delineate the area of interest. The 
combination of all EAM parameters may be used when CE-MRI is not available.
histology
Histology is the true gold standard to detect, quantify and characterize fibrosis, but its 
results, unlike CE-MRI, are not readily available during the procedure. Biopsy specimens 
revealed both interstitial and compact fibrosis in the majority of cases, although LE on 
MRI was only found remote from these areas. These findings may explain why electro-
gram characteristics were frequently abnormal even in the absence of LE on MRI. Inter-
stitial fibrosis and small amounts of compact fibrosis not detected by CE-MRI may cause 
electrogram abnormalities, as activation fronts curve around lines of block created by 
such strands of fibrosis.14 This is an important finding when considering CE-MRI as a gold 
standard for detection of fibrosis in NICM. Whether areas of fibrosis not detectable on 
CE-MRI are related to VT needs further evaluation.
Limitations
This study only analyzed mapping points that were projected on the LV epicardium and 
therefore, our findings do not apply to the RV epicardium. In addition, our findings only 
apply to the commonly used 3.5mm-tip catheters with a 2mm ring electrode and a 1mm 
interelectrode spacing. Although low voltage may have been caused by poor contact, 
this was unlikely as pericardial effusions were absent and the irrigant was removed fre-
quently. One patient with an electroanatomical small basolateral scar not clearly visible 
on CE-MRI due to imaging artifacts, was excluded illustrating that CE-MRI and EAM may 
still be used in a complementary manner.
Epicardial Mapping: Scar, Myocardium, or Fat 65
3
It should be noted that obtaining pre-procedural CT scans requires pre-procedural 
planning and is associated with radiation exposure. However, CT-derived coronary 
anatomy may also reduce the number of contrast injections before epicardial ablation 
and thus, reduce the radiation exposure during the procedure.
The relatively small number of mapping points, particularly in patients with idiopathic 
VA, may have limited the accuracy of the maps. The number of controls was small due to 
the fact that epicardial ablation is not required in the majority of patients with idiopathic 
VA. The number of NICM patients studied was also small because implanted devices fre-
quently impeded CE-MRI acquisition. For patients in whom CE-MRI is not available during 
the procedure, we provide tools to distinguish scar from viable myocardium and fat.9
Clinical implications
Substrate mapping is of key importance during epicardial VT ablation since activation 
mapping cannot be performed in the majority of VTs. However, during epicardial EAM it 
may be difficult to distinguish scar from fat, as both are associated with attenuated bi-
polar electrogram amplitudes. Moreover, even in the absence of epicardial fat, scars may 
be difficult to detect if located intramurally. The current study provides insight into the 
value of different epicardial EAM parameters for detection of scar in patients with NICM. 
Our findings have important implications when EAM is performed at areas covered by 
≥2.8mm fat, such as the basal LV13 which is often affected in patients with NICM3,15. In 
addition, epicardial unipolar voltage mapping may be particularly useful for detection 
of intramural scars, which are common in patients with NICM1 and cannot reliably be 
detected based on bipolar voltage and electrogram characteristics alone.
Magnetic resonance imaging is limited by the presence of devices and even if safe, it 
is significantly hampered by artifacts.8 Computed tomography is however available in 
all patients and may be important not only to prove, but also to exclude the presence 
of epicardial fat. The combination of CT, unipolar voltage mapping and electrogram 
characteristics is likely to improve the accuracy of epicardial substrate mapping, which 
is important for successful catheter ablation of VT.
ConCLUSIon
Bipolar voltage ≤1.81mV and unipolar voltage ≤7.95mV are the optimal cutoff values to 
differentiate between scar and viable myocardium during epicardial EAM, but both are 
attenuated by epicardial fat. Specific electrogram morphologies are not affected by fat, 
but can identify only one quarter of all scar sites. The proposed easy-to-use algorithm al-
lows more accurate differentiation between scar and viable myocardium during epicardial 
EAM. Unipolar voltage, but not bipolar voltage can be used to identify intramural scar.
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Supplemental Figure 1. histologic examination of scar architecture in biopsy specimens.
Endomyocardial biopsy specimens from the right ventricular septum (upper panels) and from the apicolat-
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There are limited data on typical arrhythmogenic substrates and associated ventricular 
tachycardias (VT) in patients with nonischemic cardiomyopathy (NICM). The substrate 
location may have implications for the ablation strategy.
Methods and results
Nineteen consecutive patients with NICM (age 58±14years, 79% male, LVEF 41±11%) 
who underwent contrast-enhanced MRI (CE-MRI) and VT ablation were included. Based 
on 3D CE-MRI-derived scar reconstructions, 8 patients (42%) had predominant basal 
anteroseptal scar, 9 (47%) predominant inferolateral scar and 2 (11%) other scar types. 
Three distinct VT morphologies (≥1 of 3 inducible in 16/19 patients) were associated with 
underlying scar type. In 9 patients with anteroseptal scar-related VT (8/9 predominant 
scar, 1/9 non-predominant), ablation target sites (defined as sites with ≥11/12 pacemap, 
concealed entrainment or VT termination during ablation) were located in the aortic 
root and/or anteroseptal left ventricular endocardium in 8 (89%) and in the anterior 
cardiac vein in 1 (11%), with additional target sites at the right ventricular septum in 
2 (22%) and at the epicardium in 1 (11%). In contrast, in 8 patients with predominant 
inferolateral scar-related VT, target sites were located at the epicardium in 5 (63%) and 
in the endocardial, inferolateral LV in 3 (37%).
Conclusion
Two typical scar patterns (anteroseptal and inferolateral) account for 89% of arrhyth-
mogenic substrates in patients with NICM. Three distinct VT morphologies are highly 
suggestive for the presence of these scars. Anteroseptal scars were in general most 
effectively approached from the aortic root or anteroseptal LV endocardium, whereas 
inferolateral scars frequently required an epicardial approach.
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InTRoDUCTIon
The substrate for ventricular tachycardia (VT) in patients with non-ischemic cardiomy-
opathy (NICM) is typically located near the base of the left ventricle (LV) close to the valve 
annuli, with an intramural or subepicardial distribution pattern.1-3 Isolated septal scars 
have been reported in approximately 12% of patients,2 but may be difficult to detect 
by electroanatomical mapping (EAM),2,4 thereby underestimating its prevalence. Viable 
myocardium overlying the substrate may prevent scar detection by bipolar EAM.2,5 Uni-
polar voltage mapping has been suggested to have a larger ‘field of view’ than bipolar 
voltage mapping, allowing detection of subepicardial scars during endocardial map-
ping.6 The exact size of this ‘field of view’ is however unclear and has not been validated 
by contrast-enhanced magnetic resonance imaging (CE-MRI), which is considered to be 
the gold standard to detect scar.
CE-MRI derived 3-dimensional (3D) scar reconstructions may provide insights into 
the geometry of the arrhythmogenic substrate4 and its spatial relation to anatomical 
structures, which may have implications for the procedural strategy, the required access 
and potential limitations for ablation.
The 12-lead morphology of scar-related VT depends on 3D scar geometry and VT exit 
site, and may help to identify the substrate in patients in whom CE-MRI is not avail-
able. Distinct VT morphologies have been described in selected patients with NICM and 
isolated septal scars,2 but not in other scar types.
The aims of the present study were 1) to identify typical MRI-derived scar patterns and 
the associated 12-lead VT morphologies in consecutive patients with NICM who under-
went CE-MRI and VT ablation, 2) to evaluate its implications for the ablation strategy and 
3) to analyze the value of bipolar and unipolar endocardial voltage mapping to detect 
the CE-MRI-derived VT substrate in patients with NICM.
MeThoDS
Patients
The study sample consisted of 19/21 consecutive patients with NICM who underwent 
CE-MRI and VT ablation. Two patients with poor CE-MRI image quality were excluded. 
Patients with coronary artery disease (>50% stenosis, assessed by coronary angiography 
in all patients), congenital heart disease, hypertrophic, arrhythmogenic right ventricular 
and restrictive cardiomyopathy, LV noncompaction, (sub)acute myocarditis, cardiac 
sarcoidosis, tachycardia-induced cardiomyopathy or primary valvular abnormalities 
were excluded. All patients were treated according to the routine clinical protocol and 
provided informed consent.
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Ce-MRI acquisition and processing
Contrast-enhanced MRI was performed on a 1.5 T Gyroscan ACS-NT/Intera MR system 
(Philips Medical Systems, Best, the Netherlands). A standardized protocol was followed, 
including cine MRI in long- axis (two- and four-chamber views) and short-axis covering 
the LV. In addition, the proximal aorta was imaged using a black-blood turbo spin-echo 
sequence. Contrast-enhanced images were acquired 15 min after bolus injection of 
gadolinium (Magnevist; Schering, Berlin, Germany; 0.15 mmol/kg) using a 3D turbo-field 
echo sequence with parallel imaging. The heart was imaged in one or two breath-holds 
with 20–24 imaging levels (dependent on heart size) in short-axis views. Images were 
acquired 600–700ms after the R-wave.
Using Mass research software, the centerline of the proximal coronary arteries was 
manually defined in the black-blood spin-echo image stack. The aortic, endocardial and 
epicardial contours were semi-automatically detected on short axis views and converted 
into 3D meshes. Myocardial tissue with 35-50% and ≥50% of maximal signal intensity were 
considered grey zone and core scar, respectively. The LV endocardial and epicardial meshes 
were color-coded for scar transmurality in the inner and outer half of the wall, respectively. 
All meshes were imported into the CARTO system using IPE-software (Figure 1).
CT acquisition and processing
Prior to epicardial ablation electrocardiogram-gated cardiac CT imaging was performed 
with an intravenous iodinated contrast agent. The endocardial, epicardial and pericardial 
contours were manually traced on short-axis reformatted CT slices to create 3D meshes 
color-coded for fat thickness (distance between epicardial and pericardial contours).7,8 
Subsequently, the original CT data and the 3D meshes were imported into the mapping 
system. These images were used during epicardial VT ablation procedures to avoid RF 
Figure 1. example of a MRI-derived basal anteroseptal scar
In panel A the core scar is displayed in red, the grey zone in yellow. Based on fused CT- and MRI-derived 
information, the scar cannot be reached from the epicardium due to overlying coronary arteries (panel B), 
the pulmonary artery (panel C) and epicardial fat (panel D). In panels B and C, the scar in the endocardial 
half of the wall is displayed in purple, scar in the epicardial half in green.
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applications in the close vicinity of coronary arteries and to provide detailed information 
on epicardial fat thickness, which may facilitate the interpretation of electrograms and 
explain ineffective RF applications.7
electrophysiological evaluation
Anti-arrhythmic drugs were discontinued for at least 5 half-lives with the exception of 
amiodarone (n=2). Programmed electrical stimulation was performed before sedation 
and opioid administration. The simulation protocol consisted of 3 drive cycle lengths 
(600, 500 and 400ms) with 1-3 ventricular extrastimuli (≥200ms) from 2 right ventricular 
(RV) sites and burst pacing (CL≥200ms), repeated with isoproterenol (2-10µg/min) when 
necessary. Positive endpoint was induction of a sustained monomorphic VT (>30s or 
requiring termination because of hemodynamic compromise).
VT morphologies
All induced sustained monomorphic VTs were categorized as right or left bundle branch 
block-like (RBBB or LBBB) morphology (defined as predominant R or S V1), inferior or 
superior axis (predominant R or S in aVF), left or right axis (predominant R or S in I) 
and precordial transition (first lead with a predominant R or S for LBBB and RBBB VTs, 
respectively).
electroanatomical mapping, real-time image integration and ablation
Epicardial access was obtained through a subxyphoid puncture. Electroanatomical 
bipolar and unipolar voltage mapping was performed using a 3.5mm irrigated-tip 
catheter (2mm ring electrode, 1mm interelectrode spacing; NaviStar ThermoCool, Bio-
sense Webster Inc, Diamond Bar, CA, USA) and the CARTO system. Electrograms were 
filtered at 30-400Hz (bipolar) and 1-240Hz (unipolar). Limited EAM of the aortic root was 
performed and the position of the left main coronary artery, confirmed by undiluted 
contrast injection through the mapping catheter, was tagged on the map. The LV was 
mapped retrogradely focusing on the MRI-derived scar areas. The RV was mapped if 
indicated. CE-MRI-derived images were aligned with the EAM using the left main land-
mark. Then, the LV surfaces were aligned with the translation tool until the lowest mean 
surface registration error was reached. The CT-derived coronary anatomy and epicardial 
fat meshes were integrated with the EAM in patients who underwent epicardial map-
ping, as previously described.8
Potential re-entry circuit sites targeted for ablation were identified based on activation 
mapping and entrainment mapping for stable VT. For unstable VT, the area of interest 
was identified by substrate mapping and pace mapping. Then, VT was reinduced and 
briefly mapped in an attempt to identify diastolic activity and terminate the VT by abla-
tion. For analyses purposes, ablation target sites were defined as sites with 1) ≥11/12 
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pace map and/or 2) concealed entrainment suggestive for a central isthmus or exit site 
and/or 3) VT slowing and termination during ablation.
At the epicardium, ablation was usually withheld when the estimated distance to a 
coronary artery was <5mm, as assessed by integrated CT-derived coronary anatomy and 
coronary angiography.7 High output pacing (10mA, 2ms) was performed to determine 
the location of the phrenic nerve. Radiofrequency (RF) energy was applied at 30-45W 









Age 58±14 61±12 56±16
Male 15(79%) 7(88%) 7(78%)
LV ejection fraction, % 41±11 40±8 44±15
LV end-diastolic volume, mL 230±73 224±36 237±102
History of atrial flutter/fibrillation 3(16%) 2(25%) 1(11%)
BMI, kg/m² 26.4±4.2 27.8±5.2 26.2±2.8
Diabetes mellitus 2(11%) 0(0%) 2(22%)
eGFR < 60 mL/min 2(11%) 1(13%) 1(11%)
Number of VTs induced 2(1-3) 3(2-6) 2(1-4)
BBR VT 0(0%) 0(0%) 0(0%)
Unstable VT 14(74%) 5(62%) 7(78%)
Mean CL of induced VTs 298±69 308±75 304±68
LV endocardial mapping 19(100%) 8(100%) 9(100%)
 Low bipolar voltage area, cm2 8.7(3.1-15.0) 9.9(4.1-14.1) 5.1(0.35-15.7)
 Low unipolar voltage area, cm2 14.4(7.1-27.9) 12.9(7.3-27.7) 14.4(0.7-27.5)
 Electrogram abnormalities* 11/6/2 5/3/0 5/3/1
Epicardial mapping 11(58%) 3(38%) 7(78%)
 Low bipolar voltage area, cm2 28.4(20.0-41.3) 20.0(16.6-22.7) 34.1(28.4-46.8)
 Low unipolar voltage area, cm2 47.1(16.4-55.9) 16.4(15.0-16.6) 51.6(35.0-55.9)
 Electrogram abnormalities* 9/1/1 2/0/1 7/0/0
Epicardial ablation 8(42%) 2(25%) 6(67%)
Procedural duration, minutes 218±83 230±117 225±44
Fluoroscopy time, minutes 49±19 55±26 46±7
Acute outcome
 Complete success 10(53%) 4(50%) 5(56%)
 Partial success 6(32%) 3(38%) 3(33%)
 Failure 3(16%) 1(13%) 1(11%)
Other scar types in 2 patients are not described separately
*Specific (double, fragmented or late potential)/only other abnormal/none
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(maximum temperature 45°C, flow 20-30ml/min, 60s) for endocardial sites and up to 
50W (flow 20ml/min) for epicardial sites.
acute and long-term outcome
After ablation, the entire stimulation protocol was repeated. Isoprenaline was adminis-
tered if required to induce VT before ablation. Complete procedural success was defined 
as non-inducibility of any sustained monomorphic VT; partial success as elimination of 
the clinical VT but inducibility of ≥1 nonclinical VT; failure as inducibility of the clinical VT. 
Patients were followed at 3, 6 and 12 months and at 6- to 12-monthly intervals thereafter.
Contrast-enhanced MRI-derived 3D scar reconstructions
Based on the short-axis slices, 3D scar reconstructions were created (MATLAB software, 
version 2009b). For each patient, the MRI-derived scar transmurality (including core 
and grey zone) was calculated and displayed on a bull’s eye image containing the 17 LV 
segments. Based on the reconstructions, the locations of the predominant (i.e. largest) 
scar and of additional scars (defined as scars involving ≥25% of a remote segment) were 
assessed. The scar distribution within the LV wall was determined by calculating the 
average endocardial and epicardial viable layers for each scar.
After the procedure, all mapping points were superimposed on the MRI-derived 3D 
scar reconstruction. For each point, a 5mm-diameter transmural cylinder was created 
and the presence of late enhancement and the thickness of the endocardial viable layer 
were assessed.
Statistical analysis
Categorical variables are displayed as number (percentage) and continuous variables 
as mean±SD or median (first-to-third quartile [Q1-to-Q3]). Categorical variables were 
compared using the Chi-square test or Fisher’s exact test. Continuous variables were 
compared using the Student’s t-test when normally distributed, or the Mann-Whitney 
U test when non-normally distributed. Mapping point-based receiver operating charac-
teristic curve analysis was performed to determine the optimal cut-off values of bipolar 
and unipolar voltage for scar detection, defined as the values maximizing the sum of 
sensitivity and specificity. An additional cutoff value with a fixed specificity of 80% was 
calculated for unipolar voltage. The bipolar and unipolar voltage of mapping points at 
scars with an endocardial viable layer of 0-2mm, 2-4mm, 4-6mm, 6-8mm, >8mm and 
non-scar areas were averaged in each patient. Paired T-tests were subsequently per-
formed to analyze the difference between the average voltage at non-scar areas and the 
average voltage at scar areas with different endocardial viable layers in the same patient. 
All analyses were performed with SPSS v20.0 (SPSS Inc., Chicago, Illinois). All p-values are 




Nineteen patients (age 58±14 years, 15 [79%] male, LV ejection fraction 41±11%) 
underwent VT-ablation with CE-MRI integration. In 11 patients who underwent epi-
cardial mapping, CT-derived coronary anatomy and epicardial fat thickness were also 
integrated. Baseline characteristics are summarized in Table 1. None of the patients had 
documented pericarditis or myocarditis. Three patients (16%) had a family history of 
NICM/sudden cardiac death.
Typical MRI-derived scar patterns
As illustrated by the bull’s eye plot color-
coded for the average MRI-derived scar 
transmurality (Figure 2), two typical scar 
patterns could be identified. One was lo-
cated in the basal anteroseptal segment 
(referred to as anteroseptal scar) and the 
other in the basal/mid inferior, infero-
lateral and/or lateral segments (referred 
to as inferolateral scar). A predominant 
anteroseptal scar was present in 8/19 
patients (42%) and a predominant 
inferolateral scar in 9 (47%, Figure 3). Of 
the remaining 2 patients (11%), one had 
a subepicardial inferoapical scar and the 
other had a subepicardial scar along the 
anterior interventricular groove.
Two of 8 patients (25%) with a predominant anteroseptal scar also had a smaller 
inferolateral scar, and 6/9 patients (67%) with a predominant inferolateral scars also had 
a smaller anteroseptal scar.
Distinct eCG patterns of VTs
A total of 60 VTs were induced (median 2 VTs per patient; Q1-to-Q3, 1–3). Three distinct 
ECG patterns were observed (Figure 4):
1) RBBB, left/right inferior axis, positive concordance (Panel A) in 12 induced VTs (20%) 
in 8 patients (42%);
2) LBBB, left/right inferior axis, early (≤V3) precordial transition (Panel B) in 7 induced 
VTs (12%) in 6 patients (32%);
Figure 2. Scar distribution
In each patient the 3D scar reconstruction was used 
to create a 17-segment bull’s eye image displaying 
the scar transmurality. These data were subsequently 
averaged to create a single bull’s eye image color-
coded for the average scar transmurality in all pa-
tients, which is displayed continuously from highest 
(in red) to lowest (in blue).
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3) RBBB, right inferior/superior axis, late (≥V5) precordial transition (Panel C) in 6 in-
duced VTs (10%) in 6 patients (32%);
Together, 25 of 60 VTs (42%) had one of these three morphologies. All patients with type 
1 or type 2 VTs had anteroseptal scar; all patients with type 3 VTs had inferolateral scar. 
A less distinct ECG pattern, LBBB VTs with a superior axis and varying transition, was 
observed in patients with anteroseptal, inferolateral or non-typical scar extending to the 
inferoseptum. Sixteen of 19 patients (84%) had at least one type 1, 2 or 3 VT. The remaining 
3 patients (16%) had extension of the scar on CE-MRI consistent with the VT morphology.
Figure 3. Typical scars
Typical examples of basal anteroseptal scars are shown in right anterior oblique (RAO) and left anterior 
oblique (LAO) views, typical inferolateral scars in posterior-anterior (PA) and left anterior oblique (LAO) 
views. Red indicates core scar; yellow, grey zone.
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electroanatomical substrate mapping and ablation target sites
Procedural data are summarized in Table 1. CE-MRI-derived data were successfully inte-
grated in all patients (mean registration error 3.7±0.8mm). Substrate mapping of the LV 
(all patients, mean 128 points) and the epicardium (11 patients [58%], mean 155 points) 
was performed focusing on the area of interest as identified by MRI (Table 1 and Figure 5).
A ≥11/12 pacemap was obtained for 31 VTs (52%). Diastolic potentials were identified 
during 26 VTs (43%) and for 7 VTs (12%) concealed entrainment was suggestive for a 
central isthmus or exit site (stimulus-QRS 43 – 254ms). Eighteen VTs (30%) slowed and 
terminated during RF applications after a median of 9 seconds (Q1-to-Q3, 7–13 sec) 
without premature ventricular contraction. Overall, ablation target sites were identified 
for 40 VTs (67%). The locations of these target sites are displayed in Figure 6. All target 
sites were located within 10mm of the CE-MRI-derived scar area.
In 9 patients with basal anteroseptal scar-related VT (predominant in 8), target sites 
were located in the aortic root and/or basal anteroseptal LV endocardium in 8 (89%) and 
in the anterior cardiac vein in 1 (11%), with additional target sites at the RV septum in 2 
(22%) and at the basal anterior epicardium in 1 (11%).
In contrast, in 8 patients inferolateral scar-related VT (all predominant scars), target 
sites were located at the inferolateral epicardium in 5 patients (63%) and in the inferolat-
eral endocardial LV in 3 (37%, both endocardial and epicardial target sites in one), with 
an additional target site at the epicardial RV outflow tract in one. No target sites could 
be identified in one patient.
anatomical limitations of mapping and ablation
In patients with a predominant anteroseptal scar, ablation was limited by the proximity 
of the proximal conduction system in 2 (25%) and by the left main ostium in another 2 
(25%). Based on integrated CT- and MRI-derived information, the entire scar could not 
Figure 4. Distinct eCG patterns of ventricular tachycardias
RBBB denotes right bundle branch block; inf, inferior; LBBB, left bundle branch block.
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be reached from the epicardium due to the RV, pulmonary artery, overlying coronary ar-































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5. Bipolar vs. unipolar voltage mapping and scar features
Panel A: Receiver operating characteristic curve analysis for bipolar/unipolar voltage and MRI-derived scar. 
Panel B: Endocardial bipolar voltage is decreased only when the endocardial viable layer is <2mm thick. 
Panel C: Endocardial unipolar voltage was affected by scar involving the endocardial 4mm and, but less pro-
nounced, by scar >4mm from the endocardium. Panel D: Endocardial low voltage areas. Panel E, G and H: 
Subendocardial and subepicardial viable layers and scar transmurality. Panel F: Epicardial low voltage areas 
in patients who underwent epicardial mapping. *** indicates p < 0.001 vs. no scar; *, p <0.05 vs. no scar; †, 
One patient with a relatively thin LV wall (6.3±1.5mm) had low unipolar voltage at the entire endocardium 
and epicardium. AUC denotes area under the curve.
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reached in the remaining 3 patients (37%). In 3 patients with an anteroseptal substrate 
epicardial mapping and ablation was performed after image integration. The expected 
epicardial accessibility of the scar was confi rmed in these patients (only part of the scar 
reachable in 2, the entire scar not reachable in one).
In patients with a predominant inferolateral scar and endocardial ablation target 
sites, endocardial ablation was not limited. Based on integrated CT-derived information, 
coronary angiography and high-output pacing, RF applications had to be withheld at 
the epicardium due to the right coronary artery or the obtuse marginal branch in 3/7 
patients (43%) and due to phrenic nerve capture in one.
Contrast-enhanced MRI-derived 3D scar reconstructions
A total of 2444 points acquired in the LV were projected on 3D scar reconstructions. 
Scar was present at 1146 sites (47%). For endocardial bipolar voltage the optimal cut-
Figure 6. ablation target sites.
Ablation target sites in all patients projected on the computed tomography-derived anatomy of a single 
patient. Green points indicate ≥11/12 pace maps; yellow points, concealed entrainment sites suggestive for 
a diastolic part of the re-entry circuit; white points, VT termination sites. LV denotes left ventricle; RV, right 
ventricle; RVOT, right ventricular outfl ow tract.
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off value to differentiate between scar and viable myocardium was 2.04mV (AUC 0.67, 
sensitivity 48%, specificity 81%, Figure 5). For endocardial unipolar voltage the optimal 
cut-off value was 9.84mV (AUC 0.75, sensitivity 73%, specificity 69%). The specificity 
could be increased to 80% using a cut-off value of 8.01mV, which resulted in a sensitivity 
of 59%. Endocardial bipolar voltage was only affected by scar involving the endocardial 
2mm, whereas endocardial unipolar voltage was affected by scar involving the endocar-
dial 4mm and, less pronounced, by scar >4mm from the endocardium (Figure 5). Two 
patients (one with a basal anteroseptal scar and one with an inferolateral scar) had an 
epicardial scar identified by MRI that significantly exceeded small endocardial bipolar 
and unipolar low voltage areas (example in Figure 7).
Low bipolar and unipolar voltage areas, thickness of endocardial and epicardial viable 
layers and average scar transmurality were similar for anteroseptal and inferolateral 
scars (all p>0.05; Figure 5, panels D-H).
acute and long-term procedural outcome
Complete success was achieved in 10 patients (53%), partial success in 6 (32%) and abla-
tion failed in 3 (16%). The acute procedural outcome did not differ between patients 
with a predominant anteroseptal or inferolateral scar (Table 1). Seventeen of 19 patients 
(90%) were discharged with an implantable cardioverter defibrillator (ICD). During a 
median 15 (Q1-to-Q3, 11–27) months follow-up, 7/19 patients (37%) had VT recurrence 
(4/8 with a predominant anteroseptal scar, 2/9 with a predominant inferolateral scar, 1/2 
with other scar type). The 6-month VT burden was reduced by ≥75% in 16/19 patients 
(84%). One patient died due to a lung cancer.
Figure 7. example of electroanatomical maps and a 3D scar reconstruction
Endocardial bipolar (panel A) and unipolar (panel B) voltage maps, epicardial bipolar voltage map (panel 
C) with integrated CT-derived anatomy, and the MRI-derived 3D scar reconstruction (panel D). Voltages 
are color coded as indicated by the color bars. AO indicates aorta; LAD, left anterior descending coronary 
artery; LM, left main coronary artery; LV, left ventricle; RCx, circumflex coronary artery; RV, right ventricle.
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DISCUSSIon
In the present study, CE-MRI-derived scar was associated with VT in patients with NICM. 
Two typical scar patterns (i.e., anteroseptal and/or inferolateral scars) were present in 
89% of patients referred for VT ablation. Three distinct 12-lead ECG morphologies of 
VTs were common and diagnostic for a typical scar pattern. Ablation target sites in 
patients with a basal anteroseptal scar were mainly identified in the aortic root and the 
basal anteroseptal LV endocardium, whereas target sites in patients with an inferolateral 
scar were located at the epicardium in 63% of patients. The typical scar patterns may 
therefore have implications for the mapping and ablation strategy. Endocardial EAM is 
insufficient to delineate these scars, as endocardial bipolar voltage was only affected by 
scar involving the endocardial 2mm, and endocardial unipolar voltage by scar involving 
the endocardial 4mm and, less pronounced, by scar >4mm from the endocardium.
Typical arrhythmogenic substrates
Prior studies have described arrhythmogenic substrates in NICM, but have not system-
atically used CE-MRI as a gold standard for scar detection.2,9 In the current study, the 
EAM and CE-MRI-derived 3D scar reconstructions allowed a detailed evaluation of the 
arrhythmogenic substrate.
Importantly, all ablation target sites were located within 10mm of the CE-MRI-derived 
scar area. A predominant basal anteroseptal scar was present in 42% of patients but 
often associated with only a small endocardial low bipolar voltage area, difficult to dis-
tinguish from a normal low voltage area at the membranous part of the interventricular 
septum.  In this group endocardial target sites could be identified in all but one patient. 
The ablation was withheld due to the location of the conduction system in one patient 
and caused expected atrioventricular block in another. Epicardial mapping in the pres-
ence of this scar pattern was considered impossible due to or hampered by overlying 
coronary arteries, fat and the left atrial appendage.
Although basal anteroseptal scars have  been described in prior studies and two case 
reports2-4,9,10, they are reported to occur in  only 11.3% of NICM patients.2 Based on the 
current data and two prior studies, these scars may however be difficult to detect by 
substrate mapping2,4 and as a result, scar-related VTs may even be mistaken for benign 
idiopathic outflow tract VTs, which may have important prognostic and therapeutic 
consequences.4
A predominant inferolateral scar was present in 47% of patients but also difficult to 
detect by endocardial bipolar voltage mapping. Endocardial unipolar voltage mapping 
allowed improved but still limited scar detection. Epicardial mapping was not limited 
and epicardial target sites were identified in 63% of these patients. Epicardial ablation 
was however partly withheld due to coronary arteries and the phrenic nerve.
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In the current study, CE-MRI served as a gold standard for LV scar. For both scar patterns 
endocardial bipolar voltage was only affected by scar involving the endocardial 2mm, 
whereas endocardial unipolar voltage was affected by scar involving the endocardial 
4mm and, less pronounced, by scar >4mm from the endocardium. . Accordingly, the 
sensitivity for bipolar and unipolar voltage mapping to detect scar in the NICM popula-
tion is poor with an overall sensitivity of 48% and 59%, respectively.  Therefore CE-MRI 
should be considered in all patients with suspected NICM before VT ablation and ICD 
implantation.
In only one patient in our study a causative mutation (phospholamban) for NICM has 
been identified (yet) and none had a history of myocarditis. However, typical septal and/
or inferolateral scars have been described in various diseases, such as myocarditis,11 
arrhythmogenic right ventricular cardiomyopathy/dysplasia with LV involvement,12 
laminopathy13 and Anderson-Fabry disease14. Rather than disease specific, these areas 
may be more vulnerable to various insults resulting in fibrosis and ultimately VT.
Typical 12-lead eCG VT morphologies
At least one of three distinct VT morphologies was observed in 84% of patients and these 
morphologies were related to the two scar patterns. Documentation of these distinct 
morphologies may be helpful if CE-MRI is not available. Two typical VT morphologies 
have been previously  described in patients with NICM but only with isolated septal 
scars, including inferior limb discordance (dominant R in II and dominant S in III, or the 
opposite) in 16% of VTs, and precordial transition break in V2 (qR/Rs morphology in V1 
and V3 but reversal of this in V2) in 24% of VTs.2 In the current study, each criterion was 
observed in 5/37 induced VTs (14%) in 2/8 patients (25%) with a predominant antero-
septal scar.
Implications for the procedural strategy
VTs related to basal anteroseptal scar were effectively approached from the aortic root 
or basal anteroseptal LV endocardium, whereas VTs related to an inferolateral scar often 
required an epicardial approach. This finding may influence the procedural strategy in 
patients with NICM and a typical substrate based on imaging or a distinct VT morphol-
ogy. An initial endocardial approach may be appropriate in patients with a presumed 
basal anteroseptal substrate. A retrograde approach to the LV may be preferred over 
an antegrade approach, allowing mapping in the aortic sinus cusps. In patients with an 
inferolateral scars, epicardial mapping and ablation are likely to be necessary and an 
initial combined endocardial and epicardial approach may be reasonable.
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Limitations
Although the present study demonstrates a clear predilection for scars in the basal 
anteroseptal and inferolateral segments, there may be nonischemic scar distributions 
(and associated VT morphologies) that are not identified in this study. The number of 
patients was limited, as only patients without an implantable device underwent CE-MRI. 
No ablation target sites could be identified for 33% of VTs, which may be due to intra-
mural circuits or subepicardial circuits in areas covered with fat. Epicardial mapping was 
not performed in 4 patients with non-complete procedural success because the septal 
substrate was likely not accessible from the epicardium based on CE-MRI.
ConCLUSIon
Basal anteroseptal and inferolateral scars account for 89% of arrhythmogenic substrates 
in patients with NICM. Typical VT morphologies, observed in 84%, may help to identify 
the underlying substrate. Basal anteroseptal scars were in general most effectively ap-
proached from the aortic root or basal anteroseptal LV endocardium, whereas inferolat-
eral scars frequently required an epicardial approach. These findings are likely to have 
implications for the procedural strategy in patients with NICM who are referred for VT 
ablation.
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CLInICaL PeRSPeCTIVe
Ventricular tachycardia ablation in patients with nonischemic left ven-
tricular cardiomyopathy is considered to be chal- lenging, which may 
partly because of the frequent intramural and subepicardial location of 
the arrhythmogenic substrate. Relatively little is known about typical 
scar patterns and its implications for the ablation strategy. In the present 
study, 19 consecutive patients with nonischemic cardiomyopathy who 
underwent contrast-enhanced MRI and ventricular tachycardia ablation 
are described. Two contrast-enhanced MRI–derived scar patterns (ie, basal 
anteroseptal and inferolateral) accounted for 89% of arrhythmogenic 
substrates, and 3 distinct 12-lead ECG morphologies of ventricular tachy-
cardias were common and diagnostic for an underlying scar pattern. Basal 
anteroseptal scars were most effectively approached from the aortic root 
or basal anteroseptal left ventricular endocardium, and they were usually 
not well accessible from the epicardium, suggest- ing that an initial en-
docardial approach may be reasonable in these patients. In patients with 
inferolateral scars, however, an initial epicardial approach may be consid-
ered because epicardial ablation target sites were frequently identified 
in these patients. Endocardial electroanatomical voltage mapping could 
identify these scars only to a limited extent, with endocardial bipolar volt-
age only being affected when the scar involved the endocardial 2 mm 
and endocardial unipolar voltage when the scar involved the endocardial 
4 mm and, less pronounced, by scar >4 mm from the endocardium. These 
findings provide insights into the arrhythmogenic substrate in patients 
with nonischemic cardiomyopathy and may have important practi- cal 
implications for preprocedural planning and intraprocedural substrate 
identification in patients undergoing ventricular tachycardia ablation.
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This study evaluates whether contrast-enhanced (CE) cardiac magnetic resonance (CMR) 
can be used to identify critical isthmus sites for ventricular tachycardia (VT) in ischemic 
and nonischemic heart disease.
Background
Fibrosis interspersed with viable myocytes may cause re-entrant VT. CE-CMR has the 
ability to accurately delineate fibrosis.
Methods
Patients who underwent VT ablation with CE-CMR integration were included. After the 
procedure critical isthmus sites (defined as sites with a ≥11/12 pacemap, concealed 
entrainment or VT termination during ablation) were projected on CMR-derived 3D scar 
reconstructions. The scar transmurality and signal intensity at all critical isthmus, central 
isthmus and exit sites were compared to the average of the entire scar. The distance to 
>75% transmural scar and to the core-border zone (BZ) transition was calculated. The 
area within 5mm of both >75% transmural scar and core-BZ transition was calculated.
Results
In 44 patients (23 ischemic/21 nonischemic, LVEF 44±12%) a total of 110 VTs were 
induced (CL 290±67ms). Critical isthmus sites were identified for 78 VTs (71%) based 
on ≥11/12 pacemap (67 VTs) and/or concealed entrainment (10 VTs) and/or termina-
tion (30 VTs). The critical isthmus sites, and in particular central isthmus sites, had high 
scar transmurality and signal intensity compared to the average of the entire scar. Of 
the pacemap, concealed entrainment and termination sites 74%, 100% and 84% were 
within 5mm of >75% transmural scar, and 67%, 100% and 94% were within 5mm of 
core-BZ transition. The areas within 5mm of both >75% transmural scar and core-BZ 
transition (median 13% of LV) contained all concealed entrainment sites and 77% of 
termination sites.
Conclusion
Both in ischemic and nonischemic VT, critical isthmus sites are typically located in close 
proximity to the CMR-derived core-BZ transition and to >75% transmural scar. These 
findings suggest that CMR-derived scar characteristics may guide to critical isthmus 
sites during VT ablation.
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InTRoDUCTIon
The aim of ventricular tachycardia (VT) ablation is to eliminate critical isthmuses, which 
can be identified by pacemapping, entrainment mapping and termination of VT by 
ablation. Applying these techniques is limited by the inducibility of multiple and often 
hemodynamically untolerated VTs, intramural location of some critical isthmuses, epi-
cardial fat, and other factors.
Fibrotic areas interspersed with viable myocytes can form the substrate for reentrant 
VTs. Contrast-enhanced (CE) cardiac magnetic resonance (CMR) can accurately delineate 
areas with dense fibrosis and CE-CMR-derived data have been successfully integrated 
with electroanatomical maps (EAM) during VT ablation with high registration accu-
racy.1-7 Integrated CE-CMR scar data may guide to the scar area and uncover intramural 
and subepicardial scars.1-4
Although CE-CMR may help to identify scar areas causing VT, there are limited data on 
specific CMR-derived scar characteristics at critical isthmus sites, which may be useful 
to guide ablation. Features of interest are scar transmurality, which has been associated 
with slow conduction ,2,4,7,8 and signal intensity (SI), which has been used to identify con-
ducting channels5,6 and to delineate core scar and border zone (BZ). Importantly, to date 
no study has analyzed the value of CMR-derived scar characteristics to identify areas 
containing critical isthmuses, thereby potentially guiding substrate-based VT ablation.
The aims of the present study are: (1) to assess CMR-derived scar characteristics at 
critical isthmus sites of ischemic and nonischemic VT and (2) to determine the potential 




The study population consisted of 44/48 consecutive patients with prior myocardial 
infarction (MI, n=23) or nonischemic cardiomyopathy (NICM, n=21) who underwent 
VT ablation with integration of CE-CMR. Three patients were excluded because of 
non-interpretable CE-CMR and one because critical isthmus sites could not be reliably 
identified due to noninducibility of VT.
The diagnosis of prior MI was based on the presence of significant coronary artery dis-
ease (≥70% stenosis on coronary angiography) and subendocardial or transmural late 
gadolinium enhancement (LGE) in a coronary artery perfusion territory. The diagnosis 
of NICM was based on the exclusion of significant coronary artery disease, congenital 
heart disease, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardio-
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myopathy, left ventricular noncompaction, restrictive cardiomyopathy, (sub)acute myo-
carditis, cardiac sarcoidosis, tachycardia-induced cardiomyopathy and primary valvular 
abnormalities. All patients were treated according to our standard clinical protocol and 
provided informed consent.
Ce-CMR acquisition and processing
Contrast-enhanced CMR was performed on a 1.5T Gyroscan ACS-NT/Intera MR system 
or on a 3.0T Ingenia MR system (Philips Medical Systems, Best, the Netherlands). A stan-
dardized protocol was followed, including cine CMR in long-axis (two- and four-chamber 
views) and short-axis. In addition, the proximal aorta was imaged using a black-blood 
turbo spin-echo sequence. Contrast-enhanced images were acquired 15min after bolus 
injection of gadolinium (Magnevist; Schering, Berlin, Germany; 0.15 mmol/kg) with an 
inversion-recovery 3D turbo-field echo sequence with parallel imaging. The heart was 
imaged in one or two breath-holds with 20-24 imaging levels in short-axis views.
Using MASS software (research version 2012; LKEB; Leiden University Medical Cen-
tre, the Netherlands), the centerline of the proximal coronary arteries and the luminal 
boundary of the proximal aorta were manually defined in the black-blood spin-echo 
images. The endocardial and epicardial contours were semi-automatically detected on 
the short axis images. The defined geometries of the proximal coronary arteries, aorta 
and myocardial boundaries were converted into 3D meshes. Scar was defined as myo-
cardium with SI ≥35% of maximal myocardial SI, and subdivided into core scar (>50% 
of maximal SI) and border zone (BZ, 35-50% of maximal SI) according to the method 
described by Roes et al.9. The vertices of the LV endocardial and epicardial meshes were 
color-coded for scar transmurality for the inner and outer half of the wall, respectively. 
All meshes were imported into the CARTO system using CARTOMerge (IPE) software. On 
the CARTO 3 system scars were also visualized as 3-dimensional structures, which were 
created using MATLAB software (version 2012a).
electrophysiological evaluation
Anti-arrhythmic drugs were discontinued for ≥5 half-lives with the exception of amioda-
rone. Programmed electrical stimulation consisted of 3 drive cycle lengths (600, 500 and 
400ms) with 1-3 ventricular extrastimuli (≥200ms) from ≥2 right ventricular sites and 
burst pacing (cycle length ≥200ms), which was repeated with isoprenaline (2-10µg/min) 
when necessary. Positive endpoint for stimulation was induction of a monomorphic VT 
lasting for >30s or requiring termination because of hemodynamic compromise.
electroanatomical mapping, real-time image integration and ablation
If indicated, epicardial access was first obtained through subxyphoid puncture. Then 
heparin was administered and EAM was performed using a 3.5mm irrigated-tip 
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catheter (NaviStar ThermoCool, Biosense Webster Inc, Diamond Bar, CA, USA) and the 
CARTO system. Limited EAM of the aortic root was performed and the position of the left 
main coronary artery, confirmed by contrast injection through the mapping catheter, 
was tagged on the map. CE-CMR-derived images were visually aligned with the EAM 
using the left main landmark. Then, the LV was mapped retrogradely focusing on the 
integrated CMR-derived scar. The LV surfaces of CMR and EAM were aligned with the 
translation tool provided by the mapping system, until the lowest mean surface registra-
tion error was reached. Multidetector computed tomography-derived coronary artery 
anatomy and epicardial fat meshes were integrated with the EAM in patients undergo-
ing epicardial mapping.4,10
Potential ablation target sites were identified by activation mapping and entrainment 
mapping for stable VT. For unstable VT, the area of interest was identified by substrate 
mapping and detailed pacemapping. To confirm the best pacemap site, pacing was 
repeated after moving the catheter in all possible directions. With the catheter placed 
in the area of interest, VT was reinduced and briefly mapped to identify diastolic activity 
and terminate the VT by ablation, also for hemodynamically unstable VT.
At the epicardium, ablation was usually withheld when the estimated distance to 
a coronary artery was <5mm, as assessed by integrated multidetector computed to-
mography-derived coronary anatomy and coronary angiography.10 High output pacing 
(10mA, 2ms) was performed to localize the phrenic nerve. Radiofrequency energy was 
applied at 30-45W (maximum temperature 45°C, flow 20-30ml/min, 60s) for endocardial 
sites and ≤50W (flow 20ml/min) for epicardial sites.
acute and long-term outcome
After ablation, the entire programmed electrical stimulation protocol was repeated. 
Isoprenaline was administered if required to induce VT before ablation. Complete 
procedural success was defined as non-inducibility of any sustained monomorphic VT; 
partial success as elimination of the (presumed) clinical VT but persistent inducibility of 
≥1 nonclinical VT; failure as persistent inducibility of the (presumed) clinical VT. Patients 
were followed at 3, 6 and 12 months after ablation and at 6- to 12-monthly intervals 
thereafter.
Critical isthmus sites
For the current analysis all studies were thoroughly reviewed on the electrophysiology 
recording system (Prucka Cardiolab recording system, Houston, TX, USA) while the ob-
server was blinded to the electroanatomical maps. Critical isthmus sites were defined by 
the following criteria:
(1) ≥11/12 pacemap (precise match of major deflections and all subtle notches in 
≥11/12 leads; site with longest S-QRS delay in case of identical match) and/or
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(2) concealed entrainment with post-pacing interval equal to tachycardia cycle length 
and/or
(3) VT slowing and termination during ablation.
Critical isthmus sites for the same VT could be identified by more than one criterion. 
Because of differences in accuracy between pacemapping, entrainment and termina-
tion, we have stratified the analysis for these different criteria. Critical isthmus sites were 
further subdivided into central isthmus sites (S-QRS or E-QRS 31-70% of VT cycle length) 
and exit sites (S-QRS or E-QRS 0-30% of VT cycle length).
The LV endocardial low bipolar (≤1.50mV) and unipolar (≤8.27mV11) voltage areas 
were measured in all patients, and the epicardial low bipolar (≤1.81mV4) and unipolar 
(≤7.95mV4) voltage areas were measured in patients with NICM who underwent epicar-
dial mapping. The location of LV endocardial critical isthmus sites with respect to the 
endocardial low voltage areas was assessed in all patients. The location of LV epicardial 
critical isthmus sites with respect to epicardial areas with low voltage and abnormal 
electrograms4 was assessed in patients with NICM.
Contrast-enhanced CMR-derived 3D scar reconstructions
CMR-derived 3D scar reconstructions and all CMR-based scar parameters were com-
puted using MATLAB software. Examples of scars are displayed in Figures 1 and 2. After 
the procedure, all mapping points at critical isthmus sites were projected onto the 
CMR-derived 3D scar reconstructions using MATLAB software (example in Figure 2). Scar 
transmurality was calculated by dividing scar thickness by wall thickness. The local scar 
transmurality and SI at a mapping point were calculated as the mean value within a 
5mm-radius transmural cylinder around the mapping point. The local scar transmurality 
and SI at critical isthmus sites were compared to the average scar transmurality and SI in 
the same patient. The distances from critical isthmus sites to >75% transmural scar and 
core-BZ transition were calculated. The core-BZ transition was defined as the line where 
core and BZ meet, projected on the endocardial or epicardial surface.
The following predefined areas were calculated for the endocardium and epicardium 
in each patient: CMR-derived scar, area within 5mm of >75% transmural scar, area within 
5mm of core-BZ transition, and areas within 5mm and 10mm of the core-BZ transition 
with >75% scar transmurality. The percentage of critical isthmus sites located within 
these areas was calculated.
CMR-derived overall scar characteristics were calculated, including total scar volume, 
core volume, BZ volume and areas of ≤50%, 51-75% and >75% transmural scar. The 
relation between these characteristics and (1) average cycle length of induced VTs, (2) 
number of induced VTs, (3) inducibility of VT after ablation and (4) VT recurrence was 
assessed.
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Statistical analysis
Categorical variables are displayed as number (percentage) and continuous variables are 
expressed as mean±standard deviation or median (interquartile range [IQR]). Continu-
ous variables were compared using the Student’s t test when normally distributed or the 
Mann-Whitney U test when non-normally distributed. For paired variables, the paired 
t test or the Wilcoxon signed-rank-test were used, respectively. The relation between 
CMR-derived overall scar characteristics and the number of induced VTs and average 
cycle length of induced VTs was fi rst analyzed by univariate linear regression analysis. 
The relation with VT inducibility after ablation was analyzed by univariate logistic re-
gression and the relation with VT recurrence by univariate Cox regression. When statisti-
cally signifi cant associations were identifi ed in univariate analyses, multivariate analyses 
were performed to assess the independent associations between the scar characteristics 
of interest and the VT or outcome parameters. All analyses were performed with SPSS 
version 20.0 (IBM, Somers, New York, USA). All tests are two-sided and p-values <0.05 
were considered signifi cant.
ReSULTS
A total of 44 patients (23 post- MI/21 NICM, age 62±13 years, CMR-based LVEF 44±12%) 
underwent VT ablation with integration of CMR-derived scar (178±76 LV mapping 
LM 





B – Preprocessed MRI 
E – Merge 
LM 
C –  D – Aorta map injection 
Left main 
F – LV map 
G –  LV map 
and scar 
Figure 1. Integration of CMR-derived 3D scar reconstruction with electroanatomical maps
Before the procedure, the original CMR (panel A) is processed to create a three-dimensional scar recon-
struction (panel B). During the procedure the position of the left main is confi rmed by contrast injection 
(panel C) and tagged on the map (panel D). The CMR data are subsequently integrated with the electroana-
tomic map based on the left main landmark (panel E). Left ventricular mapping can then be focused on the 
CMR-derived scar (panels F and G).
LM indicates left main; LV, left ventricular.
98 Chapter 5
points; average registration error 3.8±0.6mm, example in Figure 1). Epicardial mapping 
was performed in 15 patients (13 NICM, 2 post-MI; 174±99 mapping points). Baseline 
and procedural data are provided in Table 1. A total of 110 distinct VTs (cycle length 
290±67ms) could be induced during the procedure. A ≥11/12 pacemap was obtained 
in 67 VTs (61%; median S-QRS 30ms, IQR 10-48ms). Entrainment was concealed with 
Figure 2. examples of critical isthmus sites projected on CMR-derived 3D scar reconstructions
RAO indicates right anterior oblique.
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Table 1. Baseline, procedural and CMR-derived data.
all patients (n=44) Post-infarction (n=23) nICM (n=21)
Age 62±13 67±9 56±14
Male 37 (84%) 20 (87%) 17 (81%)
NYHA functional class
 I 24 (55%) 12 (52%) 12 (57%)
 II 17 (39%) 10 (44%) 7 (33%)
 III 3 (7%) 1 (4%) 2 (10%)
LV ejection fraction, % 44±12 45±12 42±11
LV end-diastolic volume, mL 209 (181-253) 203 (174-233) 213 (189-257)
LV end-systolic volume, mL 109 (87-155) 102 (84-134) 124 (89-160)
History of atrial flutter/fibrillation 8 (18%) 5 (22%) 3 (14%)
BMI, kg/m² 27±5 28±5 27±4
Diabetes mellitus 7 (16%) 5 (22%) 2 (10%)
eGFR <60 mL/min 5 (11%) 3 (13%) 2 (10%)
Number of VTs induced
 1 17 (39%) 12 (52%) 5 (24%)
 2 13 (30%) 4 (17%) 9 (43%)
 ≥3 14 (31%) 7 (31%) 7 (33%)
Hemodynamic stability of VTs
 Only stable VT 12 (27%) 7 (30%) 5 (24%)
 Only unstable VT 18 (41%) 8 (35%) 10 (48%)
 Stable and unstable VT 14 (32%) 8 (35%) 6 (29%)
Mean cycle length of induced VTs, ms 292±65 292±63 292±68
Pericardial puncture 15 (34%) 2 (9%) 13 (62%)
Radiofrequency energy applications
 Only endocardial 31 (71%) 21 (91%) 10 (48%)
 Only epicardial 4 (9%) 1 (4%) 3 (14%)
 Endocardial and epicardial 8 (18%) 1 (4%) 7 (33%)
 None 1 (2%) 0 (0%) 1 (5%)
Procedural outcome
 Complete success 26 (59%) 15 (65%) 11 (52%)
 Partial success 9 (21%) 3 (13%) 6 (29%)
 Failure 5 (11%) 1 (4%) 4 (19%)
 Indeterminate 4 (9%) 4 (17%) 0 (0%)
Procedural duration, min 201±73 179±51 225±87
Fluoroscopy time, min 44±21 37±16 51±23
CMR scar volume, % of LV wall
 Total scar volume, % 16 (12-22) 18 (12-23) 15 (11-20)
 Core scar volume, % 6 (4-9) 7 (4-10) 6 (4-8)
 BZ volume, % 10 (7-12) 10 (8-12) 9 (7-13)
CMR scar area, % of endocardial LV
 Area of ≤50% transmural scar, % 15 (12-19) 13 (11-16) 17 (13-24)
 Area of 51-75% transmural scar, % 7 (4-10) 9 (5-12) 6 (4-9)
 Area of >75% transmural scar, % 6 (3-10) 7 (3-13) 4 (2-7)
BMI indicates body mass index; BZ, border zone; eGFR, estimated glomerular filtration rate; LV, left ventricu-
lar; NYHA, New York heart association; VT, ventricular tachycardia
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post-pacing interval equaling VT cycle length in 10 VTs (9%; median E-QRS 98ms, IQR 
61-133ms). Thirty-one VTs (28%) slowed and terminated during ablation (median E-QRS 
before ablation 96ms, IQR 37-126ms; median time to termination 9sec, IQR 6-11sec). 
Based on these findings, critical isthmus sites could be identified in 78 of 110 VTs (71%) 
at the following locations: LV endocardium (46 VTs, 59%), epicardium (16 VTs, 21%), 
right ventricular septum (7 VTs, 9%), aortic root (5 VTs, 6%), both aortic root and LV 
endocardium (2 VTs, 3%), both right ventricular endocardium and epicardium (1 VT, 1%) 
and anterior cardiac vein (1 VT, 1%). Complete procedural success was achieved in 26 
patients (59%), partial success in 9 (21%), failure in 5 (11%), and the acute outcome was 
indeterminate in 4 (9%) due to non-inducible clinical VT prior to ablation.
Scar transmurality, signal intensity and distance to core-BZ transition at critical 
isthmus sites
The mapping points at critical isthmus sites were successfully projected on the CE-CMR-
derived 3D scar reconstructions (examples in Figure 2). One epicardial VT originated 
from the right ventricular outflow tract and was excluded from further analyses. Sites 
with a ≥11/12 pacemap had a scar transmurality of 66±22%, compared with an average 
scar transmurality in the same patients of 59±12% (p=0.005, Figure 3). The difference 
in transmurality was larger at concealed entrainment sites (concealed entrainment 
76±16% vs. average 62±10%, p=0.024) and termination sites (termination 70±21% vs. 
average 62±12%, p=0.018).
The scar SI at critical isthmus sites was higher than the average scar SI in the same 
patients (≥11/12 pacemap 68±24% vs. average 59±16%, p=0.001; concealed entrain-
ment 72±21% vs. average 58±15%, p=0.074; termination 69±21% vs. average 59±15%, 
p=0.010; Figure 3).
The median distance to >75% transmural scar was 1.5mm (IQR, 0.0-5.6mm) at ≥11/12 
pacemaps, 0.0mm (IQR, 0.0-3.0mm) at concealed entrainment sites and 1.8mm (IQR, 
0.0-3.8mm) at termination sites (Figure 4). The critical isthmus sites clustered around the 
core-BZ transition, with a median distance to the transition of 3.7mm (IQR, 1.5-7.0mm) at 
≥11/12 pacemaps, 1.9mm (IQR, 0.0-2.6mm) at concealed entrainment sites and 2.5mm 
(IQR, 1.1-4.2mm) at termination sites.
Scar characteristics at exit and isthmus sites
Based on pacemapping, exit sites could be identified in 60 VTs and central isthmus sites in 
6 VTs. Scar transmurality and SI were higher at pacemapping-based central isthmus and 
exit sites, compared to the average (Figure 5). The differences were more pronounced at 
central isthmus sites (transmurality 78±14% vs. average 64±8%, p=0.051; SI 77±17% vs. 
average 59±6%, p=0.012), than at exit sites (transmurality 65±23% vs. average 59±12%, 
p=0.019; SI 67±25% vs. average 59±17%, p=0.004).
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Of the 31 termination sites, 16 (52%) were consistent with an exit site and 15 (48%) 
with a central isthmus site. Scar transmurality was above average at central isthmus sites 
(75±22% vs. 60±13%, p=0.008), but not at exit sites (66±19% vs. 63±10%, p=0.58). Simi-
larly, SI was above average at central isthmus sites (74±21% vs. 56±13%, p=0.006), but 
not at exit sites (65±21% vs. 62±15%, p=0.54). The number of concealed entrainment 
sites was too small for subgroup analyses.
nonischemic cardiomyopathy vs. post-myocardial infarction
At ≥11/12 pacemaps and termination sites, the CMR-derived scar characteristics (includ-
ing scar transmurality, SI, distance to >75% transmural scar and distance to core-BZ 
transition) were not significantly different between patients with NICM or prior MI (all 
p>0.05, data not shown).
CMR-based identification of critical isthmus sites
The CMR-derived scar area (median 24% of LV, IQR 16-30%) contained 77% of ≥11/12 
pacemap sites, 90% of concealed entrainment sites and 90% of termination sites (Figure 























































































































































Figure 3. Scar transmurality and signal intensity at critical isthmus sites.
Scar transmurality and SI at critical isthmus sites compared to the average scar transmurality and SI in the 
same patient. Values are displayed as mean±standard deviation.
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13% of LV, IQR 7-19%) included only 56% of ≥11/12 pacemap sites, but still 100% of 
concealed entrainment sites and 77% of termination sites.
In post-MI patients the areas within 5mm of >75% transmural scar, within 5mm of the 
core-BZ transition and the low bipolar voltage areas were limited in size and contained 
the majority of LV endocardial critical isthmus sites (Figure 6B).
For patients with NICM the areas within 5mm of both >75% transmural scar and 
core-BZ transition (median 13% of LV, IQR 6-19%), and the LV endocardial low unipolar 
voltage area (median 11% of LV, IQR 2-16%) were comparably small and contained the 
majority of LV endocardial critical isthmus sites (Figure 6C). The LV epicardial low bipolar 
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Figure 4. Distance from 
critical isthmus sites to 
>75% transmural scar and 
the core-BZ transition.
The distance from critical 
isthmus sites to >75% trans-
mural scar is displayed in 
panel A, and the distance 
to the core-BZ transition in 
panel B. Panel C illustrates 
the remarkable bell-shaped 
distribution of critical isth-
mus sites around the core-
BZ transition.
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and unipolar voltage areas with abnormal electrograms were large (median 27% of LV, 
IQR 15-41% and median 43% of LV, IQR 25-65%, respectively), while the area within 5mm 
of both >75% transmural scar and core-BZ transition was smaller (median 12% of LV, 
IQR 6-19%) and contained the majority of epicardial entrainment and termination sites 
(Figure 6D).
CMR-derived scar characteristics, VT characteristics and outcome
Univariate analysis revealed that total scar, core and BZ volumes, and areas of 51-75% 
and >75% transmural scar were associated with slower induced VTs (supplemental Table 
1). In a multivariate model including scar transmurality areas, only the area of >75% 
transmural scar remained associated with VT cycle length (+17ms per 5cm2, 95% con-
fidence interval 7-27ms, p=0.001). In a multivariate model including the core and BZ 
volumes, only the BZ volume remained associated with VT cycle length (+20ms per 5mL 
BZ, 95% confidence interval 9-32ms, p=0.001). BZ volume and area of >75% transmural 
scar were interrelated (R2 0.50, p<0.001) and became non-significant if both parameters 
were included in a model. None of the overall scar characteristics were associated with 





































































































































































Figure 5. Scar transmurality and signal intensity at central isthmus and exit sites
Scar transmurality and SI at central isthmus and exit sites compared to the average scar transmurality and 
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DISCUSSIon
In the present study critical VT isthmus sites in patients with prior MI or NICM were 
typically located in close proximity to the CMR-derived core-BZ transition and >75% 
transmural scar. In particular central isthmus sites had high scar transmurality and signal 
intensity compared to the average of the entire scar, suggesting that slow conducting 
pathways are located within relatively dense and transmural scar. The area within 5mm 
of both >75% transmural scar and the core-BZ transition covered a median of 13% of 
the LV, but contained all concealed entrainment sites and 77% of VT termination sites, 
allowing CE-CMR-based delineation of relatively small areas containing critical parts of 
the reentry circuit. The BZ volume and area of >75% transmural scar were positively cor-
related with the cycle length of induced VTs, providing further support to the premise 
that the BZ and >75% transmural scar are associated with slow conduction.
Scar transmurality and signal intensity
The current study comprises the largest series of patients undergoing VT ablation with 
CE-CMR-integration to date, and provides detailed analyses of CMR-derived scar param-
eters at VT-related sites. Critical isthmus sites were typically located within, or in close 
proximity to, >75% transmural scar in post-MI and NICM patients. In one prior study in 
23 post-MI patients, 62% of reentrant VT critical sites were identified in regions with 
>75% transmural scar8. Several studies have demonstrated a strong correlation between 
electrogram prolongation and scar transmurality2,4,7,8, which is in line with our finding 
that the area of >75% transmural scar correlated positively with the cycle length of 
induced VTs. Scar transmurality may therefore be an important aspect of the substrate 
for reentrant VT.
The scar density at critical isthmus sites is reported in only one study in 9 patients 
with ischemic VT, in which 71% of VT isthmus sites were located in the infarct core and 
29% in the BZ.7 All critical sites in the BZ were in an area of transmural infarct, with SI 
slightly lower than the cutoff defining core infarct. In the present study, the remarkable 
bell-shaped distribution of critical isthmus sites around the core-BZ transition suggests 
that the 50% of maximal SI threshold may indicate a critical mix between fibrosis and 
viable myocytes that allows for slow conduction and thereby, reentrant VT.
CMR-derived BZ channels through higher SI scar areas have been correlated with 
critical isthmus sites.5,6,12 Notably, in the present study we observed relatively high SI at 
critical isthmus sites, contradicting the premise that VT isthmuses manifest as relatively 
low SI channels on CE-CMR.
Prior investigations demonstrated differences in scar features between patients with 
NICM and prior MI. One study demonstrated a lower LGE SI in patients with atypical LGE 
patterns, compared to patients with infarct LGE pattern, suggesting a higher scar den-
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sity in post-MI patients.13 A study in 33 patients with NICM or prior MI who underwent 
VT ablation showed that patients after MI had more pronounced EAM-based conduc-
tion delay than patients with NICM.14 In the current study we could demonstrate that, 
although overall scar characteristics may be different, CMR-derived scar characteristics 
at critical isthmus sites were similar between patients with prior MI or NICM.
CMR-based identification of the area of interest
We could demonstrate the added value of CMR-based scar characteristics for identifica-
tion of areas containing critical isthmus sites during VT ablation. A limited area within 
5mm of both >75% transmural scar and core-BZ transition encompassed all concealed 
entrainment sites and 77% of termination sites, which are considered to be reliable 
markers for critical isthmus sites. This area may therefore serve as a target area for 
substrate-guided ablation approaches. Only 56% of ≥11/12 pacemap sites was located 
in these regions. However, ≥11/12 pacemaps may also be recorded in the vicinity of 
exit sites and may therefore be less accurate. Importantly, the CMR-derived target area 
can be displayed and used as a guide for ablation using single landmark-based image 
integration without extensive electroanatomical substrate mapping.
Limitations
No critical isthmus sites could be identified in 29% of VTs, which may be due to intramu-
ral reentry circuits, epicardial reentry circuits in patients who did not undergo epicardial 
mapping, or epicardial reentry circuits that could not be mapped due to epicardial fat.
Pacemapping is considered to be a less accurate technique for defining critical isthmus 
sites, in particular if no S-QRS delay is observed. Therefore we have stratified the analysis 
for different techniques to identify critical isthmus sites and for different E/S-QRS delays.
Scar transmurality and signal intensity were calculated for a 5mm-radius transmural 
cylinder and therefore, they do not depend on the endocardial or epicardial location. 
The present data can thus not be used to predict whether an endocardial or epicardial 
ablation procedure will be successful.
Data from endocardial and epicardial critical isthmus sites were pooled, since the 
distance to >75% transmural scar and core-BZ transition did not differ between endo-
cardial and epicardial pacemapping-based or termination-based critical isthmus sites in 
patients with NICM.
Clinical implications
Based on the present findings, CMR may be used to guide to areas that are likely to 
contain critical isthmus sites. Within these areas, ablation target sites may be further 
specified (e.g., based on electrogram characteristics or pace-mapping). Importantly, the 
CMR-derived area of interest is available before extensive substrate mapping and not 
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limited by intramural or subepicardial location of scars, or by epicardial fat. Moreover, it 
is relatively small compared to low voltage areas, in particular to epicardial low voltage 
areas in NICM. VT cycle length was not different between VTs with and without an iden-
tifiable critical isthmus site (294±65ms vs. 282±70ms, p=0.40), indicating that both slow 
and fast VTs are represented in the analysis. CMR may be particularly useful if no or only 
limited mapping time is available for poorly tolerated fast VT. Future prospective studies 
are required to assess whether CMR guidance to preselected regions that are likely to 
contain critical isthmus sites may improve the efficiency and efficacy of VT ablation.
ConCLUSIon
In ischemic and nonischemic VT, critical parts of the reentry circuit are typically located 
in close proximity to >75% transmural scar and the core-BZ transition. The area within 
5mm of both >75% transmural scar and core-BZ transition contained all concealed en-
trainment sites and 77% of termination sites. These findings suggest that CMR-derived 
scar characteristics may be used to guide to critical isthmus sites during VT ablation.
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Supplemental Table 1. Relation of CMR features with average cycle length of induced VTs
effect size (95%CI) p
Univariate analysis
Total scar volume, per 5 mL +12 ms (5 - 19ms) 0.001
Core scar volume, per 5 mL +22 ms (6 - 39ms) 0.01
Border zone volume, per 5 mL +20 ms (9 - 32ms) 0.001
Area of ≤50% transmural scar, per 5 cm2 -1 ms (-7 - 5) 0.77
Area of 51-75% transmural scar, per 5 cm2 +19 ms (3 - 35ms) 0.023
Area of >75% transmural scar, per 5 cm2 +17 ms (7 - 27ms) 0.001
Multivariate model 1
Core scar volume, per 5 mL -4 ms (-32 - 24) 0.77
Border zone volume, per 5 mL +23 ms (3 - 43) 0.027
Multivariate model 2
Area of ≤50% transmural scar, per 5 cm2 +1 ms (-6 - 7) 0.86
Area of 51-75% transmural scar, per 5 cm2 - 1 ms (-28 - 25) 0.91
Area of >75% transmural scar, per 5 cm2 +18 ms (1 - 34) 0.039
Multivariate model 3
Border zone volume, per 5 mL +13 ms (-3 - 29) 0.101
Area of >75% transmural scar, per 5 cm2 +9 ms (-5 - 22) 0.188
Supplemental Table 2. Relation of CMR features with number of induced VTs
effect size (95%CI) p
Univariate analysis
Total scar volume, per 5 mL +0.04 VT (-0.28 - 0.36) 0.81
Core scar volume, per 5 mL +0.05 VT (-0.68 - 0.77) 0.89
Border zone volume, per 5 mL +0.08 VT (-0.44 - 0.60) 0.76
Area of ≤50% transmural scar, per 5 cm2 -0.07 VT (-0.31 - 0.18) 0.60
Area of 51-75% transmural scar, per 5 cm2 -0.12 VT (-0.82 - 0.57) 0.72
Area of >75% transmural scar, per 5 cm2 +0.22 VT (-0.22 - 0.66) 0.32
Supplemental Table 3. Relation of CMR features with inducibility of VT after ablation
odds ratio (95%CI) P
Univariate analysis
Total scar volume, per 5 mL 1.11 (0.87 - 1.41) 0.41
Core scar volume, per 5 mL 1.24 (0.72 - 2.15) 0.44
Border zone volume, per 5 mL 1.18 (0.79 - 1.75) 0.42
Area of ≤50% transmural scar, per 5 cm2 0.98 (0.81 - 1.19) 0.81
Area of 51-75% transmural scar, per 5 cm2 1.31 (0.77 - 2.24) 0.32
Area of >75% transmural scar, per 5 cm2 1.23 (0.87 - 1.72) 0.24
CMR-Identified VT Isthmus Sites 111
5
Supplemental Table 4. Relation of CMR features with VT recurrence during follow-up
hazard ratio (95%CI) P
Univariate analysis
Total scar volume, per 5 mL 0.96 (0.79 - 1.16) 0.67
Core scar volume, per 5 mL 0.73 (0.45 - 1.18) 0.20
Border zone volume, per 5 mL 1.06 (0.77 - 1.46) 0.74
Area of ≤50% transmural scar, per 5 cm2 0.87 (0.69 - 1.09) 0.22
Area of 51-75% transmural scar, per 5 cm2 0.93 (0.60 - 1.43) 0.73
Area of >75% transmural scar, per 5 cm2 0.94 (0.72 - 1.23) 0.66
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Specific 12-lead ECG criteria have been reported to predict an epicardial site of origin 
(SoO) of induced ventricular tachycardias (VTs) in left ventricular nonischemic cardio-
myopathy (NICM).
objectives
This study aimed to (1) determine the value of ECG criteria to predict an epicardial SoO 
of clinically documented VTs, (2) analyze the effect of VT cycle length (CL) and antiar-
rhythmic drugs on the accuracy of ECG criteria, and (3) assess interobserver variability.
Methods
In 36 consecutive NICM patients (age 58±16y, 75% male) who underwent combined 
endocardial/epicardial VT ablation, all clinically documented and induced right bundle-
branch block (RBBB) VTs were analyzed for previously reported ECG criteria to determine 
the SoO, as defined by ≥11/12 pacemap, concealed entrainment, and/or VT termination 
during ablation.
Results
In 21 patients with clinically documented (25mm/s) RBBB VT, none of the ECG criteria 
differentiated between patients with and without an epicardial SoO. In induced VTs 
(100mm/s), 2/4 interval criteria differentiated between an endocardial and epicardial 
SoO for slow VTs (CL>350ms) and 2/4 criteria in patients on amiodarone, but none for 
fast VTs (CL≤350ms) or those off amiodarone. The Q-wave in lead I was the most accurate 
criterion for an epicardial SoO (sensitivity, 88%; specificity, 80%).
In both clinically documented and induced VTs, interobserver agreement was poor for 
pseudodelta wave and moderate for other criteria.
Conclusion
When applied to clinically documented VTs, no ECG criterion could differentiate between 
patients with and without an epicardial SoO. Published interval-based ECG criteria do 
not apply to fast VTs and patients off amiodarone.
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InTRoDUCTIon
In patients with ventricular tachycardia (VT) due to nonischemic cardiomyopathy 
(NICM), the substrate for VT is frequently—but not always—located intramurally or sub-
epicardially.1 Endocardial ablation and/or epicardial ablation may therefore be required 
to abolish VT. Prior studies have demonstrated that 12-lead ECG criteria can identify VTs 
with an epicardial site of origin (SoO), suggesting a need for epicardial access.2-4
Reported ECG criteria have been assessed for relatively slow VTs (average cycle length 
[CL] >390-400 ms4,5) on electrophysiology recording systems with electronic calipers at 
a sweep speed of 100 mm/s,2-4 but their accuracy has not been evaluated on 25mm/s 
12-lead ECGs of clinically documented VTs, which may be more relevant for planning 
the ablation approach.
In addition, the effect of VT CL and antiarrhythmic drug (AAD) use on the accuracy 
of ECG criteria has not been analyzed. In particular, interval criteria that depend on the 
determination of the VT QRS onset, preceded by an isoelectric interval, and the “earliest 
fast deflection” in precordial leads may be less accurate for fast VTs and prone to a high 
interobserver variability, thereby limiting its practical use.
The aims of the present study were to (1) determine the value of the reported ECG 
criteria when applied to 25 mm/s 12-lead ECGs of clinically documented VTs, (2) analyze 




Consecutive patients with NICM who underwent combined endocardial and epicardial VT 
ablation at the Leiden University Medical Center between 2007 and 2012 were included. 
The study excluded patients with coronary artery disease (>50% stenosis), congenital 
heart disease, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardio-
myopathy, left ventricular noncompaction cardiomyopathy, restrictive cardiomyopathy, 
(sub)acute myocarditis, cardiac sarcoidosis, tachycardia-induced cardiomyopathy, or 
primary valvular disease. All patients were treated according to the clinical institutional 
protocol.
In patients undergoing elective VT ablation, AADs were discontinued for ≥5 half-lives, 
with the exception of amiodarone. Patients were admitted the day before the procedure 
and monitored with implantable cardioverter defibrillator therapy programmed off to 
allow recording of 12-lead ECGs of spontaneous VTs. Effort was taken to obtain 12-lead 
ECGs of all spontaneous VTs.
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electrophysiologic evaluation
Programmed electrical stimulation was performed under conscious sedation or gen-
eral anesthesia (3 drive CL [600, 500, and 400ms], 1-3 ventricular extrastimuli [coupling 
interval ≥200ms], 2 right ventricular [RV] sites, and burst pacing, with isoproterenol 
[2-10µg/min] when necessary). The positive end point for stimulation was induction of 
a sustained monomorphic VT lasting for >30 seconds or requiring termination because 
of hemodynamic compromise.
electroanatomical mapping and ablation
Epicardial access was obtained through a subxiphoid puncture. Electroanatomical map-
ping (EAM) was performed using a 3.5mm irrigated-tip NaviStar ThermoCool catheter 
(Biosense Webster Inc., Diamond Bar, CA, USA) and the CARTO™ system. Limited EAM 
of the aortic root was performed, and the left main coronary artery position, confirmed 
by undiluted contrast injection through the mapping catheter, was tagged on the map. 
The left main landmark and the surface registration tool were used to integrate the 
CT-derived coronary artery anatomy and epicardial fat thickness with the EAM.6,7 The 
left ventricle (LV) was mapped retrogradely via the aorta, and the RV was mapped if 
indicated. After endocardial mapping, epicardial mapping of the region of interest was 
performed.
Ablation target sites were identified based on activation mapping and entrain-
ment mapping for stable VT. For unstable VT, the area of interest was identified by 
substrate mapping and pace mapping. Then, VT was reinduced and briefly mapped in 
an attempt to identify diastolic activity and terminate the VT by ablation. In addition, 
limited substrate-based ablation was performed, targeting fragmented electrograms 
and late potentials in areas presumed to be related to VT based on pace, activation and 
entrainment mapping. Radiofrequency (RF) energy was applied at 30-45W (maximum 
temperature, 45°C; flow, 20-30 mL/min; 60 seconds) at endocardial sites and up to 50W 
(flow 20mL/min) at epicardial sites.
VT morphology and eCG criteria
Clinically documented and induced sustained monomorphic VTs were categorized as 
right or left bundle branch block-like (RBBB or LBBB) morphology (defined as predomi-
nant R or S in lead V1), inferior or superior axis (predominant R or S in lead aVF), left or 
right axis (predominant R or S in lead I), and by precordial transition (first lead with a 
predominant R or S for LBBB and RBBB VTs, respectively). The ECG features assessed for 
all RBBB-like morphology VTs, as previously described2-4, were:
- QRS duration: interval from the earliest ventricular activation to the offset of the QRS 
in the precordial leads.
- Diastolic interval: VT CL minus QRS duration.
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- Pseudodelta wave (PDW): interval from the earliest ventricular activation to the 
onset of the earliest fast deflection in any precordial lead.
- Intrinsicoid deflection time in V2 (IDT): interval from the earliest ventricular activa-
tion to the peak of the R wave in V2.
- Shortest RS complex (SRS): interval from the earliest ventricular activation to the 
nadir of the first S wave in any precordial lead.
- Maximum deflection index (MDI): interval from the earliest ventricular activation to 
the peak of the largest amplitude deflection in each precordial lead (taking the lead 
with the shortest time) divided by the QRS duration, as described in patients with 
idiopathic VT.5
- Q wave in lead I (Q-I): initial negative deflection in lead I, occasionally preceded by a 
short isoelectric segment.
- Q waves in inferior leads (Q-INF): initial negative deflections in lead II, III, and aVF, 
occasionally preceded by a short isoelectric segment.
- Absence of Q waves in inferior leads (Abs-Q-INF): initial positive deflection in lead II, 
III, or aVF, occasionally preceded by a short isoelectric segment.
Previously published cutoff values were applied (≥34 ms for PDW, ≥85 ms for IDT, ≥121 
ms for SRS, and ≥0.45 for MDI).2 The PDW, IDT, SRS, and MDI are further referred to as 
“interval” criteria, and the Q-wave criteria are referred to as “morphology” criteria. For 
the Q-I and Abs-Q-INF criteria, only inferior-axis VTs were analyzed, and for the Q-INF 
criterion, only superior-axis VTs were analyzed.
Clinical VTs that were documented on a 25mm/s, 10mm/mV 12-lead ECG were 
analyzed using pens and manual calipers. Induced VTs were analyzed using electronic 
calipers on an electrophysiologic recording system (Prucka CardioLab EP; GE Healthcare, 
Waukesha, WI, USA) at a sweep speed of 100mm/s and an amplification of 10mm/mV. All 
measurements were performed by one observer (SP) and repeated by another indepen-
dent observer (MRS) to analyze the interobserver reproducibility. Both observers were 
blinded to the SoO.
Site of origin
The SoO of a VT was defined as a site that was considered as ablation target site, with (1) 
the best pace map (≥11/12 leads match), (2) entrainment suggestive of an isthmus site (i.e., 
concealed entrainment with the postpacing interval equaling VT CL), and/or (3) VT slowing 
and termination during ablation. An induced VT was considered as a clinical VT if the 12-lead 
ECG showed an exact morphologic match with the clinically documented VT in ≥11/12 leads.
To analyze the value of ECG criteria, VTs with a SoO located at the epicardium or in the 
cardiac venous system were classified as epicardial VTs and those with a SoO at the LV en-
docardium as endocardial VTs. The analyses excluded VTs with a SoO located in the aortic 
sinus cusps and with both endocardial and epicardial sites fulfilling the definition of a SoO.
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eCG criteria and the need for an epicardial approach
To assess the value of the ECG criteria in standard 12-lead VT ECGs to predict the require-
ment for an epicardial approach, the following analyses were performed: (1) the presence 
of an epicardial SoO was compared between clinical VTs with positive vs negative ECG, 
(2) the presence of an epicardial SoO of any spontaneous or induced VT was compared 
between patients with positive vs negative ECG criteria for the clinically documented VT, 
and (3) the number of epicardial RF applications was compared between patients with 
positive vs negative ECG criteria to analyze the potential therapeutic consequences of 
ECG criteria.
Statistics
Statistical analyses were performed with SPSS 20 software (IBM, Armonk, NY, USA). The 
categoric variables are expressed as number (percentage), and continuous variables as 
mean ± standard deviation, or median and interquartile range (IQR) where appropriate. 
Fisher exact tests, χ2 tests and Mann-Whitney U tests were performed where applicable. 
For each ECG criterion, the sensitivity, specificity, positive predictive value (PPV), and 
negative predictive value (NPV) were calculated.
To analyze the effect of VT CL and AADs on the accuracy of the ECG criteria, the VTs 
were categorized according to CL (prespecified as ≤350ms or >350ms) and according to 
amiodarone use.
The percentage interobserver agreement and the Cohen’s Kappa value were calcu-
lated for all criteria. The interobserver variability was analyzed by Bland-Altman plots for 
continuous parameters. The mean bias (mean difference between observer 1 and 2) and 
the 95% limits of agreement are reported. All p values are 2-tailed, and a value of p < 0.05 
was considered to be statistically significant.
ReSULTS
Baseline characteristics
A total of 36 NICM patients (age, 58±16 years; LV ejection fraction, 42±14%) underwent 
combined endocardial and epicardial VT ablation (Table 1); of these, 13 (36%) had VT 
recurrence after prior endocardial ablation, 6 (17%) were rescheduled for combined 
endocardial and epicardial VT ablation after a failed endocardial procedure, and the 
remaining 17 (47%) had no prior VT ablation.
Clinically documented VTs
Before ablation, 34 distinct VTs in 25 patients were documented on 12-lead ECGs (ex-
amples in Figure 1). Of these VTs, 18 (53%) were recorded in our center and 16 (47%) in 
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other centers. Six VTs (18%) were documented while the patient was on a class I AAD, 6 
(18%) on sotalol, 20 (59%) on amiodarone, and 1 (3%) on a class IV AAD. Four patients 
(12%) were on 2 AADs, 25 (74%) on 1 ADD, and 5 (15%) were off AADs.
Mapping and ablation
A total of 111 distinct VTs (CL 342±89ms) were induced in 34 patients; of these, 66 VTs 
(59%) in 32 patients (94%) had RBBB-like morphology and were further analyzed. A SoO 
could be identified for 45 of these 66 VTs (68%) in 28 of 32 patients (88%). A ≥11/12 
pace map was obtained for 34 VTs (52%), with a median S-QRS interval of 40ms (IQR, 
15–65ms). Entrainment was concealed, and the postpacing interval was equal to the VT 
CL in 3 VTs (5%), with S-QRS intervals of 9%, 17%, and 46% of VT CL. During ablation, 21 
VTs (32%) slowed and terminated without a premature ventricular contraction, with a 
median E-QRS percentage of VT CL before ablation of 24% (IQR 14%–35%) and median 




LV ejection fraction, % 42±14
LV end-diastolic volume, mL 162±48
History of atrial flutter/fibrillation 8 (22%)
eGFR < 60 mL/min/1.73m2 2 (6%)
Anti-arrhythmic drugs
 Class I 5 (14%)
 Class II 20 (56%)
 Class III–Sotalol 8 (22%)
 Class III–Amiodarone 16 (44%)
 Class IV 0 (0%)
Number of VTs induced 3 (1–4)
BBR VT 1 (3%)
Unstable induced VT 27 (75%)
Mean CL of induced VTs, ms 346±74
Endocardial RF applications 25 (69%)
Epicardial RF applications 22 (61%)
Acute outcome
 Complete success 11 (31%)
 Partial success 16 (44%)
 Failure 9 (25%)
BBR, bundle-branch re-entry; CL, cycle length; LV, left ventricular; eGFR, estimated glomerular filtration rate; 
RF, radiofrequency energy; VT, ventricular tachycardia
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Figure 1. examples of induced and clinically documented VTs
Panel A: Examples of clinically documented spontaneous VTs displayed at 25 mm/s. Panel B: Examples of 
induced VTs displayed at 100 mm/s. Panel C: Measurements of observers 1 and 2 for one fast and one slow 
VT. For the fast VT, the onset of the QRS complex is defi ned diff erently by observer 1 and 2, aff ecting all 
interval criteria. For the slow VT, a slurred onset of the QRS complex is observed (indicated with triangles), 
which may be diffi  cult to detect if VT is faster, with a potential overlap with the preceding T-wave. CL, cycle 
length; SoO, site of origin.
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termination time of 11 seconds (IQR, 8–29 seconds). The SoOs were classifi ed as epicar-
dial in 15 patients (54%), as endocardial in 6 (21%), and as endocardial and epicardial 
SoO in 7 (25%). Epicardial ablation was performed in 22 patients (61%).
eCG criteria applied to clinically documented VTs
Of 66 induced RBBB VTs, 19 (29%) corresponded to a clinically documented VT. Twelve 
of these 19 clinical VTs (63%) had a SoO at the LV epicardium, 3 (11%) at the LV endo-
cardium, 1 (4%) in the LV and at the epicardium (termination In the LV, best pacemap at 
the epicardium), and 1 (4%) in the aortic sinus cusps. No SoO could be identifi ed for 2 
VTs (7%). The 15 VTs with a SoO categorized as LV endocardial or epicardial were further 
analyzed.
When applied to the clinically documented VTs, none of the interval criteria diff ered 
between endocardial and epicardial VTs (Table 2). The value of the Q-wave criteria could 
not reliably be assessed due to the limited number of endocardial and epicardial VTs in 
the inferior and superior axes subgroups.
The percentage of patients with an epicardial SoO of at least 1 RBBB VT was not 
signifi cantly diff erent between patients with positive or negative ECG criteria for the 
clinical VTs (Table 2). Depending on the applied criterion, 33% to 100% of patients with 
a negative criterion for the clinically documented VT had at least 1 epicardial RBBB VT 
necessitating an epicardial approach.
The number of epicardial RF applications tended to be higher in patients with positive 
vs negative criteria for clinical VTs, which was statistically signifi cant for the Q-I criterion 
(Table 2), suggesting that the substrate may be more amenable to epicardial ablation in 
patients with a Q-wave in lead I during VT.
eCG criteria applied to induced VTs
For induced RBBB VTs, the SoO were located at the epicardium for 26 of 66 VTs (39%), 
at the endocardial LV for 11 VTs (17%), at the epicardium and at the endocardial LV for 
4 VTs (6%), in the aortic root for 2 VTs (3%), and in the anterior cardiac vein for 2 VTs 
(3%). No SoO could be identifi ed for the remaining 21 VTs (32%). The 39 VTs with a SoO 
categorized as LV endocardial or epicardial were further analyzed.
When measured in these induced VTs (examples in Figure 1), the PDW (p=0.040), IDT 
(p=0.008), SRS (p=0.022), and MDI (p=0.034), but not the QRS duration (p=0.32), diff ered 
signifi cantly between endocardial and epicardial VTs (Figure 2). Of interest, the ECG 
criteria were similar for epicardial VTs and VTs of unknown origin (all p>0.05, interval 
criteria displayed in Figure 2). The most accurate ECG criteria to distinguish epicardial 
from endocardial VTs were Q-I for inferior-axis VTs (sensitivity, 88%; specifi city, 80%) and 
Q-INF for superior-axis VTs (sensitivity, 73%; specifi city, 67%). The diagnostic accuracy of 
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effect of VT cycle length
For induced slow VTs (CL ≥350ms, n=16), the QRS duration, IDT and the SRS were sig-
nificantly longer for epicardial VTs compared with endocardial VTs (Table 3). A trend was 
observed for a longer PDW and MDI. However, for fast VTs (CL <350ms, n=23), none of 
the interval criteria differed significantly between endocardial and epicardial VTs. The 
QRS duration was similar for slow and fast VTs (235±43 vs 213±41ms, p=0.19), but the 
diastolic interval was significantly longer in slow VTs than in fast VTs (median, 228ms 
[IQR, 174-302ms] vs 58ms [IQR, 27-92ms], p<0.001).
effect of amiodarone use
For the 15 induced VTs in patients on amiodarone, the IDT and SRS were significantly 
longer in epicardial VTs than in endocardial VTs. The QRS duration, PDW and MDI also 
tended to be longer in epicardial VTs (Table 4). For the 24 VTs in patients off amiodarone, 
however, none of the interval criteria could distinguish epicardial from endocardial VTs. 
The QRS duration was similar in patients on and off amiodarone (228±53ms vs 218±36ms, 
p=0.62); however, compared with patients off amiodarone, patients on amiodarone 
had a significantly longer CL (422±91 ms vs 306±89ms, p<0.001) and median diastolic 



































































































































































































































































Figure 3. accuracy of eCG criteria applied to induced VTs
NPV, negative predictive value; PPV, positive predictive value.
* Only for inferior-axis VTs ** Only for superior-axis VTs
Table 3. effect of VT cycle length on the accuracy of eCG criteria in induced VTs
Slow VT (CL ≥350ms, n=16) Fast VT (CL <350ms, n=23)
epicardial vs. endocardial VTs
(n=11 vs. n=5)
p
epicardial vs. endocardial VTs
(n=17 vs. n=6)
p
QRS, ms 247±45 vs. 208±26 0.038 214±25 vs. 212±75 0.92
PDW, ms 55±22 vs. 31±18 0.052 38±19 vs. 28±17 0.20
IDT, ms 130±38 vs. 61±19 0.002 108±26 vs. 94±52 0.81
SRS, ms 175±28 vs. 118±18 <0.001 133±23 vs. 119±65 0.32
MDI 0.46±0.08 vs. 0.39±0.07 0.12 0.47±0.07 vs. 0.42±0.09 0.16
Q-I, %* 7/8 (88%) vs. 1/3 (33%) 0.15 8/9 (89%) vs. 0/2 (0%) 0.055
Abs-Q-INF, %* 7/8 (88%) vs. 1/3 (33%) 0.15 6/9 (67%) vs. 2/2 (100%) 1.00
Q-INF, %† 2/3 (67%) vs. 1/2 (50%) 1.00 6/8 (75%) vs. 1/4 (25%) 0.22
Abbreviations as in Table 2. *Only for inferior-axis VTs †Only for superior-axis VTs
Table 4. effect of amiodarone on the accuracy of eCG criteria in induced VTs
VTs on amiodarone (n=15) VTs off amiodarone (n=24)
epicardial vs. endocardial VTs
(n=8 vs. n=7)
p
epicardial vs. endocardial VTs
(n=20 vs. n=4)
p
QRS, ms 242±43 vs. 211±61 0.12 220±34 vs. 208±52 0.79
PDW, ms 53±24 vs. 28±17 0.054 42±20 vs. 32±18 0.39
IDT, ms 123±37 vs. 71±34 0.009 114±31 vs. 94±57 0.63
SRS, ms 176±25 vs. 127±51 0.040 139±29 vs. 104±45 0.16
MDI 0.48±0.10 vs. 0.40±0.07 0.072 0.46±0.07 vs. 0.42±0.11 0.48
Q-I, %* 4/5 (80%) vs. 1/3 (33%) 0.46 11/12 (92%) vs. 0/2 (0%) 0.033
Abs-Q-INF, %* 5/5 (100%) vs. 2/3 (67%) 0.11 8/12 (67%) vs. 2/2 (100%) 1.00
Q-INF, %† 2/3 (67%) vs. 2/4 (50%) 1.00 6/8 (75%) vs. 0/2 (0%) 0.13
Abbreviations as in Table 2. *Only for inferior-axis VTs †Only for superior-axis VTs
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Because the subgroups of endocardial and epicardial VTs with inferior and superior 
axes were small, the effects of VT CL and amiodarone on the Q-wave criteria could not 
be reliably analyzed.
Interobserver variability of eCG criteria
Bland-Altman plots of interval criteria measurements are provided in Supplemental 
Figures 1 and 2. The mean bias for the interval criteria was high, and the 95% limits of 
agreement were wide for induced VTs and, in particular, for the clinically documented 
VTs (Table 5). The interobserver agreement for clinically documented and induced VTs 
was poor for the PDW, SRS, and MDI, but moderate or good for IDT, Q-I, and Q-INF.
DISCUSSIon
The clinical VT documentation in the present study demonstrated that the suggested 
ECG criteria could not reliably identify NICM patients who needed an epicardial ap-
proach. When applied to induced VTs on 100 mm/s electrophysiology recording system 
tracings, some ECG criteria proved useful for the identification of epicardial VTs, but not 
for all VT subgroups. Two of 4 interval criteria differed between induced endocardial 
and epicardial slow VTs (CL >350ms) and 2 of 4 criteria in patients on amiodarone, but 
none when applied to fast VTs (CL ≤350ms) or in patients off amiodarone. The Q-wave 
in lead I (Q-I) was the most accurate criterion. In clinically documented and induced VTs, 
the interobserver agreement was poor for the PDW but moderate for IDT, Q-I, and Q-INF.
Table 5. Interobserver variability and agreement

























































































QRS, ms 265±51 43 -33–119 NA NA 222±44 27 -41–96 NA NA
PDW, ms 18±15 27 -88–34 44% 0.08 39±22 4 -48–55 68% 0.37
IDT, ms 132±54 24 -62–110 85% 0.51 107±39 7 -42–56 82% 0.61
SRS, ms 172±56 25 -88–139 74% 0.38 141±40 19 -48–86 74% 0.51
MDI 0.46±0.11 0.02 -0.20–0.24 63% 0.26 0.44±0.09 0.02 -0.18–0.23 68% 0.36
Q-I* 31% NA NA 77% 0.42 66% NA NA 74% 0.44
Abs-Q-INF* 0% NA NA 100% 1.00 23% NA NA 86% 0.53
Q-INF† 50% NA NA 93% 0.86 48% NA NA 84% 0.68
Abbreviations as in Table 2.
*Only for inferior-axis VTs (induced VTs, n=35; clinically documented VTs, n=13).
†Only for superior-axis VTs (induced VTs, n=31; clinically documented VTs, n=14).
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eCG criteria applied to clinically documented VTs: the need for an epicardial 
approach
Applying ECG criteria to the 12-lead VT ECG for the identification of a potential epicardial 
SoO has been considered to be useful for selection of patients who may benefit from 
epicardial ablation.2-4 To assist preprocedural planning, ECG criteria are typically applied 
to clinically documented VTs. However, this approach may have important limitations. 
First, measurements need to be performed on 25mm/s 12-lead ECGs, which may be less 
accurate than on 100mm/s recordings as used in the electrophysiology laboratory.
Second, not clinically documented VTs are frequently induced, which may originate 
from other parts of the scar and need to be targeted if noninducibility is pursued. In 
the current study, at least 1 VT originated from the epicardium in 79% of patients with 
induced RBBB VTs.
Third, 12-lead ECG morphology and thereby ECG criteria are particularly influenced by 
the VT exit site; however, the VT may be abolished by ablation at any part of the reentry 
circuit.
Based on the present data we conclude that, although potentially useful as a guide to 
the area of interest for VTs induced during the procedure, the ECG criteria do probably 
not allow identification of patients who are likely to benefit from an epicardial approach.
eCG criteria applied to induced VTs
When applied to induced VTs, most of the ECG criteria had a high PPV, indicating that an 
epicardial SoO may be likely when criteria are positive. All criteria have moderate and 
often even poor NPV, indicating that induced VTs may still originate and be targeted 
from the epicardium if the ECG criteria are negative. Interestingly, the ECG criteria did 
not differ between epicardial VTs and VTs of unknown origin, which is in line with prior 
observations,4 perhaps suggesting that most of these VTs may also be of epicardial 
origin. Thick layers of epicardial fat and the coronary arteries may have prevented the 
identification of some epicardial SoO.
In NICM, the effect of the VT CL and AADs on the accuracy of ECG criteria has not 
been analyzed. The initial reports on ECG criteria have included VTs with a mean CL of 
>400ms4 and 390ms.5 However, in patients with NICM currently considered for VT abla-
tion, fast VTs are frequently induced (CL 342±89ms in this study and CL 346±74ms in a 
recent report8), and therefore, evaluation of the accuracy of ECG criteria for fast VTs is 
important. All criteria rely on an accurate identification of the onset of the QRS complex, 
which may be particularly difficult to define when the QRS is broad, in the absence 
of an isoelectric interval, and when there is overlap with a previous T-wave, which is 
commonly observed in fast VTs. In the present study, the IDT and SRS differed between 
endocardial and epicardial slow (CL >350ms), but not fast, VTs (CL ≤350ms). The IDT and 
SRS also differed between endocardial and epicardial VTs in patients with amiodarone, 
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but not in patients without amiodarone. Although the number of RBBB inferior-axis VTs 
was limited, the Q-I criterion appeared not to be affected by VT CL or amiodarone use. 
The diastolic interval was significantly shorter in fast VTs and in patients off amiodarone, 
which may hamper determination of the QRS onset. Owing to the limited number of VTs, 
the independent effects of VT CL and amiodarone use could not be analyzed.
Interobserver agreement
Only one study in postmyocardial infarction patients reported interobserver agreement 
of ECG criteria for epicardial VTs.9 The interobserver agreement in the present study 
was particularly poor for the PDW criterion, as has been observed in postmyocardial 
infarction patients,9 and for the MDI, which relies on an accurate identification of the 
QRS onset, QRS offset, and maximum deflection in all precordial leads. In contrast, the 
IDT relies only on the identification of the onset of the QRS and the well-defined peak 
of the R wave in V2, perhaps explaining the relatively high interobserver agreement. 
The Q-wave criteria are typically easier to assess, with moderate to good interobserver 
agreement, but may be less clear when the onset of the QRS is difficult to define or when 
a putative initial R wave is very small.
Limitations
The number of patients and VTs was too small for analysis in some subgroups. Owing to 
inclusion of patients after endocardial ablation failure, it may be expected that the num-
ber of NICM patients with an epicardial SoO will be overrepresented. However, among 
the 32 patients with inducible RBBB VT, 9 of 14 patients (64%) who had not undergone 
prior ablation had an epicardial SoO compared with 13 of 18 patients (72%) who had 
undergone prior endocardial ablation (p=0.71).
The SoO could be identified for only 68% of induced RBBB VTs, with ≥1 identified SoO 
in 88% of patients with inducible RBBB VTs, which may be explained by the strict defini-
tion of a SoO, intramural reentry circuits, epicardial SoOs covered with epicardial fat, fast 
VTs without a reasonable pacemap, and other reasons.
Limb leads are typically placed on the torso in the electrophysiology lab, while the 
clinically documented VT may be recorded with the leads placed on the extremities. 
The resulting differences in extremity lead vectors may affect Q-waves, but were not 
analyzed in the present study.
ConCLUSIon
When applied to 25mm/s ECGs of clinically documented VTs, none of the ECG criteria 
could differentiate between patients with and without epicardial VTs. These data sug-
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gest that the ECG criteria do not allow identification of patients who are likely to benefit 
from a primary epicardial ablation approach. The VT CL and the use of AADs affect the 
accuracy of ECG criteria in induced VTs.
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Supplemental Figure 1. Interobserver 
variability of eCG criteria for clinically 
documented VTs
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Supplemental Figure 2. Interobserver vari-
ability of eCG criteria for induced VTs
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This study evaluates the influence of 3 therapeutic approaches on the incidence of 
pericarditis and atrial fibrillation (AF) following percutaneous epicardial mapping and 
ablation for ventricular tachycardia (VT).
Methods and Results
Eighty-five consecutive procedures (2006 to 2011) were retrospectively reviewed. After 
the first 17 procedures (20.0%), no steroids were administered. For the subsequent 30 
(35.3%), systemic steroids were administered intravenously or orally (IV/PO) while the 
last 38 (44.7%) were followed by intrapericardial steroid injection.
Compared to no steroids, the incidence of pericarditic chest pain was significantly 
reduced by intrapericardial steroids (58.8% vs. 21.1%, p=0.006), but not by IV/PO ste-
roids (58.8% vs. 43.4%, p=0.31). There was no significant difference in the incidence of 
pericarditic ECG with steroids (36.8, 30.0%, and 41.2% for intrapericardial, IV/PO and 
none, respectively). There was a non-significant reduced incidence of chest pain with 
ECG changes with steroids (13.2%, 10.0%, and 29.4% for intrapericardial, IV/PO and 
none, respectively). Radiofrequency applications (65.9% of procedures), did not affect 
the incidence of pericarditic ECG changes, pericarditic chest pain or pericarditis (all 
p>0.05). In 7 (8.3%) patients with no prior history of AF, AF was documented a median 
36 hours post procedure. Patients with pericarditic ECG tended to be at greater risk of 
AF (16.7 vs. 3.6%, p=0.091)
Conclusion
There is a high incidence of pericarditic chest pain and ECG changes following epicardial 
VT mapping and ablation. Pericarditic chest pain is significantly decreased by intraperi-
cardial steroids. Procedure-related AF is relatively frequent and tends to occur more 
commonly with pericarditic ECG changes.
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InTRoDUCTIon
Catheter ablation of ventricular tachycardia (VT) is increasingly employed for both 
idiopathic and scar-related etiologies.1 In particular, in patients with nonischemic 
cardiomyopathy, the substrate for VTs is often located intramurally or subepicardially 
and may require a percutaneous, transpericardial approach. In virtually all patients who 
undergo an epicardial procedure, pericarditis occurs to a variable extent as a result of 
local inflammation.4 This can manifest clinically from mild pericarditis to hemorrhagic 
pericardial effusion and, rarely, cardiac tamponade.4 If symptoms occur, patients may 
be treated with oral anti-inflammatory nonsteroidal and corticosteroid agents. Data 
on the pharmacokinetic profile of intrapericardially delivered agents has proven 
favorable suggesting that targeted local concentrations can be reached with minimal 
systemic concentrations (therefore reducing the potential risk of systemic side effects).4 
Intrapericardial corticosteroids and Hyaluronic Acid have been successfully used to 
treat recurrent noninfectious pericarditis5-8 and to prevent adhesions after open-chest 
cardiac surgery.9, 10  The intrapericardial instillation of 2 mg/kg of triamcinolone acetate 
after epicardial radiofrequency ablation was demonstrated to successfully prevent the 
occurrence of postprocedure pericarditis and adhesions in porcine animal.4 Prevention 
of adhesions may be important given the potential need to re-obtain access to the 
pericardial space due to recurrence of arrhythmia.
The occurrence of new onset atrial fibrillation (AF) after epicardial VT ablation was 
recently reported to be 19.5% within 7 days.13 In that study, all patients who developed 
AF had symptoms of pericarditis. Of note, episodes of AF after epicardial VT ablation 
may be accompanied by the risk for thromboembolic complications, as oral anticoagula-
tion is relatively contraindicated due to the risk for pericardial bleeding.
This study was thus designed to evaluate the influence of 3 therapeutic approaches 
on the incidence of pericarditis and AF following percutaneous epicardial mapping and 
ablation for VT.
MeThoDS
A total of 85 consecutive procedures in which epicardial mapping or mapping and 
radiofrequency ablation was performed for VT between 2006 and 2011 were retrospec-
tively reviewed. All patients were treated according to our standard clinical protocol and 
provided informed consent.
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access to the pericardial space
Prior to the procedure, oral anticoagulation was discontinued. On the day of the proce-
dure, all forms of heparin were withheld. Local anesthesia with conscious sedation was 
the standard approach for procedural analgesia. Femoral venous and arterial access was 
obtained and a quadripolar catheter was positioned at the right ventricular (RV) apex. 
The pericardial space was then entered via a transthoracic percutaneous subxyphoid 
puncture with a 17-gauge Tuohy needle. Under fluoroscopic guidance, contrast media 
was injected as the needle was advanced to the pericardium. Once access into the 
pericardial space was obtained, a guidewire was passed through the needle, over which 
a 6F introducer sheath was advanced. A 6F pigtail catheter was then introduced into 
the epicardial space to protect the sheath and the guidewire was removed. Intravenous 
heparin was then administered to allow for safe endocardial mapping and ablation.
Mapping and ablation Procedure
Prior to epicardial mapping, detailed endocardial mapping was performed to determine 
the epicardial area of interest in order to restrict epicardial mapping and minimize 
potentially painful manipulations. A 3.5mm irrigated-tip catheter (NaviStar ThermoCool, 
Biosense Webster Inc, Diamond Bar, CA, USA) was then inserted after replacing the 6F 
by an 11cm 8F introducer sheath (Cordis) and was maneuvered within the pericardial 
space for cardiac mapping and ablation. A 63 cm, 8.5F sheath (SLO St-Jude Medical) and 
subsequently a steerable 71 cm 8.5F sheath (Agilis NxT, medium curl, St-Jude Medical) 
was used in later procedures. The radiofrequency (RF) ablation generator used was the 
Stockert generator (Biosense-Webster Inc). Epicardial applications were delivered up to 
50W, flow rate 20ml/min with a temperature limit of 45°C, and delivered for up to 60 
seconds each. Fluid was removed after a maximum of 5 RF applications corresponding 
to an estimated amount of 100cc.
administration of anti-inflammatory agents
The therapeutic approach evolved over time from no steroid therapy to systemic steroids 
to intrapericardial steroids without overlap between the groups. At the end of the first 
17 procedures (20.0%), no steroids were administered. For the subsequent 30 (35.3%), 
systemic steroids were administered intravenously or orally (IV/PO) at a dose of 1mg per 
kg per day for 3 consecutive days. The last 38 (44.7%) procedures were followed by com-
plete fluid removal and intrapericardial steroid injection, consisting of triamcinolone ac-
etate (2mg/kg), which was injected in the pericardial space via a pigtail catheter and left 
in-situ by capping the pigtail. The pigtail was not placed under vacuum. Non-steroidal 
anti-inflammatory drugs (NSAIDS), in the form of diclofenac 50 mg every 8 hours, were 
offered on an as-needed basis to all patients who did not have contraindications.
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Postablation Care and evaluation
Standard post-operative monitoring was performed in all patients, consisting of the first 
24 hours in the coronary care unit and at least another 48 hours on the ward. Electrocar-
diograms (ECGs) were obtained immediately following the procedure and subsequently 
every 12 hours until discharge. Trans-thoracic echocardiography was performed prior to 
pigtail removal, and again 12 and 24 hours after pigtail removal.
Anticoagulation, where indicated, was restarted after removal of the pigtail catheter. 
In patients who developed AF, an early cardioversion at < 24 hours of AF duration was 
favored in order to avoid the need for anticoagulation. Otherwise, for persistent AF, 
anticoagulation was initiated ≥24 hours after pigtail removal.
Pericarditis definition
Pericarditis was defined as typical pericarditic chest pain (pleuritic, improved with sit-
ting upright) with acute pericarditic ECG changes (new widespread ST elevation or PR 
depression).
Statistical analysis
Statistical analyses were performed with SPSS version 20 (IBM, Somers, New York, USA). 
The continuous variables were expressed as number (percentage), mean ± SD or median 
(interquartile range) where appropriate. Chi-square tests, Fisher’s exact tests, Student’s t 
tests and Mann-Whitney U tests were performed where applicable. To analyze the effect 
of steroid treatment on pericarditic chest pain, pericarditic ECG changes and pericarditis, 
overall chi-square tests were performed to compare the three treatment groups. Then, 
two one-by-one comparisons were performed, applying the Bonferroni correction for 
multiple comparisons so that a p-value of p < 0.025 was considered to be statistically 
significant. For all other tests, a p-value of p < 0.05 was considered to be statistically 
significant.
ReSULTS
Eighty-five epicardial procedures were reviewed which were performed in 76 patients. 
Seven patients required a second epicardial procedure (4 of 7 within 2 weeks after the 
first procedure) and of those 7 patients, 2 underwent a third epicardial procedure 67 and 
84 days after the second procedure. The patient characteristics are presented in Table 1. 
Only 8 procedures (9.4%) were performed under general anesthesia.
Epicardial mapping alone was performed in 29 (34.1%) while 56 (65.9%) underwent 
mapping and ablation. A non-steerable long sheath (SR0 or SL0) was used in 22 cases 
(25.9%) while an Agilis sheath was used in 42 cases (49.4%). In the mapping only group, 
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epicardial ablation was not performed due to anatomical limitations (coronary arteries 
or thick fat layer), or because no epicardial ablation target site for VT could be identified.
In the first 17 procedures (20.0%), no steroids were administered. In the subsequent 
30 (35.3%), systemic steroids were administered IV or PO while in the last 38 (44.7%), 
intrapericardial steroids were given. On the ward, 62% of patients received NSAIDS 
for a variety of complaints including chest pain, pain at the pigtail insertion site but 
also headaches, back pain and others. The distribution of NSAIDS was the following: 4 
of 17 patients (24%) received NSAIDS who had received no steroids, 28 of 30 patients 
(93%) received NSAIDs who had received systemic steroids, and, 21 of 38 patients (55%) 
received NSAIDs who had received intrapericardial steroids (p < 0.001).
Pericarditis occurred after 15.3% of procedures. Pericarditic ECG changes alone, or 
typical pericarditic chest pain alone, were diagnosed in 20.0% and 21.2%, respectively. 
There was no age difference between the patients who developed pericarditis and those 
who did not, with mean ages of 57.6±17.3 vs. 58.9±15.1 years respectively (p=0.474). 
Clinical chest pain developed within 12 hours of the procedure while the ECG changes 
occurred within 20 hours at the latest.
The results of the influence of steroid therapy on the incidence of pericarditis are 
presented in figure 1. The incidence of pericarditic chest pain was significantly reduced 
if patients received intrapericardial steroids (21.1%) compared to no steroids (58.8%) 
(p=0.006). Systemic steroids administration did not significantly reduce the incidence 
of pericarditic chest pain (43.4% vs. 58.8% for patients receiving IV/PO steroids or no 
steroids, respectively, p=0.31). There was no significant difference in the incidence of 
pericarditic ECG with steroid therapy (36.8%, 30.0%, and 41.2% for intrapericardial, IV/









Age (years) 58 ±17 56 ±21 58 ±17 59 ±15
Male, n (%) 67 (79%) 16 (94,1%) 22 (73,3%) 29 (76,3%)
LVEF(%) 42 ±13 46 ±13 40 ±15 41 ±12
VT related to
 Ischemic CMP, n (%) 13 (15,3%) 1 (5,9%) 6 (20,0%) 6 (15,8%)
 DCM, n (%) 32 (37,6%) 8 (47,1%) 12 (40,0%) 12 (31,6%)
 Other structural heart disease, n (%) 26 (30,6%) 5 (29,4%) 8 (26,6%) 13 (34,2%)
 Idiopathic VT, n (%) 14 (16,5%) 3 (17,6%) 4 (13,3%) 7 (18,4%)
Beta-blocker therapy, n (%) 45 (52,9%) 8 (47,1%) 18 (60,0%) 19 (50,0%)
Amiodarone, n (%) 32 (37,6%) 6 (35,3%) 13 (43,3%) 13 (34,2%)
Other AAD, n (%) 38 (44,7%) 5 (29,4%) 15 (50,0%) 18 (47,4%)
ADD: anti-arrhythmic drug; CMP: cardiomyopathy; DCM: dilated cardiomyopathy; LVEF: left ventricular 
ejection fraction; VT: ventricular tachycardia
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PO or none, respectively). There was a non-significant reduced incidence of chest pain 
with ECG changes with steroids (13.2%, 10.0%, and 29.4% for intrapericardial, IV/PO or 
none, respectively. Results were similar when only first procedures were analyzed.
There was no statistical difference between mapping alone and mapping with abla-
tion in the incidence of pericarditic chest pain (44.8 vs. 32.1%, p=0.249), pericarditic ECG 
(34.5 vs 35.7%, p=0.910), or both chest pain and ECG changes (24.1 vs. 10.7%, p=0.103) 
as demonstrated in Figure 2.
The details relating to procedure duration are displayed in Table 2 including proce-
dure duration from time of sheath insertion to sheath removal (median 4h:01min, IQR 
3h:20min – 4h:40min),  procedural duration from pericardial puncture to pigtail place-
ment (median 3h:08min, IQR 2h:15min – 4h:02min) and procedure duration from start of 






























































































Figure 2. Influence of mapping and ablation on 
the incidence of pericarditis
Table 2. Procedural length
all patients
Procedure duration from sheath placement to sheath removal 4h:01min (3h:20min – 4h:40min)
Duration from pericardial puncture to pigtail placement 3h:08min (2h:15min – 4h:02min)
Duration from start epicardial mapping to pigtail placement 2h:00min (1h:14min – 2h:40min)
Fluoroscopy time 47 min (32 – 56 min)
Variables are expressed as median (interquartile range).
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There was no difference comparing the above three duration times between patients 
with vs. without chest pain, with vs. without pericarditic ECG changes, and with vs. 
without both chest pain and pericarditic ECG changes.
A pigtail catheter was left in the pericardial space less than 3 hours in 8% of patients 
while 44% patients had the pigtail for greater or equal to 24 hours. Patients with a pigtail 
for ≥24 hours more often had chest pain (51% vs. 25%, p=0.012), but less often ECG 
changes (19% vs. 48%, p=0.006) as shown in Table 3.
A total of 13 patients developed a post-procedural pericardial effusion or tamponade 
with a mean effusion of 12 +/- 7 mm by transthoracic echocardiography, observed 18 
+/- 14 hours after the procedure. The effusion was noted at first echo in 8 of 13 patients, 
at second echo in 4 patients (20, 20, 20 and 19 hours after procedure) and at third echo 
in 1 patient (50 hours after procedure, but < 5mm).
In 7 (8.3%) patients with no prior history of AF, procedure-related AF was documented 
(paroxysmal in 4 and persistent in 3, requiring cardioversion). The median time to new 
AF was 36 hours (IQR 19 – 60 hours). For the persistent cases, 2 underwent rapid cardio-
version while the last was anticoagulated for 6 weeks prior to cardioversion. Patients 
who developed new onset AF were older than the patients who did not, with ages of 
64.7±7.6 vs. 57.2±17.3 years (p=0.016). Patients with a pericarditic ECG tended to be 
at greater risk of developing AF (16.7 vs. 3.6%, p=0.091). There were no complications 
associated with the episodes of AF. One patient had a recurrence of paroxysmal AF 18 
months after resolution of the pericarditis.
The median length of stay in hospital post-procedure was 5 days (IQR 3 – 8 days). 
There was no statistically significant increase in the hospital stay duration due to the 
incidence of pericarditic chest pain (median 5 days, IQR 3 – 9 days vs. median 5 days, IQR 
3 – 7 days, p = 0.75), pericarditic ECG (median 5 days, IQR 3 – 8 days vs. median 4 days, 
IQR 3 – 8 days, p = 0.98) or of pericarditis (median 5 days, IQR 3 – 9 days vs. median 5 
days, IQR 3 – 8 days, p = 0.88).
In 7 patients, repeat epicardial access was required for a total of 9 procedures. In 
only one case, epicardial access to the area of interest could not be re-obtained. The 
patient thus underwent surgical dissection of adhesions and cryoablation. This patient 
had received oral steroids after his first 2 procedures. Of the 6 patients who underwent 
Table 3. Influence of the presence of a pigtail catheter on the incidence of pericarditis
Pigtail ≥24 hours Pigtail < 24 hours p
Chest pain 19/37 (51%) 12/48 (25%) 0.012
ECG changes 7/37 (19%) 23/48 (48%) 0.006
Chest pain and ECG changes 4/37 (11%) 9/48 (19%) 0.31
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unimpeded repeat procedures, one had received no steroid, 3 had received oral steroids 
while 2 had received intrapericardial steroids after the first procedure.
Figure 3 demonstrates pericardial adhesions as photographed in the operating room. 
Interestingly, although an inflammatory process clearly took place, this patient never re-
ported chest pain and the ECG never demonstrated ECG changes typical of pericarditis.
Complications
In total, 5 patients experienced a bleeding complication which can be further described 
as follows: 1 case (1.2%) of groin hematoma and 4 cases (4.7%) of moderate to severe 
pericardial bleeding (>80cc) occurring acutely in 2 and delayed in 2. For the acute bleed-
ing cases, one occurred following epicardial puncture (without evidence of RV punc-
ture) and resolved within 20 minutes while the second was due to RV puncture. In the 
first of the delayed bleeding cases, an echo performed due to clinical deterioration with 
shortness of breath demonstrated tamponade 13 hours post procedure in a patient who 
had accidentally been administered low-molecular weight heparin. The second case of 
delayed bleeding cases occurred in a patient on heparin and dual-antiplatelet therapy 
due to recent coronary artery stenting and was noted 4.75 hours post procedure on an 
echo performed due to low blood pressure and poor diuresis. The bleeding persisted for 
Figure 3. Dissection of epicardial adhesions during surgery
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the following 48 hours. Both were managed with percutaneous drainage. There were no 
procedure-related deaths.
There were no adverse consequences from the use of IP triamcinolone more specifi-
cally, no infection or myocardial perforation. The patients who underwent redo proce-
dures did so, either as a planned staged approach due to extensive disease and lengthy 
first ablation procedure or, following VT recurrence more than a month after the first 
ablation procedure.
DISCUSSIon
The prophylactic instillation of 2 mg/kg of intrapericardial corticosteroids has been 
demonstrated to effectively prevent inflammatory adhesions in a porcine model of post 
procedural pericarditis after epicardial mapping and ablation.4 To date, the impact of 
intrapericardial steroid administration after epicardial mapping and ablation has not 
been studied in humans. In the present study, it is demonstrated for the first time that 
the use of intrapericardial steroids portends an important clinical benefit by significantly 
reducing the incidence of pericarditic chest pain. This is a valuable clinical gain as it 
is associated with increased patient satisfaction. The clinical benefits of the use of in-
trapericardial steroids may stem from the mode of delivery, the pharmacokinetics and 
metabolism of the drug and, the duration of exposure to the drug. Triamcinolone is an 
intermediate acting, liver metabolized glucocorticoid. Triamcinolone acetate is the more 
potent type of triamcinolone, being about eight times as effective as prednisone. The 
drug thus delivered directly and left in the pericardial space can be absorbed locally. In 
addition, in this work the drug was left in-situ rather than being simply flushed through 
the epicardial space.
Intrapericardial instillation of steroids has also been used in other clinical settings 
including recurrent idiopathic pericarditis and uremic pericarditis where studies have 
consistently demonstrated safety. In the present series, a therapeutic dose of intraperi-
cardial triamcinolone 2mg/kg was thus chosen. Importantly, there were no adverse con-
sequences from the use of IP triamcinolone more specifically, no infection or myocardial 
perforation.
Two recently published studies have reported a widely varying incidence of chest pain 
after mapping and/or ablation in the epicardium.11,12 The first reported chest pain in 
almost all patients,11 whereas the second reported a 21% incidence with 1 out of 6 par-
ticipating centers using systemic steroids routinely and another 1 out of 6 participating 
centers using intrapericardial infusion of steroids routinely12.  The etiology of the pain in 
some cases was felt to be related, not only to the epicardial mapping and ablation, but 
also to the friction of the pigtail left in the pericardium for continuous drainage.12
Influence of Steroids after Epicardial VT Ablation 145
7
In our series, we report an incidence of chest pain of 36.5% (21.2% chest pain only and 
15.3% chest pain with ECG changes). Some of the difference in the reported numbers 
may arise from the difficulty in accurately assessing the quality of the pain retrospective-
ly. In addition, similarly to our approach, the centers included in the above series used 
a conscious sedation approach, where the analgesic drugs and dosages administered 
varied and thus provided a varying degree of post-procedural pain control. Also, the 
type of ablation catheter and sheaths varied from center to center. Furthermore, the use 
of NSAIDs was not uniform, where in one series it ranged from being left to the discre-
tion of the physician to being prescribed almost routinely for a week11. Nevertheless, in 
the series where steroids were used,12 including but not only intrapericardial steroids, a 
lower incidence of chest pain was reported.
With respect to AF, the incidence of 8.3% reported in the present series sits within 
the range previously quoted in the literature. Already in 1976, the incidence of AF in a 
cohort of 100 patients with pericarditis was reported to be 5%.14 An incidence of 19.5% 
was reported for new onset AF within 7 days of procedure in a recent series of 41 pa-
tients undergoing epicardial VT ablation.13 In that series, patients developing AF were 
significantly younger than those without AF whereas our study demonstrated the op-
posite. They also described lack of amiodarone therapy as a risk factor for procedurally 
related new onset AF. Interestingly, in the data presented here, none of the patients who 
developed new onset AF were receiving amiodarone therapy for VT nor did they receive 
it post-procedurally for AF prevention. On a more concordant note, in their series, all 
patients with new onset AF had clinical symptoms of pericarditis while in the present 
data there was a trend towards AF occurring more commonly in patients with pericar-
ditic ECG changes. In addition, 85.7% of the patients with new onset AF in the present 
series had both mapping and ablation performed. The diverging results between the 
2 studies can be in large part explained by the small number of patients developing 
procedure-related AF in the present series.
Limitations
No randomization was performed, however, the therapeutic approaches in the current 
study were applied non-selectively in consecutive patients. The findings are therefore 
highly suggestive for an effect of intrapericardial steroids on pericarditic chest pain after 
epicardial mapping and/or ablation. As this is a retrospective study, it is difficult to as-
certain from the charts whether patients requested NSAIDs only after the onset of chest 
pain. The use of NSAIDs however may have had an influence on clinical variables such 
as pericarditic ECG changes, even if the NSAIDs were started after the onset of chest 
pain. The dose of steroids was unchanged over time and as a result, the most effective 
dose of steroids for the prevention of pericarditic chest pain could not be determined. 
Although the number of procedures in this study was relatively large, some subgroup 
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analyses were still limited by the sample size. In addition, given that the introduction 
of the Agilis sheath was contemporary to the introduction of intrapericardial steroids, 
the relative impact of each variable on the incidence of pericarditis cannot be further 
determined. However, as the steerable Agilis sheath is assumed to be more traumatic 
than a non-steerable sheath, the impact of the intrapericardial steroid on the reduction 
of clinical pericarditic chest pain may be even underestimated.
ConCLUSIon
There is a high incidence of pericarditic chest pain and, of pericarditic ECG following 
percutaneous epicardial access for VT mapping and ablation. Complaints of pericarditic 
chest pain are significantly decreased by the administration of intrapericardial steroids, 
but not IV/PO steroids. Procedure-related AF is relatively frequent and tends to occur 
more commonly in patients with pericarditic ECG changes.
CLInICaL PeRSPeCTIVe
Catheter ablation for ventricular tachycardia is increasingly used and may 
require a percutaneous, epicardial approach. Complications of an epicar-
dial approach include, among others, pericarditis and atrial fibrillation. 
This study was thus designed to evaluate the influence of steroid therapy, 
delivered systemically or intrapericardially versus the absence of steroids, 
on the incidence of pericarditis and atrial fibrillation after percutaneous 
epicardial mapping and ablation for ventricular tachycardia. The results 
demonstrate a high incidence of pericarditic chest pain and ECG changes 
after epicardial ventricular tachycardia mapping and ablation. Pericarditic 
chest pain is significantly decreased by the use of intrapericardial steroids. 
Procedure- related atrial fibrillation is relatively frequent and tends to 
occur more commonly with pericarditic ECG changes. There were no 
adverse consequences from the use of intrapericardial triamcinolone. The 
administration of intrapericardial triamcinolone does thus provide clinical 
benefits, specifically greater patient comfort, and may be considered for 
routine use after epicardial ventricular tachycardia ablation procedures.
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Ablation failure and recurrence rates after ventricular tachycardia (VT) ablation in 
nonischemic cardiomyopathy (NICM) are high and the optimal procedural endpoint is 
not well defined. This study assessed the outcome after ablation, the impact of nonin-
ducibility and other potential predictors of VT recurrence.
Methods and Results
Forty-five patients with NICM (60±16 years, LVEF 44±14%) accepted for VT ablation were 
included. Epicardial mapping was performed in 29 (64%). A median of 2 (first-to-third 
quartile, 2–4) VTs (cycle length [CL] 342±77ms) were induced per patient. After ablation, 
the complete programmed electrical stimulation protocol (3 drive CL, 3 extrastimuli 
≥200ms, burst, ≥2 sites) was repeated. Complete success (non-inducibility of any mono-
morphic VT) was achieved in 17 patients (38%), partial success (elimination of clinical 
VT, persistent inducibility of non-clinical VT) in 17 patients (38%), and failure (persistent 
inducibility of clinical VT) in 11 patients (24%). During 25±15 months follow-up VT oc-
curred in 24 patients (53%), but the 6-month VT burden was reduced by ≥75% in 79%. 
Recurrence rates were low after complete procedural success (18%), but high after both 
partial success (77%) and failure (73%). Non-complete procedural success was the stron-
gest predictor of VT recurrence (hazard ratio 8.20, 95% confidence interval 2.37-28.43, 
p=0.001).
Conclusions
Although 53% of patients had VT during follow-up, the 6-month VT burden was de-
creased by ≥75% in 79%. Recurrence rates are low after complete procedural success, 
but high after both partial success and failure. Non-complete procedural success was 
the strongest predictor of VT recurrence.
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InTRoDUCTIon
In patients with left ventricular (LV) non-ischemic cardiomyopathy (NICM) several as-
pects of ventricular tachycardia (VT) ablation require elucidation.
First, the procedural endpoint is not well defined. Although non-inducibility of VT 
by programmed electrical stimulation (PES) is frequently used as an endpoint, data 
supporting its predictive value for VT recurrence are mainly derived from patients after 
myocardial infarction (MI)1,2 who are likely to have different substrates, higher proce-
dural success  and lower VT recurrence rates.1,3 In addition, studies in post-MI patients 
are inconsistent, perhaps due to different induction protocols, incomplete application 
of protocols and differences between patient populations.1,2,4-6 Data on the value of PES 
as a procedural endpoint in NICM are limited to two small series.3,7 Recently, alternative 
endpoints have been proposed such as elimination of abnormal bipolar electrograms 
or late potentials consistent with slow conduction4,8, late potentials are however less 
frequently found in patients with NICM than in post-MI patients.3
Second, risk factors for VT recurrence in NICM are not established. Risk stratification 
may allow an individually tailored treatment strategy. A conservative approach may be 
appropriate in patients at low risk, whereas patients at high risk may require either more 
extensive ablation or concomitant drug therapy.
Third, the role of VT ablation early in the therapeutic course (e.g. for a first VT, symp-
tomatic ATP or a single ICD shock) is unclear in NICM patients. The indication for VT 
ablation in patients with structural heart disease has changed over time.9  Recent rec-
ommendations apply to all patients with structural heart disease, although evidence is 
limited and based on trials conducted in post-MI patients.10,11 The risk-benefit ratio of VT 
ablation early in the therapeutic course may be different in patients with NICM, in whom 
VT ablation is reported to be less effective1,3 and may more often requires epicardial 
ablation, which is associated with a higher procedural risks.12,13
The aims of the current study are fourfold: 1) to determine the outcomes of VT ab-
lation in NICM, 2) to assess the value of PES as a procedural endpoint, 3) to identify 
predictors of acute and long-term outcome, 4) to evaluate the role of VT ablation early 
in the therapeutic course in NICM.
MeThoDS
Patients
The study population consisted of 45 consecutive NICM patients who underwent VT 
ablation at the Leiden University Medical Centre between 1/2007 and 6/2011, including 
patients in whom no radiofrequency (RF) energy was delivered. All patients had systolic 
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impairment and evidence of scar in the LV based on contrast-enhanced MRI and/or 
electroanatomical mapping. Patients with significant coronary artery disease (>50% 
stenosis, assessed by coronary angiography in all patients), congenital heart disease, 
hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, left 
ventricular noncompaction, restrictive cardiomyopathy, (sub)acute myocarditis, cardiac 
sarcoidosis, toxic cardiomyopathy, tachycardia-induced cardiomyopathy or primary val-
vular abnormalities were excluded. All patients were treated according to the routine 
clinical protocol and provided informed consent.
Clinical presentation and procedural strategy
In patients presenting with incessant VT, ≥2 implantable cardioverter defibrillator (ICD) 
shocks or multiple VT recurrences after prior endocardial ablation, VT ablation was 
classified as ‘late in the therapeutic course’. In these patients, epicardial mapping was 
always attempted if endocardial ablation did not result in complete success. In patients 
presenting with a first VT, symptomatic ATP or a single ICD shock, VT ablation was clas-
sified as ‘early in the therapeutic course’. In these patients, epicardial mapping was not 
attempted in case of 1) prior surgery, 2) a septal or basal anterior substrate likely not 
reachable from the epicardium due to coronary arteries and/or a basal fat layer, 3) only 
remaining non-clinical very fast VT (cycle length [CL] ≤250ms), 4) patient preference.
Ventricular tachycardia induction
The procedure was performed under conscious sedation (n=43) or general anesthesia 
(n=2); anti-arrhythmic drugs (AADs) were discontinued for ≥5 half-lives with the excep-
tion of amiodarone (n=19; 42%). In patients who were not under general anesthesia, PES 
was performed before sedation and opioid administration. PES consisted of three drive 
CLs (600, 500 and 400ms) with 3 ventricular extrastimuli (≥200ms) from ≥2 right ven-
tricular sites and burst pacing. Positive endpoint was induction of sustained monomor-
phic VT lasting >30s or requiring termination because of hemodynamic compromise. 
Isoprenaline was used if the (presumptive) clinical VT could not be induced. Induced VTs 
were regarded clinical if the 12-lead ECG matched that of a spontaneous VT, or presump-
tive clinical when the CL matched that of an ICD-recorded VT (difference <30ms).
electroanatomical mapping and ablation
Electroanatomical LV endocardial mapping was performed retrogradely during pacing 
or sinus rhythm using a 3.5mm, irrigated-tip catheter and an electroanatomical mapping 
system (NaviStar ThermoCool and CARTO XPTM, Biosense Webster Inc, Diamond Bar, CA, 
USA). Epicardial mapping was performed through a subxyphoid puncture. Electrograms 
were filtered at 30-400Hz (bipolar) and 1-240Hz (unipolar). Endocardial areas with low 
bipolar voltage (≤1.50mV) or low unipolar voltage (≤8.27mV14), and epicardial areas 
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with low bipolar voltage (≤1.81mV15) and low unipolar voltage areas (≤7.95mV15) were 
considered abnormal and consistent with scar if ≥1cm2 in size and accompanied by 
double potentials, fragmented electrograms, late potentials or other prolonged electro-
grams ≥50ms.15 Substrates were classified as septal if they were predominantly located 
in one of the anteroseptal or inferoseptal segments. Endocardial and epicardial ablation 
target sites were identified based on the combination of substrate, pace, activation 
and entrainment mapping for stable VT, and based on substrate and pace mapping for 
unstable VT (defined as VTs requiring prompt termination9). At the epicardium, ablation 
was usually withheld when the estimated distance to a coronary artery was <5mm, as 
assessed by integrated CT-derived coronary anatomy and coronary angiography.16 High 
output pacing (10mA, 2ms) was performed to determine the location of the phrenic 
nerve. RF energy was applied at 30-45W (maximum temperature 45ºC, flow 20-30mL/
min, 60s) for endocardial sites and ≤50W (flow 20mL/min) for epicardial sites.
acute procedural outcome and reasons for non-complete procedural success
After the last RF application, the entire PES protocol was repeated in each patient. 
Isoprenaline was administered if required to induce VT before ablation. Complete 
procedural success was defined as non-inducibility of any sustained monomorphic 
VT regardless of VT CL; partial success as elimination of the (presumptive) clinical VT 
but persistent inducibility of ≥1 nonclinical VT; failure as persistent inducibility of the 
(presumptive) clinical VT.
Reasons for non-complete procedural success (partial success and failure) were 
categorized as 1) vicinity of coronary arteries and/or epicardial fat, 2) proximity of the 
His bundle, 3) pericardial adhesions, 4) prolonged low cardiac output after electrical 
cardioversion, 5) no identifiable target site for fast clinical VT, 6) multiple cardioversions 
for non-clinical fast VT with hemodynamic collapse, 7) patient preference for medical 
therapy.
Follow-up
ICDs were offered to all patients regardless of acute procedural outcome. ICDs were 
typically programmed to include 3 zones: monitor zone (150-188bpm, ATP if indicated), 
fast VT zone (188-210bpm, ATP and shock), VF zone (>210bpm, if available ATP during 
charging, and shock). Patients were followed at 3, 6 and 12 months after ablation and 
at 6- to 12-monthly intervals thereafter. Recordings were analyzed by two experienced 
observers. Recurrence was defined as any VT treated with ATP or shock and any sus-
tained VT occurring in the monitor zone, including VTs that occurred before discharge 
from the hospital. In patients without an ICD, VT recurrence was defined as sustained VT 
documented on a 24h Holter ECG or any complaints suggestive for VT. The reduction of 
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VT burden was calculated as follows: 1 – (# of VT episodes in period post-ablation / # of 
VT episodes in same period pre-ablation).
Disease progression
To analyze the effect of disease progression on VT recurrence, the LV end-diastolic 
volume (LVEDV) and LV ejection fraction (LVEF) were assessed by transthoracic echo-
cardiography before the procedure and during follow-up. The annual changes in LVEDV 
and LVEF were calculated as follows: (value last echocardiogram – value baseline echo-
cardiogram)/time interval in years.
Statistical analysis
Categorical variables are displayed as number (percentage) and continuous variables 
are expressed as mean±SD when normally distributed or median (first-to-third quartile 
[Q1-to-Q3]) when non-normally distributed. Categorical variables were compared using 
the χ2 test or the Fisher’s exact test when the expected value in any cell was below 5. Con-
tinuous variables were compared using the Student’s t test when normally distributed 
or the Mann-Whitney U test when non-normally distributed. The VT burden before and 
after ablation was compared using the Wilcoxon signed-rank test. Survival curves were 
estimated by the Kaplan-Meier method and compared by the log-rank test. Univariable 
logistic regression and Cox regression analysis were performed to identify predictors of 
acute procedural success and predictors of VT recurrence, respectively. Start of cardiac 
resynchronization therapy (CRT) during follow-up was included as a time-dependent 
covariate. Multivariable analyses were not performed due to the limited number of 
patients and events. Probability values are all 2-sided and, if not otherwise specified, a 
probability value <0.05 was considered statistically significant. Analyses were performed 
using SPSS 20.0 software (SPSS Inc, Chicago, Ill).
ReSULTS
Patients
Forty-five consecutive patients with NICM (76% male, age 60±16 years) were included 
after failure of 1.8±1.0 AADs. Twelve patients (27%) had previously undergone endocar-
dial VT ablation, 2 of them at another center.  Baseline characteristics are displayed in 
Table 1, the procedural strategy in Figure 1.
Procedure
A median of 2 (Q1-to-Q3, 2–4) VTs with a mean CL of 342±77ms was induced per patient. 
Clinical VTs (mean CL 363±98ms) were induced in 43 patients (96%) and only non-clinical 
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VT in 2 patients (4%), which was based on the 12 lead ECG in 36 patients (80%) and on 
ICD recordings in 9 patients (20%). In only one patient isoprenaline administration was 
required to induce the clinical VT before ablation (2%). Bundle branch re-entry (BBR) VT 
was induced in 3 patients (7%).





 I 17 (38%)
 II 13 (29%)
 III or IV 15 (33%)
LV ejection fraction, % 44±14
LV end-diastolic volume, mL 171±70
History of atrial flutter/fibrillation 14 (31%)
History of hypertension 16 (36%)
Body mass index, kg/m² 27±5
Diabetes mellitus 5 (11%)
Estimated GFR
 30-60 mL/min 6 (13%)
 <30 mL/min 4 (9%)
VT burden 6 months (episodes) 7 (3 - 25)
VT burden 12 months (episodes) 8 (3 - 31)
Incessant VT 5 (11%)
VT storm9 17 (38%)
ICD shocks in last 12 months
 0 23 (51%)
 1 9 (20%)
 ≥2 13 (29%)
Electrical storm in last 12 months 8 (18%)
Clinical VTs >1 morphology 13 (29%)
Cycle length of clinical VT(s) 363±98
Failed anti-arrhythmic drugs
 Class I 9 (20%)
 β-blocker 33 (73%)
 Sotalol 15 (33%)
 Amiodarone 22 (49%)
 Calcium-antagonist 2 (4%)
ICD before ablation 30 (67%)
Prior endocardial VT ablation 12 (27%)
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Endocardial mapping was performed in all patients, percutaneous epicardial mapping 
in 29 patients (64%) and intraoperative epicardial mapping in 2 patients (4%, in one 
both percutaneous and intraoperative). Abnormal low bipolar or low unipolar voltage 
areas were present in all patients who underwent both endocardial and epicardial 
substrate mapping. Neither RF catheter ablation, nor intraoperative cryoablation was 
performed in 2 patients (4%) because no target site could be identified. Procedural data 
are summarized in Table 2.
acute procedural outcome and reasons for non-complete success
Complete success was achieved in 17 patients (38%), partial success in 17 (38%) and 
failure in 11 (24%, including the 2 patients in whom neither RF nor cryoablation was 
performed). In 2 patients the clinical VT was abolished but the final induction protocol 
could not be completed due to prolonged low cardiac output after non-clinical VT 
induction; partial success was achieved in both.
The reasons for non-complete procedural success were proximity of coronary arteries 
and/or epicardial fat in 5 (18%), the proximity of the His bundle in 2 (7%), adhesions due 
to prior surgery in 1 (4%), prolonged low cardiac output after cardioversion in 2 (7%), 
no identifiable target site for fast clinical VT in 5 (18%), multiple cardioversions due to 
non-clinical fast VT with hemodynamic collapse in 11 (39%) and patient preference for 
medical therapy in 2 patients (7%).
Seven patients did not undergo epicardial mapping despite non-complete procedural 
success, because of prior surgery in one, a basal septal substrate likely not reachable 
from the epicardium based on contrast-enhanced MRI in one, patient preference in 
one and only remaining very fast non-clinical VT in the setting of ablation early in the 
therapeutic course in 4 patients.
Figure 1. Procedural strategy
* In patients who have ≥6 months follow-up. ** Despite intraoperative cryoablation in 2 patients
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Predictors of acute procedural outcome
A higher age (odds ratio [OR] 1.78, p=0.01) and lower creatinine clearance (OR 1.28 per 
10 mL/min decrease, p=0.03) were associated with non-complete procedural success 
(Figure 2). A trend was observed for lower LVEF (OR 1.52 per 10% decrease, p=0.09) and 
induction of unstable VT (OR 3.26, p=0.08).
Table 2. Procedural data.
n=45
Number of VTs induced
 1 10 (22%)
 2 16 (36%)
 ≥3 19 (42%)
Bundle branch re-entry VT 3 (7%)
Hemodynamic stability of VTs
 Only stable VT 14 (31%)
 Only unstable VT 11 (24%)
 Stable and unstable VT 20 (44%)




Pericardial puncture 29 (64%)
Endocardial substrate mapping 42 (93%)
 Bipolar voltage area ≤1.50mV 29/42 (69%)
 Unipolar voltage area ≤8.27mV 39/42 (93%)
Epicardial substrate mapping 27 (60%)
 Bipolar voltage area ≤1.81mV 23/27 (85%)
 Unipolar voltage area ≤7.95mV 23/27 (85%)
Predominantly septal substrate 19/42 (45%)
Substrate location/extent involves
 Any basal segment 40/42 (95%)
 Any mid segment 25/42 (56%)
 Any apical segment 12/42 (27%)
Radiofrequency energy applications
 Only endocardial 22 (49%)
 Only epicardial 2 (4%)
 Endocardial and epicardial 18 (40%)
 None 3 (7%)
Intra-operative cryoablation 2 (4%)
Procedural duration (min) 206±86
Fluoroscopy time (min) 45±21
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Complications
One patient developed a pseudo-aneurysm of the femoral artery. Acute pericardial 
bleeding >80mL occurred in 2/29 patients (7%) who underwent pericardial puncture. 
One patient (3%) who accidentally received heparin developed tamponade after the 
procedure managed by drainage.
VT recurrence during follow-up
All but 4 patients were discharged with an ICD; 8 patients (18%) were discharged on 
class I AADs, 29 (64%) on β-blocker, 10 (22%) on sotalol and 17 (38%) on amiodarone. 
During median 24 (Q1-to-Q3, 12–37) months follow-up (no patient lost to follow-up; at 
least 6 months follow-up in 42 patients, remaining 3 patients died within 6 months) 24 
patients (53%) had VT recurrence, 20 (44%) received ≥1 ICD shock and 6 patients (13%) 
experienced an episode of electrical storm (defined as ≥3 appropriate ICD shocks within 
24 hours). Only 1/8 patients with electrical storm before ablation had electrical storm 
recurrence.
The 6-month VT burden was reduced by ≥75% in 33/42 patients (79%) with at least 
6 months follow-up (Figure 3). The 6-month VT burden was reduced equally in patients 
with and without an ICD before ablation (78% vs. 80% of patients ≥75% reduction, 
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Figure 2. Predictors of non-complete procedural success
CI denotes confidence interval. CL, Cycle length




































































































































































































































































































































































p>0.05). The 12-month VT burden was reduced by ≥75% in 68%, 78% and 71% of pa-
tients in the first, second and third year after ablation, respectively.
Eleven of 24 patients (46%) with VT recurrence had ≥1 fast VT (CL≤300ms) and 20/24 
patients (83%) with VT recurrence received ≥1 appropriate ICD shock. A median of 23% 
(Q1-to-Q3, 5–64%) of all VTs per patient required a shock for termination.
Impact of noninducibility
Only 3/17 patients (18%) with complete procedural success had VT recurrence, com-
pared with 13/17 patients (77%) with partial procedural success and 8/11 patients (73%) 
with procedural failure (Figure 4). The 6-month VT burden was reduced by ≥75% in 94%, 
67% and 70%, respectively. Importantly, 6/11 patients (55%) with induction of a very fast 
VT (CL≤250ms) at the end of the procedure had VT recurrence, including 2/3 patients 
(67%) with persistent inducibility of clinical very fast VT and 4/8 patients (50%) with 
inducibility of non-clinical very fast VT.
Predictors of VT recurrence
Non-complete procedural success (hazard ratio [HR] 8.20, p=0.001), lower LVEF (HR 1.61 
per 10% decrease, p=0.004), VT storm (HR 2.50, p=0.03), a higher number of failed AADs 
(HR 1.62, p=0.01) and a longer mean CL of induced VTs (HR 1.08 per 10ms increase, 
p=0.02) were identified as predictors of VT recurrence (Figure 5). A trend was observed 
for the number of induced VTs (HR 1.08 per VT, p=0.09).
Disease progression and VT recurrence
Disease progression was assessed by repeat echocardiography up to 19±9 months after 
baseline echocardiography in the 21/42 patients (50%) with at least 6 months follow-up. 
Figure 4. Ventricular tachycardia recurrence and reduction of the 6-month VT burden according to 
acute procedural outcome
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The LVEF decreased by a median of 1.4% (Q1-to-Q3, -3.0–4.5%) and the LVEDV increased 
by a median of 10mL (Q1-to-Q3, -10–26mL) per year. In 5 patients (24%) the LVEF 
decreased by ≥5%/year, all had VT recurrence (100%). In 11 patients (31%) the LVEDV 
increased by ≥10mL/year, 7 had VT recurrence (64%).
VT ablation early in the therapeutic course
Epicardial mapping was performed in 12/25 patients (48%, Figure 1) who underwent VT 
ablation early in the therapeutic course (i.e. for a first VT, symptomatic ATP or a single 
ICD shock). Complete success was achieved in 11 (44%), partial success in 8 (32%) and 
ablation failed in 6 (24%). The procedure was complicated by a pseudo-aneurysm of the 
femoral artery in 1 patient (4%) and tamponade after the procedure in another (4%). 
During a median follow-up of 24 months (Q1-to-Q3, 13–37 months), 14 patients (56%) 
were free from VT and 15 (60%) were free from appropriate ICD shocks. Twelve of 25 
patients (48%) were both off amiodarone and without recurrent VT during follow-up.
The acute success rate and VT recurrence rate were not significantly different between 
patients undergoing ablation early in the therapeutic course and the other patients 
(p=0.58 and p=0.17, Figure 1).
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Figure 5. Predictors of ventricular tachycardia recurrence
CI denotes confidence interval; CRT, cardiac resynchronization therapy
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Repeat ablation
Repeat VT ablation was performed in 8/45 patients (18%) 11±11 months after the in-
dex procedure because of incessant VT and/or ≥1 appropriate ICD shock. Seven had 
prior partial success and one complete success. Pericardial puncture was performed in 
4 (50%), but was unsuccessful due to adhesions in 2 patients who underwent epicar-
dial mapping at baseline, despite intravenous steroids after the procedure. Complete 
procedural success was achieved in 3/8 patients (38%), partial success in 4 (50%) and 
failure in 1 (13%). During a mean follow-up of 17±13 months, 4 patients (50%) had VT 
recurrence and 2 (25%) received one appropriate ICD shock. Three of 6 patients (50%) 
with ≥6 months follow-up had ≥75% reduction of the 6-month VT burden.
Mortality during follow-up
Six patients (13%) died during follow-up. The cause of death was terminal heart failure 
(n=2), incessant VT in the setting of progressive heart failure (n=2), respiratory insuf-
ficiency after cardiac surgery (n=1) and cancer (n=1). Two patients (4%) underwent 
cardiac transplantation.
DISCUSSIon
The main findings of this study can be summarized as follows: 1) although VT occurs in 
53% of NICM patients after ablation, the 6-month VT burden was substantially reduced 
in 79%, 2) complete procedural success, defined as non-inducibility of any VT after the 
last RF application, was associated with low VT recurrence rates, whereas partial suc-
cess and procedural failure were both associated with high recurrence rates, 3) non-
complete procedural success, a lower LVEF, a higher number of clinical VTs, VT storm, a 
higher number of failed AADs and a higher mean CL of induced VTs are predictors of VT 
recurrence and 4) after VT ablation early in the therapeutic course, 56% of NICM patients 
remain free from VT recurrence.
Prior reports
To our knowledge, this series of NICM patients undergoing VT ablation and complete 
PES after the last RF delivery is the largest reported to date. Patients  had a higher 
LVEF than patients in prior studies (44% vs. 27-34%3,7,13,17-20), had less frequently an ICD 
before ablation (67% vs. 71-100%3,7,13,17-20) and were less often on amiodarone (42% vs. 
43-88%3,13,17-20), suggesting that VT ablation was employed at an earlier stage, which is in 
line with recently extended indications for VT ablation.9
Complete procedural success was achieved in 38% of patients, which is lower than 
some prior studies7,17,18 but similar to others.3,13,21  However, the currently reported recur-
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rence rate of 53% during median 24 (Q1-to-Q3, 12–37) months follow-up is, considering 
differences in follow-up duration, favorable when compared to two studies employing 
epicardial mapping in the majority of patients3,13 and similar to one study with epicardial 
mapping in all patients.17 An overview of studies analyzing outcome of VT ablation in 
NICM is provided in a supplemental Table.
noninducibility as a procedural endpoint
The majority of available data on the predictive value of non-inducibility is derived from 
post-MI patients.1,2,4-6 NICM patients may however have a different arrhythmogenic sub-
strate.3,22 Of interest, 96% of our patients were inducible for the clinical VT, suggesting 
the presence of a fixed substrate. The small number of patients under general anesthesia 
and the fact that initial PES was performed before sedative and opioid administration 
may also have contributed to this finding.
Only 2 small prior studies (including 13 and 16 patients) have analyzed the value of 
PES at the end of VT ablation procedures in patients with NICM.3,7 In the present study 
PES was performed after the last RF application in all 45 patients. Perhaps due to the 
consistent application of the induction protocol, patients remained more often induc-
ible for non-clinical and in particular fast VTs, and therefore partial success may have 
been achieved more frequently compared to prior studies (supplemental Table). Pro-
longed depression of cardiac output prevented completion of the induction protocol in 
only 2 patients, which may be partly due to the higher LVEF and our strategy to perform 
substrate mapping and only limited mapping during VT in all patients independent of 
VT CL.
Both partial procedural success and failure were associated with high VT recurrence 
rates, indicating that partial success may not be superior to ablation failure. Importantly, 
55% of patients with induction of a very fast VT (CL≤250ms) after ablation had VT recur-
rence, suggesting that induction of these VTs after ablation is not a non-specific finding. 
However, the latter does not necessarily imply that very fast, nonclinical VTs should 
always be targeted. Persistent inducibility of very fast VTs may be a marker for a more 
complex or functional arrhythmogenic substrate less amenable to VT ablation. This is in 
line with the observation that 83% of patients required one or more ICD shocks to termi-
nate ≥1 VT which may be due to ATP failure or short VT CL. Further studies are needed to 
assess whether additional ablation can abolish these nonclinical, usually rapid VTs and 
improve long-term outcomes after ablation.
Predictors of acute procedural success and VT recurrence
Higher age was strongly associated with non-complete procedural success, also after 
adjustment for epicardial access, LVEF and AADs (data not shown), perhaps due to a 
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different substrate in older patients. Interestingly, although age was associated with 
non-complete procedural success, it seemed not to predict VT recurrence.
All patients with a significantly decreasing LVEF and 64% of patients with a significantly 
increasing LVEDV had VT recurrence during follow-up, perhaps indicating that patients 
with deteriorating LV function and dimensions may be at high risk for VT recurrence. 
Previous studies in post-MI patients demonstrated that a lower LVEF6,23, a higher number 
of induced VTs23,24, a higher number of clinical VTs6 and acute procedural failure6 are 
associated with VT recurrence. The current study suggests that most of these factors 
also apply to patients with NICM. Different substrates may however result in comparable 
clinical features, such as lower LVEF, and to date little is known about the VT substrates in 
NICM. Therefore, more studies are needed to identify potentially different substrates and 
their impact on VT occurrence. So far, PES after the last RF application is the strongest 
predictor of VT recurrence and may therefore be an important tool to identify patients 
who may need additional ablation, epicardial mapping and/or enhanced drug therapy.
VT ablation early in the therapeutic course
This is the first study reporting on the results of VT ablation in NICM patients presenting 
with a first VT, symptomatic ATP or a single ICD shock. Importantly, no complication 
resulted in serious sequelae. Fifty-six percent had no VT recurrence and 60% were free 
from ICD shocks during follow up. Twelve of 25 patients (48%) were off amiodarone and 
without recurrent VT during follow-up. These findings suggest that VT ablation may be 
considered for indications such as a first VT, symptomatic ATP or a single ICD shock in 
NICM patients and perhaps even be considered as an alternative to life-long amioda-
rone therapy, particularly in young patients. The risks of VT ablation should be weighed 
carefully against the risks of medical therapy, which persist during follow-up and may 
include serious side effects. When considering epicardial ablation, the risk of pericardial 
adhesions preventing future pericardial access should also be taken into account, which 
may occur even after administration of intrapericardial steroids.
Limitations
Non-complete procedural success may have been caused by lack of epicardial access 
in 7 patients (16%). One patient preferred not to undergo epicardial mapping and in 
the remaining 6 patients the potential benefits were considered not to outweigh the 
risks based on the clinical presentation. In a significant proportion of patients an ICD 
was implanted only after the procedure and therefore, ICD therapy for non-sustained VT 
after the procedure may have led to an underestimation of the reduction of VT burden. 
Echocardiography was performed in 50% of patients who survived ≥6 months after 
ablation and therefore, the relation between LVEF decrease and LVEDV increase and VT 
recurrence should be interpreted with caution.
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ConCLUSIon
Although VT recurs in 53% of the patients during follow-up, the 6-month VT burden is 
reduced by ≥75% in 79% of patients. Noninducibility may be an appropriate endpoint in 
patients with NICM, as recurrence rates are low after complete procedural success, but 
high after both partial success and failure. Importantly, induction of very fast VT after 
ablation appears not to be a non-specific finding. Non-complete procedural success, a 
lower LVEF, VT storm, a higher number of clinical VTs, a higher number of failed AADs 
and a higher mean CL of induced VTs are predictors of VT recurrence. After ablation for 




There are limited data on ventricular tachycardia (VT) ablation in patients 
with nonischemic left ventricular cardiomyopathy, in particular, on the 
procedural end point. The present study comprised 45 patients with 
nonischemic cardiomyopathy who underwent VT ablation. The complete 
programmed electric stimulation protocol was consistently applied after 
the last radiofrequency energy application in each patient, resulting in 
noninducibility of any VT in 38%, induction of nonclinical VT in another 
38%, and inducibility of the clinical VT in 24%. Although VT recurred in 
approximately half of the patients during follow-up, the VT burden was 
substantially reduced in the majority. In 25 patients VT ablation was 
performed because of a first VT, symptomatic ATP, or a single implantable 
cardioverter defibrillator shock; 56% of these patients remained free 
from VT during follow-up, suggesting that catheter ablation may also be 
considered early in the therapeutic course. Programmed electric stimula-
tion after ablation seemed to provide important prognostic information. 
Noninducibility of any VT was associated with a very low recurrence rate 
during long-term follow-up, whereas persistent inducibility of clinical or 
nonclinical VT was associated with a poor prognosis. Induction of very 
fast VT, which has previously been considered a nonspecific finding, 
also seemed to be associated with a high recurrence rate. Inducibility 
of VT after ablation was the strongest predictor of VT recurrence. These 
data support the role of programmed electric stimulation to assess the 
procedural end point in patients with nonischemic cardiomyopathy and 
may, therefore, significantly aid clinicians who perform VT ablation in this 
population.
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This study aimed to evaluate the impact of early reperfusion during acute myocardial 
infarction (MI) on ventricular tachycardia (VT) inducibility, inducible VT cycle length (CL) 
and occurrence of spontaneous VT late after MI.
Methods and results
Five-hundred-six patients (440 male, 63±11yr) with prior MI who underwent electro-
physiology study before implantation of an implantable cardioverter defibrillator for 
primary or secondary prevention were assessed. Patients were classified according to 
the reperfusion strategy {reperfusion (thrombolysis (n=44) or percutaneous coronary in-
tervention (n=65)) vs. no reperfusion (n=397)} during acute MI. Monomorphic sustained 
VT was inducible in 351 (69%) patients. Inducibility in reperfused and non-reperfused 
patients was similar in primary prevention patients (56% vs.58%) but significantly higher 
for non-reperfused patients in secondary prevention patients (56% vs.79%, p=0.001). In-
duced VTCL was shorter (247±40 vs.287±63, p<0.001) and very fast VT (CL≤250 ms) was 
more often induced in reperfused patients (71% vs.47%, p=0.001). In primary preven-
tion patients, non-reperfusion was associated with a doubled risk for first spontaneous 
VT during follow-up.
Conclusion
There are important differences in VT inducibility, induced VTCL and occurrence of 
spontaneous VT in the chronic infarct healing phase between patients with and without 
successful reperfusion during acute MI. These findings suggest differences in the chronic 
arrhythmogenic substrate.
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InTRoDUCTIon
Survivors of acute myocardial infarction (MI) may be at risk for reentrant ventricular 
tachycardia (VT) originating from infarct scar.1 In the past decades, early reperfusion 
therapies such as thrombolysis and primary percutaneous coronary intervention (PCI) 
have significantly improved outcome after acute MI.2 Early reperfusion during MI re-
sults in myocardial salvage and improved ventricular function but also influences size, 
transmurality and geometry of myocardial fibrosis, which may function as a substrate 
for ventricular arrhythmias.3-7 A fixed substrate may lead to reentrant tachycardias repro-
ducible induced during electrophysiology study (EPS) and more than 90% of patients 
with sustained VT late after MI had the arrhythmia induced in the lab.8 However, these 
data were derived before the widespread availability of reperfusion therapy and the role 
for EPS in patients late after reperfused MI is less clear. Mapping studies demonstrated 
that the 3-dimensional geometry of the infarcted area may determine VT reentry circuit 
characteristics.9-12 In a small group of patients referred for treatment of VT late after MI, 
we previously demonstrated that early reperfusion affects the electroanatomical VT 
substrate.13 In addition, cycle length (CL) of spontaneous and induced VTs was shorter 
in patients who underwent early reperfusion as compared to non-reperfused patients.
The aim of the present study was to evaluate the effect of early reperfusion during 
acute MI on VT inducibility, induced VTCL and the occurrence of spontaneous VT during 
follow-up in a larger population of patients with prior MI in one coronary territory who 
underwent EPS before implantable cardioverter defibrillator (ICD) treatment.
MeThoDS
Patients
Since 1996, information on all patients who received an ICD at the Leiden University 
Medical Center was prospectively collected in the departmental Cardiology Informa-
tion System (EPD-Vision®, Leiden University Medical Center). Patient’s history, baseline 
characteristics and results of studies before ICD-implantation were recorded. For the 
current study, all consecutive patients (1) with a prior MI in a single coronary territory 
and documented reperfusion strategy during the index MI; (2) without evidence of re-
versible ischemia assessed by coronary angiogram and nuclear imaging at the time of 
evaluation, and (3) who underwent EPS before ICD implantation were included. Patients 
with documented spontaneous monomorphic VT or ventricular fibrillation (VF) in the 
absence of a reversible cause were considered as secondary prevention ICD recipients 
and asymptomatic patients with left ventricular ejection fraction (LVEF) <40% without 
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prior documentation of a sustained ventricular arrhythmia primary prevention ICD 
recipients.14-16
All coronary angiograms performed in reperfused patients within 6 months before 
EPS were reviewed by an interventional cardiologist to evaluate the late patency of 
the infarct related artery. Patients with ≤ TIMI II flow of the infarct related artery were 
excluded from analysis. All patients were followed at our institute.
Myocardial infarction
The presence of prior MI was assessed using the definition for MI, as defined by the Task 
Force for the Redefinition of Myocardial Infarction.17 Either acute MI had to be docu-
mented, or evidence of prior MI had to be present, based on any of the following criteria: 
1) development of new pathological Q-waves with or without symptoms; 2) imaging 
evidence of a region of loss of viable myocardium that is thinned and fails to contract, 
in the absence of a non-ischemic cause; 3) pathological findings of a healed or healing 
MI.17
MI was considered to be present in more than one coronary artery region if the criteria 
for acute or prior MI were met for more than one of the regions provided by the three 
main coronary arteries.
The treatment of prior MI was assessed using the patients’ medical charts. Patients 
were categorized as reperfused when TIMI flow grade 3 was achieved within 9 hours 
after onset of symptoms. Reperfused patients were subdivided into patients who had 
underwent primary PCI (defined as angioplasty and/or stenting without prior or con-
comitant fibrinolytic therapy)18 and patients who had received thrombolytic therapy. All 
other patients were categorized as non-reperfused.
electrophysiology study
Electrophysiological studies to test inducibility of VT were performed according to 
the current international guidelines.19 Patients were studied in the post absorptive, 
non-sedated state. Antiarrhythmic drugs were discontinued for 5 half-lives, with the 
exception of amiodarone. EPS consisted of up to three basic drive cycle lengths (600, 
500 and 400ms) with up to three ventricular extrastimuli and burst pacing from the right 
ventricular apex and right ventricular outflow tract. The positive endpoint of EPS was 
reproducible induction of a sustained monomorphic VT (SMVT).19 Arrhythmias induced 
by anti-tachycardia pacing (ATP) to terminate the induced VT were not included in the 
analysis.
Ventricular arrhythmia during electrophysiology study
Ventricular arrhythmias were categorized according to the EHRA/HRS consensus docu-
ment.20 SMVT was defined as continuous VT with a similar QRS configuration from beat 
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to beat lasting for more than 30 seconds or requiring an intervention for termination. 
Separately scored arrhythmia not considered diagnostic for the presence of fixed reentry 
circuits and therefore non-specific were polymorphic VT, defined as VT with continu-
ously changing QRS configuration from beat to beat and VF.19
For each patient, the mean CL of all induced SMVTs was calculated. Patients with 
missing data on one or more CLs were excluded from all analyses involving VTCL. Mono-
morphic VTs were categorized into the following four pre-defined subgroups according 
to CL: ≤250, 251-286, 287-320 and >320 ms (corresponding to a rate of  ≥240, 240-210, 
210-188 and <188bpm, respectively). A very fast VT was defined as a VT with CL ≤250 ms.
Implantable cardioverter defibrillator settings and follow-up
Defibrillators were programmed as follows: a ventricular arrhythmia monitor zone was 
programmed in all patients (150-188bpm). Ventricular arrhythmias faster than 188bpm 
were initially attempted to be terminated with two bursts of ATP followed by a defibril-
lator shock, if appropriate. In the case of a ventricular arrhythmia faster than 210bpm, 
device shocks were the initial therapy. Atrial arrhythmia detection was set to >170bpm 
with supraventricular tachycardia discriminators enabled. Settings were adapted, only 
when clinically indicated (i.e. hemodynamic well tolerated VT at high rate; VT in the 
monitor zone).
Patient follow-up was scheduled every three-six months. Device interrogation 
printouts were checked for appropriate and inappropriate ICD therapy (ATP or shocks). 
Therapies were classified as appropriate when they occurred in response to VT or VF 
and as inappropriate when triggered by sinus or supraventricular tachycardia, T-wave 
oversensing, or electrode dysfunction.
In both primary and secondary prevention ICD recipients, the correlation between 
treatment of acute MI and the occurrence of first spontaneous monomorphic VT during 
follow-up was assessed.
Statistical analysis
Dichotomous and categorical data are displayed as numbers and percentages. Continu-
ous data are expressed as mean ± standard deviation or median and interquartile range 
where appropriate. Patients were grouped according to acute MI treatment. Different 
groups were compared for 1) inducibility of SMVT, 2) mean CL of induced SMVTs, 3) 
inducibility of very fast VT (CL ≤250ms), and 4) the occurrence of first spontaneous VT 
during follow-up in primary and secondary prevention ICD patients. Data were analyzed 
by means of the Chi-square test, the Student’s t-test or the Mann-Whitney U-test as 
appropriate. For the Student’s t-test, equal variances were assumed if Levene’s test for 
equality of variances showed a p-value >0.05. Univariate relationships between baseline 
parameters and the mean CL of induced VTs were analyzed with linear regression analy-
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sis. For each variable, the effect on the mean CL with a 95% confidence interval (95%-CI) 
was calculated. Variables with a p-value <0.10 were further evaluated in a multivariate 
model, using backward stepwise selection. At each step, the least significant variable 
was discarded from the model, until all variables in the model reached a p-value <0.25.
The cumulative incidence of first spontaneous VT during follow-up in primary and 
secondary prevention ICD patients was analyzed by method of Kaplan-Meier. The effect 
of acute MI treatment on the risk of spontaneous VT was assessed in a Cox regression 
model. As with linear regression analysis, first, univariate analyses were performed and 
variables with a p-value <0.10 were further evaluated in a multivariate model, using 
backward stepwise selection. At each step, the least significant variable was discarded 
from the model, until all variables in the model reached a p-value <0.25.
All analyses were performed with SPSS for Windows, version 17.0 (SPSS, Chicago, IL). 




Since 1996, 996 patients with prior MI in one coronary artery region received an ICD 
at the Leiden University Medical Center. Of these patients, 511 had a documented 
reperfusion strategy and underwent EPS before ICD implantation and after exclusion 
of reversible ischemia. Five patients (1%) were excluded due to lack of late patency of 
the infarct related artery. The remaining 506 patients (87% male, age 63 ± 11 years) 
comprised the studied sample. The presenting and documented arrhythmia was SMVT 
in 221 patients (44%) and VF in 113 (22%); 172 patients (34%) had no prior sustained 
arrhythmia. The majority of patients had a depressed left ventricular ejection fraction 
(36 ± 13%). Mean QRS duration was 115 ± 29 ms and mean creatinin clearance was 79 
± 39mL/min. Medication during EPS included amiodarone in 22% and ACE-inhibitors or 
ATII-antagonists in 75% of patients. Baseline characteristics are summarized in Table 1.
Myocardial infarction treatment
One-hundred-nine (22%) of 506 patients were treated with reperfusion therapy during 
the acute MI and 397 (78%) were not reperfused. Of the 109 reperfused patients, 65 
(13%) underwent primary PCI and 44 (9%) received thrombolytic therapy. Before elec-
trophysiological evaluation, the infarct-related artery was patent in 97 (89%), collaterally 
perfused in 11 (10%) and bypassed in one (1%) of the initially reperfused patients. In 
non-reperfused patients, the infarct-related artery was patent in 140 (35%), occluded in 
116 (29%), collaterally perfused in 88 (22%) and bypassed in 53 (13%). Patients who were 
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reperfused were younger than non-reperfused patients (59 ±11 vs. 65 ±10, p<0.001), 
presented less often with SMVT (22% vs. 49%, p<0.001) and had a shorter interval 
between MI and electrophysiological evaluation (median 1.6, IQR 0.2 – 5.9 vs. median 
10.5, IQR 2.1 – 17.5, p<0.001). In addition, reperfused patients had an anterior MI more 
frequently (72% vs. 52%, p<0.001), a shorter QRS-duration (median 100, IQR 90 – 120 
vs. median 110, IQR 100 – 138, p=0.001), were less often treated with amiodarone (12% 
vs. 25%, p=0.001) but were more likely to receive beta-blockers (53% vs. 40%, p=0.014).









Male sex 440 (87%) 341 (86%) 99 (91%) 0.176
Age, y 65 (57–71) 66 (58–73) 60 (51–68) <0.001
Presenting arrhythmia <0.001
 Sustained VT 221 (44%) 197 (50%) 24 (22%)
 Ventricular fibrillation 113 (22%) 94 (24%) 19 (17%)
 No sustained arrhythmia 172 (34%) 106 (27%) 66 (61%)
Location of MI <0.001
 Anterior 285 (56%) 206 (52%) 79 (72%)
 Nonanterior 221 (44%) 191 (48%) 30 (28%)
Years from MI to EPS 7.5 (0.9–15.0) 10.5 (2.1–17.5) 1.6 (0.2–5.9) <0.001
LVEF, % 36±13 35±13 37±13 0.180
NYHA classification 0.555
 I 227 (45%) 172 (43%) 55 (50%)
 II 201 (40%) 164 (41%) 37 (34%)
 III 72 (14%) 56 (14%) 16 (15%)
 IV 6 (1%) 5 (1%) 1 (1%)
QRS duration, ms 110 (94–130) 110 (100–138) 100 (90–120) 0.001
Renal clearance, mL/min* 79±39 77±41 85±27 0.066
Documented AF or atrial flutter 89 (18%) 69 (17%) 20 (18%) 0.823
Current smoking 126 (25%) 94 (24%) 32 (29%) 0.253
Amiodarone 111 (22%) 98 (25%) 13 (12%) 0.004
β-blocker 217 (43%) 159 (40%) 58 (53%) 0.014
ACE inhibitor or ARB 380 (75%) 291 (73%) 89 (82%) 0.070
ACE indicates angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; 
ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; MI, myocardial infarction; 
NYHA, New York Heart Association; EPS, electrophysiological study; and VT ventricular tachycardia.
Data are expressed as No. (percentages), mean±SD, or median (interquartile range).
* Renal clearance was determined with the formula of Cockroft-Gault.
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Inducibility of ventricular arrhythmia
In 422 patients (83%), at least one ventricular arrhythmia was inducible: SMVT was in-
duced in 351 (69%) patients, 45 of them were also inducible for polymorphic VT or VF. In 
71 (14%) patients, only polymorphic VT or VF was induced. Inducibility of SMVT consisted 
of only one VT morphology in 222 (63%) and two or more different morphologies in 
129 (37%) patients. Inducibility for SMVT was similar in reperfused and non-reperfused 
patients without prior documentation of sustained VT or VF (56% vs 58%, p=ns). How-
ever, in the secondary prevention group inducibility for SMVT was significantly lower 
in reperfused patients as compared to non-reperfused patients (56% vs 79%, p=0.001).
Ventricular tachycardia cycle length
In 37 (11%) out of 351 patients with inducible SMVT, one or more induced VTCL was un-
known, these patients were excluded from VTCL analyses. In the remaining 314 patients, 
the mean CL was 280 ± 61 ms (Table 2). In 161 (51%) patients, at least one monomorphic 
fast VT (CL ≤ 250) was induced.
Reperfused patients had a shorter mean CL of the induced VT than non-reperfused 
patients (247 ± 40ms vs. 287 ± 63ms, p<0.001, Table 2). This difference was even more 
pronounced when patients who underwent primary PCI were compared to non-reper-
fused patients (238 ± 40ms vs. 287 ± 63ms, p<0.001). Patients treated with thrombolysis 
also had a significantly shorter mean CL than non-reperfused patients, but the differ-
ence was smaller (260 ± 37ms vs. 287 ± 63ms, p=0.038). After exclusion of patients on 
amiodarone during EPS the induced VTCL remained significantly shorter in reperfused 
patients (244 ± 40ms vs. 274 ± 58ms, p<0.001). Of importance, reperfused patients were 
more often inducible for very fast VT (CL ≤ 250ms) than non-reperfused patients (71% 
vs. 47%, p=0.001, Figure 1). The difference was mainly attributable to patients treated 
with primary PCI, while patients treated with thrombolysis had a similar percentage 
of very fast VT, as compared to non-reperfused patients. Univariate and subsequent 
Table 2. Difference of Mean Cycle Length of Induced Monomorphic Ventricular Tachycardias by t 
Tests.
n Mean CL Difference* (95% CI) P Value
All patients 314 280±61 NA NA
Nonreperfused 258 287±63 NA NA
Reperfused 56 247±40 40 (27–53) <0.001
 Thrombolysis 23 260±37 27 (2–53) 0.038
 Primary PCI 33 238±40 49 (27–70) <0.001
CI indicates confidence interval; CL, cycle length; NA, not applicable; and PCI, percutaneous coronary in-
tervention.
* When compared with nonreperfused patients.
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multivariate analysis identified the following five variables as independently affecting 
the mean CL of induced VTs: no reperfusion, QRS > 120 ms, presenting arrhythmia, use 
of amiodarone and age. After adjustment, no reperfusion at MI was correlated with 17 
ms (95%-CI 0-34 ms, p=0.048) increase in VT CL at EPS (Figure 2).
Spontaneous ventricular tachycardia
The 172 primary prevention ICD recipients were followed for a median of 28 months 
(IQR 11 – 45). During follow-up, spontaneous VT, triggering appropriate ICD therapy was 
observed in 51 (30%) patients. The cumulative incidence of first appropriate therapy 
was 13% (95% CI 8-18%) at one year, 22% (95% CI 15-28%) at two years, and 30% (95% 
CI 22-39%) at three years follow-up.
The three year cumulative incidence of first appropriate device therapy was 36% (95% 
CI 26-47%) in non-reperfused patients and 18% (95% CI 7-29%) in reperfused patients 
(Figure 3). Cox regression modeling demonstrated that non-reperfused patients exhibited 
a more than doubled risk for spontaneous VT (hazard ratio 2.2, 95% CI 1.2- 4.3, p=0.010).
The 334 secondary prevention ICD recipients were followed for a median of 37 
months (IQR 9 – 68). Spontaneous VT occurred in 170 (51%) patients. The three year 
cumulative incidence of first appropriate device therapy was 38% (95% CI 32-44%) in 
Figure 1.
Cycle length of the fastest induced monomorphic ventricular tachycardia, categorized into 4 subgroups. 
Percentages are for all patients with induced monomorphic ventricular tachycardia in the specific group. 
PCI indicates percutaneous coronary intervention.
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Figure 2.
Forest plot of the effect of baseline parameters on the mean cycle length of induced monomorphic ven-
tricular tachycardias (VT). For example, in multivariate analysis, patients who did not receive reperfusion 
therapy at the index myocardial infarction on average had a 17-ms (95% confidence interval [CI], 0 to 34 
ms) longer Vt cycle length (ie, a slower Vt), as compared with patients who did receive reperfusion therapy. 
AF indicates atrial fibrillation; LVEF, left ventricular ejection fraction; EPS, electrophysiology study; VA, ven-
tricular arrhythmia; and VF, ventricular arrhythmia.
Figure 3.
Kaplan-Meier curve for the occurrence of first appropriate implantable cardioverter-defibrillator therapy in 
patients with primary-prevention implantable cardioverter-defibrillator with reperfusion versus no reper-
fusion at prior acute myocardial infarction.
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non-reperfused patients and 26% (95% CI 12-39%) in reperfused patients (Figure 4). 
In this population with prior sustained ventricular arrhythmia, MI treatment did not 
significantly correlate with the occurrence of spontaneous VT during follow-up (hazard 
ratio 1.4, 95% CI 0.9-2.3).
DISCUSSIon
Early reperfusion therapy for acute MI has dramatically increased over the last decen-
niums and is likely to influence the chronic arrhythmogenic substrate for reentrant 
tachycardias after infarct healing.
The current study evaluates the effects of early reperfusion during acute MI on VT 
inducibility, induced VT CL and occurrence of spontaneous VT late after the index MI. 
Reperfused patients who presented with sustained VT or VF were less likely inducible 
for monomorphic VT as compared to non-reperfused patients. Reperfused and non-
reperfused patients without prior sustained arrhythmia had comparable VT induction 
rates; however reperfused patients were less likely to experience spontaneous VT during 
follow-up. Among inducible patients VTCL of induced VTs was significantly shorter and 
inducible VT was more often very fast VT (CL ≤ 250 ms) in reperfused patients. These 
differences were even more pronounced in patients treated with primary PCI as com-
pared to thrombolytic therapy. After adjustment for potential confounders, treatment 
of the index MI appeared to have an independently significant effect on the mean CL of 
induced VTs.
Figure 4.
Kaplan-Meier curve for the occurrence of first appropriate implantable cardioverter-defibrillator therapy 
in patients with secondary-prevention implantable cardioverter-defibrillator with reperfusion versus no 
reperfusion at prior acute myocardial infarction.
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early reperfusion during MI and inducibility of VT
Former studies performed before the widespread availability of reperfusion therapy 
have demonstrated that in patients with coronary artery disease VT was inducible in 92% 
of patients who presented with sustained VT and in 83% of patients who presented with 
cardiac arrest due to VF.8 Accordingly, 79% of the non-reperfused patients in our study 
who presented with sustained VT or VF were inducible for monomorphic VT. In contrast, 
in only 56% of reperfused patients with documented VT or VF monomorphic VT was 
inducible. Although all patients had a chronic substrate as spontaneous arrhythmias oc-
curred in the absence of a reversible cause the sensitivity of an EPS for substrate assess-
ment after reperfusion therapy seems to be low. This finding is of clinical importance if 
EPS is performed for the evaluation of patients who present with unexplained syncope 
due to non-documented VT or during ablation procedures of VT if non-inducibility of 
monomorphic VT is considered as endpoint for ablation.
Acute reperfusion has resulted in a lower prevalence of spontaneous and induced 
ventricular arrhythmias in the acute phase of MI..4, 21-23 In small series, 9-48% of patients 
receiving thrombolysis were inducible for ventricular arrhythmias as compared to 
88-100% of patients without reperfusion therapy.24, 25 However, the arrhythmogenic 
substrate causing late ventricular arrhythmias may develop over time. In our series, 
EPS was performed in the chronic healing phase of MI. Of interest, non-reperfused and 
reperfused patients without prior spontaneous arrhythmia showed high inducibility 
rates of 58% and 56%, respectively. However, during follow-up the three year cumula-
tive incidence of appropriate device therapy was 36% in non-reperfused patients and 
only 17% in reperfused patients. This finding suggest that despite the presence of an ar-
rhythmogenic substrate the value of EPS to predict VT occurrence is lower in reperfused 
patients as compared to non-reperfused patients.
effect of early reperfusion and inducible VTCL
Early reperfusion during MI results in myocardial salvage and reduced mortality during 
follow-up.3 Histological studies in patients and animal models of acute MI have shown 
that the duration of coronary artery occlusion is proportionally correlated to the size 
and transmural extent of myocardial scar.4, 5, 26 Scar size and geometry are important 
determinants for the reentrant circuit geometry and may contribute to  occurrence and 
cycle length of VT.9, 27
We recently demonstrated that reperfused patients referred for ablation of recurrent 
VT late after MI appeared to have smaller and less confluent electroanatomical scars 
with thick layers of surviving myocardium found at histology. Interestingly, the CL of 
spontaneous and induced VTs was shorter in reperfused than in non-reperfused patients 
likely due to the observed differences in scar geometry after reperfusion therapy.13 The 
association between acute reperfusion therapy and shorter inducible VTCL was con-
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firmed and extended, as the present study is conducted in a large population of post-MI 
patients also including patients without previously documented ventricular arrhythmia. 
In addition, we adjusted for all baseline characteristics that affect induced VTCL.
Limitations
Our study was performed in a selected population of ICD recipients with prior MI and low 
LVEF, who are not representative for the general population with prior MI. In addition, 
our cutoff of 9 hours for early reperfusion is arbitrarily chosen. Furthermore, we studied 
induced VTs, and our findings do not necessarily apply to spontaneous VTs. However, in 
the previous study by Wijnmaalen et al., spontaneous VTs were taken into account and 
similar differences were found, as compared to induced VTs. Finally, therapy for acute 
MI was not randomly assigned and time from MI to EPS differs between groups, which 
could have resulted in selection bias. However, since primary PCI has been shown to be 
the preferred treatment for acute MI, a study in which patients would be randomly as-
signed to primary PCI, thrombolysis or conservative treatment is ethically unacceptable 
and therefore, selection bias is now inevitable in studying the effects of reperfusion. To 
correct for it, we adjusted for baseline characteristics using linear regression and could 
demonstrate that reperfusion independently affects the CL of induced VTs.
ConCLUSIon
There are important differences in VT inducibility, induced VTCL and occurrence of spon-
taneous VT in the chronic phase of MI between patients with and without successful 
reperfusion during acute MI. Reperfused patients who present with sustained VT/VF are 
less likely inducible for monomorphic VT. Despite similar VT induction rates in patients 
without prior documented sustained arrhythmias, reperfused patients are at lower risk 
for spontaneous VT. However, early reperfusion is associated with faster induced VT.
These findings suggest important differences in the chronic arrhythmogenic substrate 




Early reperfusion during myocardial infarction (MI) results in myocar-
dial salvage and improved ventricular function, but it also influences the 
specific dimensions and geometry of myocardial fibrosis and thus the 
propensity for ventricular arrhythmia occurring late after MI. Recently, it 
has been demonstrated that reperfusion is associated with smaller, less 
confluent myocardial scars that appear to give rise to faster spontaneous 
and induced ventricular tachycardias (VTs) in patients referred for VT abla-
tion late after MI. The present study comprised a large population of post-
MI patients referred for electrophysiological evaluation and implantation 
of implantable defibrillators, without previously documented ventricular 
arrhythmia. In this population, reperfusion during MI affects inducibility, 
spontaneous occurrence, and cycle length of VTs. Monomorphic VT was 
inducible in only 56% of reperfused patients as compared with 79% of 
nonreperfused patients with documented VT or ventricular fibrillation. 
Reperfused and nonreperfused patients without prior sustained arrhyth-
mia had comparable VT induction rates, but reperfused patients were less 
likely to have spontaneous VT during follow-up, suggesting that the value 
of electrophysiological study to predict VT occurrence is lower in reper-
fused patients as compared with nonreperfused patients. Finally, induced 
VTs were faster in reperfused patients. These findings probably reflect a 
different chronic arrhythmogenic substrate in reperfused patients, mani-
fest by faster VTs and less reliably assessed by electrophysiological study.
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The relation between myocardial scar and different types of ventricular arrhythmias in 
patients with non-ischemic dilated cardiomyopathy (NIDCM) is unknown.
objectives
To analyze the effect of myocardial scar, assessed by late gadolinium enhancement 
(LGE)-CMR, on the occurrence and type of ventricular arrhythmia in patients with NIDCM.
Methods
Consecutive patients with NIDCM who underwent LGE-CMR and ICD implantation at 
two centers were included. LGE was defined by signal intensity ≥35% of maximal signal 
intensity, subdivided into core and border zone (≥50% and 35-50% of maximal signal 
intensity, respectively), and categorized according to (non)basal location and transmu-
rality. ICD recordings and ECGs were reviewed to determine the occurrence and type of 
ventricular arrhythmia during follow-up.
Results
Of 87 patients (age 56±13 years, 62% male, LVEF 29±12%), 55 (63%) had LGE (median 
6.3g, interquartile range 0.0–13.8g). During a median follow-up of 45 months, mono-
morphic VT occurred in 18 (21%) patients, and polymorphic VT/VF in 10 (11%). LGE 
predicted monomorphic VT (Log-rank, p<0.001), but not polymorphic VT/VF (Log-rank, 
p=0.40). The optimal cut-off value for LGE to predict monomorphic VT was 7.2g (area 
under curve 0.84). Features associated with monomorphic VT were core extent, basal 
location, and area with 51-75% LGE transmurality.
Conclusions
Myocardial scar assessed by LGE-CMR predicts monomorphic VT, but not polymorphic 
VT/VF in NIDCM. The risk for monomorphic VT is particularly high when LGE shows a 
basal transmural distribution and a mass ≥7.2g. Importantly, patients without LGE on 
CMR remain at risk for potentially fatal polymorphic VT/VF.
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InTRoDUCTIon
The presence of myocardial scar, as assessed by late gadolinium enhancement (LGE)-
CMR, is an independent predictor of appropriate ICD therapy, sudden cardiac death and 
all-cause mortality in patients with non-ischemic dilated cardiomyopathy (NIDCM).1-4 
Ventricular arrhythmias do however occur in patients without LGE and may be caused 
by a different underlying substrate.1,2,4
Sustained monomorphic ventricular tachycardias (VTs) in patients with NIDCM under-
going catheter ablation are often due to scar-related fixed re-entry. Slow-conducting 
parts of these re-entry circuits are found in regions with myocardial scar, as demon-
strated by integrating LGE-CMR data with 3D electroanatomical maps during VT abla-
tion.5-8 Several mechanisms for monomorphic VT have however been proposed9 and the 
association between LGE and monomorphic VT has never been systematically analyzed 
in the general population of patients with NIDCM.
In contrast to sustained monomorphic VT, polymorphic VT and VF are thought to be 
related to multiple wavelet re-entry or a mother rotor fractionating to daughter wave 
fronts, resulting in continuously changing activation.10 Although normal myocardium 
can sustain VF, different cardiac fibrosis patterns may contribute to the initiation and 
maintenance of polymorphic VT/VF.
The aims of the present study were (1) to analyze the effect of myocardial scar, as 
assessed by LGE-CMR, on the occurrence and type of ventricular arrhythmias in patients 
with NIDCM and (2) to evaluate the predictive value of LGE presence, extent and charac-
teristics, for monomorphic VT.
MeThoDS
Patients
All patients with NIDCM who underwent LGE-CMR before ICD implantation at Leiden 
University Medical Centre (n=46) and Maastricht University Medical Centre (n=41), the 
Netherlands, between 2004 and 2012 were included. Patients who were implanted at 
the Maastricht University Medical Centre but followed at another center were excluded. 
The diagnosis of NIDCM was based on World Heart Organization definitions11 and on 
CMR findings, requiring increased LV end-diastolic volume index and decreased LV 
ejection fraction (LVEF) compared with published 95% reference ranges normalized for 
gender, age and body surface area.12 Significant coronary artery disease (≥70% stenosis 
in a major coronary artery) was excluded by coronary angiography or MDCT in all pa-
tients. Patients with sarcoidosis, amyloidosis or subendocardial LGE in a coronary artery 
perfusion territory were excluded.
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The Dutch Central Committee on Human-related Research (CCMO) allows use of 
anonymous data without prior approval of an institutional review board provided that 
the data is acquired for patient care. All data used for this study was acquired for clinical 
purposes and handled anonymously.
LGe-CMR acquisition
CMR was performed on a 1.5T Gyroscan ACS-NT/Intera MR system (Philips Medical Sys-
tems, Best, the Netherlands) at the two centers. A standardized protocol was followed, 
including cine imaging in long-axis (two- and four-chamber) views, and in short-axis 
view covering the complete LV.
Approximately 15 minutes after bolus injection of gadolinium (Magnevist; Schering, 
Berlin, Germany; 0.15 mmol/kg) a look-locker sequence was acquired in short axis orienta-
tion at mid-ventricular level. T1-weighted LGE images were acquired with an inversion-
recovery 3D turbo-field echo sequence with parallel imaging. Typical scan parameters 
were: average TR/TE 3.7/2.4ms, Flip angle 15°, FOV 400mm, matrix 256×206, acquired and 
reconstructed voxel size 1.56x1.94x5mm. The inversion time was optimized to null normal 
appearing myocardium. The heart was imaged in long-axis two- and four-chamber views 
(between 5-10 slices), and short-axis views (between 20-24 slices). Signal outside the field 
of view was suppressed using two saturation slabs to avoid fold-over artifacts.
CMR image analysis
All CMR analyses were performed using Mass software (research version 2012; LKEB; 
Leiden University Medical Centre, the Netherlands). The LV and RV end-diastolic and 
end-systolic endocardial contours were traced on cine images to calculate LV mass, end-
diastolic volumes, end-systolic volumes and ejection fractions. Volumes and LV mass 
were indexed to body surface area.
To measure post-contrast T1-values, LV endocardial and epicardial contours were 
semi-automatically traced on look-locker images. Signal intensity was plotted against 
time and fitted to an exponential curve to obtain T1-values for the six midventricular 
segments, according to the American Heart Association (AHA) 17-segment model. The 
overall T1-value was defined as the average of these T1-values, excluding segments with 
LGE, to analyze the effects of myocardial scar and diffuse fibrosis separately. Similar to 
the method reported by Gai et al.13, T1-values were normalized to a heart rate of 60 bpm 
using the following formula: T1 corrected = T1 uncorrected + α*(60–heart rate), where 
α equals -3.409, i.e. the slope of the regression line of heart rate vs. T1 of nonenhanced 
segments. Shorter T1 values indicate more diffuse myocardial fibrosis.14
Myocardial scar was assessed while the observer was blinded to clinical data and 
outcome, and was only considered to be present if LGE was visible in 2 orthogonal 
views. LGE was defined by signal intensity ≥35% of maximal myocardial signal intensity, 
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and subdivided into core (≥50% of maximal signal intensity) and border zone (35-50% 
of maximal signal intensity).15 To assess the predictive value of LGE location, intensity 
and transmurality for monomorphic VT, the following parameters were calculated using 
Mass research software:
1. Extent of LGE (≥35% of maximal signal intensity, in grams) in basal and nonbasal 
segments (American Heart Association segments 1-6 and 7-17, respectively);
2. Extent of LGE (in grams) according to pre-defined signal intensity categories (30-
40%, 40-50%, 50-60%, 60-70% and >70% of maximal signal intensity)
3. Endocardial surface area of myocardial regions with LGE (≥35% of maximal signal 
intensity, in cm2) according to pre-defined transmurality categories (1-25%, 26-50%, 
51-75% and 76-100% transmurality).
ICD programming and follow-up
ICDs were typically programmed to include 3 zones: monitor zone (150-188bpm, an-
titachycardia pacing [ATP] if clinically indicated), fast VT zone (188-210bpm, ATP and 
shock), VF zone (>210bpm, if available ATP during charging, and shock). Patients were 
followed at 6-monthly intervals. Intracardiac recordings were analyzed by an experi-
enced observer who was blinded to clinical and CMR data when reviewing the record-
ings. The combined endpoint of any ventricular arrhythmia consisted of monomorphic 
VT and polymorphic VT/VF. Monomorphic VT was defined as VT with ≤30ms beat-to-
beat variation in cycle length and stable far-field electrogram morphology, lasting 
>30 seconds or treated with ATP and/or shock. Polymorphic VT/VF was defined as any 
ventricular arrhythmia with >30ms beat-to-beat variation in cycle length and unstable 
far-field electrogram morphology, lasting >30 seconds or treated with ATP and/or shock. 
If ICD recordings and/or 12-lead ECGs were not available for some of the episodes, the 
missing episodes were considered to be of the same type as the documented episodes 
provided that the cycle length was similar. When ICD recordings and/or 12-lead ECGs 
were missing for all episodes, patients were excluded from all analysis involving the type 
of arrhythmia.
Statistical analysis
Categorical variables are displayed as number (percentage) and compared using the χ2 
test or the Fisher’s exact test. Continuous variables are expressed as mean ± standard 
deviation or median (interquartile range [IQR]), and compared using the Student’s t test 
or the Mann-Whitney U test when appropriate. The LGE extent in basal and nonbasal 
segments was compared using the Wilcoxon signed rank test.
Kaplan Meier survival analysis and Cox proportional hazard analysis were performed to 
identify predictors for arrhythmic events during follow-up. Multivariable Cox proportional 
hazard analyses were performed to analyze the independent predictive value of LGE and 
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specific LGE features, adjusting for other predictors with a p-value<0.10 in univariable 
analyses and for other LGE features of interest, respectively. A maximum of 1 variable 
per ~10 endpoints was included in the models. Receiver operating characteristic curve 
analysis was performed to determine the optimal cut-off values of LGE for prediction of 
monomorphic VT, which were defined as the values maximizing the sum of sensitivity and 
specificity. All analyses were performed with SPSS version 20.0 (IBM, Somers, New York, 
USA). All tests are two-sided and p-values<0.05 were considered significant.
ReSULTS
Patients
Of the 87 patients (age 56±13 years, 62% male), 64 (74%) underwent ICD implantation 
for primary prevention, 10 (11%) after presentation with sustained monomorphic VT 
and 13 (15%) after out-of-hospital cardiac arrest with VF as the initial recorded rhythm 
(OHCA-VF)(Table 1). Forty-six patients (53%) were implanted with a cardiac resynchroni-
zation therapy-defibrillator.
CMR parameters and presenting arrhythmia
Patients presenting with OHCA-VF and in particular patients presenting with sustained 
monomorphic VT had lower LV end-diastolic and end-systolic volume indexes and 
higher LVEF, compared to primary prevention patients (Table 1).
Overall, LGE was present in 55 patients (63%, examples in Figure 1A-F), with a median 
LGE extent of 6.3 g (IQR, 0.0–13.8). LGE was observed in 9 of 10 patients (90%) presenting 
with sustained monomorphic VT and in only 4 of 13 patients (31%) with OHCA-VF, com-
pared to 42 of 64 primary prevention patients (66%). The LGE extent was substantially 
higher in patients presenting with sustained monomorphic VT compared with primary 
prevention patients. In contrast, patients presenting with OHCA-VF tended to have less 
LGE than primary prevention patients.
The corrected T1 did neither differ between groups (Table 1) nor between patients 
with and without LGE (340±64 vs. 336±50, respectively, p=0.78).
Ventricular arrhythmias during follow-up
One patient (1%) was lost to follow-up after ICD implantation. During a median follow-up 
of 45 months (IQR, 23–67 months), 392 episodes of ventricular arrhythmia occurred in 
28 patients (32%) (examples in Figure 1G-H). The ICD tracings or 12-lead ECGs could be 
reviewed for 298 episodes (76%), with at least one reviewed episode in 26 of 28 patients 
(93%). Of the 2 remaining patients, one had a dislocated RV lead and was resuscitated 
because of OHCA-VF, with VF as the first recorded rhythm, and the other had one single 
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episode with ATP, with no available tracings. These 2 patients were excluded from all 
analysis involving the type of arrhythmia.
Monomorphic VT occurred in 18 patients (median 5, IQR 3–23 episodes per patient; 
mean cycle length 308±47ms). At least one episode was terminated by ATP in 15 patients 












Age 56±13 56±13 61±12 0.30 51±15 0.20
Male 54(62%) 37(58%) 8(80%) 0.30 9(69%) 0.44
NYHA functional class
 I 28(32%) 11(17%) 7(70%) 0.001 10(77%) < 0.001
 II 32(37%) 26(41%) 3(30%) 3(23%)
 III-IV 27(31%) 27(42%) 0(0%) 0(0%)
History of AF/atrial flutter 14(16%) 12(19%) 0(0%) 0.20 2(15%) 1.00
History of hypertension 25(29%) 18(28%) 3(30%) 1.00 4(31%) 1.00
Diabetes mellitus 6(7%) 4(6%) 2(20%) 0.18 0(0%) 1.00
eGFR, mL/min/1.73m2 72±24 69±22 74±12 0.51 86±31 0.027
QRS duration, ms 132±32 130±31 128±35 0.84 142±31 0.21
LV volumes and function
 LVEDV, mL 288 (231–358) 318 (248–376) 219 (180–241) 0.001 244 (213–302) 0.033
 LVESV, mL 209 (145–279) 228 (170–309) 119 (102–147) < 0.001 150 (128–197) 0.004
 LVEF, % 29±12 25±11 44±7 < 0.001 37±11 0.001
 LV mass, g 147 (111–176) 150 (114–177) 135 (102–155) 0.31 138 (93–194) 0.45
RV volumes and function
 RVEDV, mL 158 (129–204) 153 (129–208) 160 (126–192) 0.90 166 (133–182) 0.83
 RVESV, mL 80 (57–118) 80 (57–125) 75 (54–129) 0.68 71 (55–84) 0.16
 RVEF, % 47±15 44±15 49±14 0.40 56±11 0.004
T1 corrected 339±59 335±54 341±79 0.80 355±74 0.27
LGE
 LGE presence 55(63%) 42(66%) 9(90%) 0.16 4(31%) 0.019
 LGE extent
  Total LGE, g 6.3 (0.0–13.8) 5.8 (0.0–12.8) 16.6 (9.5–24.3) 0.007 0.0 (0.0–10.9) 0.14
  Core, g 2.8 (0.0–5.8) 2.6 (0.0–4.8) 10.0 (5.6–15.3) 0.002 0.0 (0.0–3.3) 0.094
  Border zone, g 3.0 (0.0–7.7) 2.5 (0.0–7.6) 5.9 (4.0–10.0) 0.070 0.0 (0.0–7.6) 0.14
Data are expressed as number (percentage), mean ± standard deviation or median (interquartile range).
AF indicates atrial fibrillation; BMI, body mass index; eGFR, estimated glomerular filtration rate; LGE, late 
gadolinium enhancement; LV, left ventricular; LVEDV, LV end-diastolic volume; LVEF, LV ejection fraction; 
LVESV, LV end-systolic volume; NYHA, New York Heart Association; OHCA, out-of-hospital cardiac arrest; RV, 
















Figure 1. examples of LGe-CMR and ventricular arrhythmias
Examples of a patient without LGE (panels A&D), small amount of LGE (panels B&E) and extensive LGE 
(panels C&F). Red indicates LGE core and yellow border zone. Monomorphic VT was related to LGE and 
frequently terminated by antitachycardia pacing (panel G), whereas polymorphic VT/VF was not related to 
LGE and typically terminated by an ICD shock (panel H).
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(83%) and ≥1 episode by an ICD shock in 9 (50%). Seven patients (39%) had ≥1 episode 
lasting >30 seconds in the monitor zone or below detection rate.
Polymorphic VT/VF occurred in 10 patients (one episode in 8 patients (80%), 2 and 
4 episodes in the remaining 2 patients). Nine of 10 patients (90%) only had episodes 
terminated by an ICD shock, while one patient had 4 episodes of polymorphic VT that 
stopped after a single burst of ATP.
Of note, only 2 patients had both monomorphic VT and polymorphic VT/VF – the 
other 26 patients with ventricular arrhythmias during follow-up had only one type of 
ventricular arrhythmia.
Predictors of different types of ventricular arrhythmia during follow-up
Predictors of monomorphic VT and polymorphic VT/VF were remarkably different. 
The presence of myocardial scar, as assessed by LGE-CMR, predicted the occurrence 
of monomorphic VT (p<0.001), but not of polymorphic VT/VF (p=0.41) (Figure 2, Table 
2, Supplemental Table 1). Accordingly, the total LGE extent was a strong predictor of 
monomorphic VT (p<0.001), but not of polymorphic VT/VF (p=0.66).
Monomorphic VT was also predicted by male gender, presentation with sustained 
monomorphic VT, hypertension, diabetes mellitus, LVEF and corrected T1 values. The 
LGE extent remained an independent predictor for monomorphic VT when adjusted for 
each of these parameters separately (Supplemental Table 2), and also when only primary 
prevention patients were analyzed (Supplemental Table 3 and supplemental Figure 1).
The only predictor of polymorphic VT/VF during follow-up was presentation with 
OHCA-VF (Table 2). Of importance, LV and RV volumes and function, and LGE presence 
and extent were not associated with the occurrence of polymorphic VT/VF.
The combined endpoint of any ventricular arrhythmia was predicted by the presence 
and extent of LGE, male gender, hypertension, diabetes mellitus, LVEF and corrected T1 
values (Figure 3, Table 2, Supplemental Table 1). The LGE extent remained an indepen-
dent predictor when adjusted for each of these parameters separately, except diabetes 
mellitus (Supplemental Table 2), which may be due to the small number of patients with 
diabetes mellitus.
Myocardial scar characteristics and monomorphic VT
Receiver operating characteristic curve analysis of the association between the total LGE, 
core and border zone extent and monomorphic VT during follow-up yielded areas under 
the curve of 0.84, 0.86 and 0.78, respectively. The optimal cut-off values for prediction of 
monomorphic VT were 7.2g for total LGE extent (sensitivity 94%, specificity 67%), 3.0g for 
core (sensitivity 94%, specificity 64%) and 2.3g for border zone (sensitivity 100%, specific-
ity 58%). Patients with LGE <7.2g were at very low risk for monomorphic VT (Figure 2) and 
at relatively low risk for any ventricular arrhythmia during follow-up (Figure 3).
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The LGE extent was larger in basal segments than in nonbasal segments (basal median 
2.0g (IQR 0.0-7.7g), vs. nonbasal median 1.1g (IQR, 0.0-4.0g), p=0.011). The LGE extent 
in basal segments was a stronger predictor for monomorphic VT than the extent in 
nonbasal segments (Table 3). When both were included in a single model, only the 
LGE extent in basal segments remained an independent predictor of monomorphic VT 
(Supplemental Table 4).
When subdivided into 5 signal intensity categories, categories with LGE >60% of maxi-
mal signal intensity carried stronger prognostic information than categories with LGE 
30-60% of maximal signal intensity (Table 3). When the two categories of LGE 30-60% 
and >60% of maximal signal intensity were included in a single model, only LGE >60% 
of maximal signal intensity remained associated with monomorphic VT (Supplemental 
Table 4).
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Figure 2. LGe on CMR and different types of 
ventricular arrhythmia during follow-up.
LGE presence did not predict polymorphic VT/
VF during follow-up (left panel). Patients with-
out LGE did however remain free from mono-
morphic VT during follow-up (middle panel) 
and the high risk of monomorphic VT seemed 
to be restricted to patients with ≥7.2g LGE 
(right panel).
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Finally, the area with 51-75% transmural LGE was a particularly strong predictor for 
monomorphic VT, whereas the area with 1-25% transmural LGE was not significantly 
associated with monomorphic VT (Table 3). Only the area of 51-75% transmural LGE 
remained an independent predictor when adjusted for each of the other transmurality 
categories (Supplemental Table 4).














Age, per 5 years 1.03 (0.90–1.19) 0.65 1.17 (0.96–1.42) 0.13 0.88 (0.71–1.10) 0.27
Male gender 3.59 (1.24–10.35) 0.018 2.89 (0.83–9.99) 0.094 4.42 (0.56–34.92) 0.16
Presenting arrhythmia
 OHCA vs. none 2.29 (0.82–6.39) 0.12 0.68 (0.08–5.43) 0.71 7.77 (1.90–31.69) 0.004
 SMVT vs. none 6.54 (2.75–15.54) < 0.001 11.52 (4.22–31.42) < 0.001 3.01 (0.55–16.51) 0.21
Symptomatic heart failure 0.66 (0.31–1.40) 0.28 0.62 (0.24–1.57) 0.31 0.55 (0.16–1.89) 0.34
History of AF / atrial flutter 1.04 (0.39–2.74) 0.94 0.98 (0.28–3.40) 0.98 0.47 (0.06–3.76) 0.48
History of hypertension 2.36 (1.11–5.02) 0.025 4.81 (1.86–12.47) 0.001 1.04 (0.26–4.07) 0.96
Diabetes mellitus 7.27 (2.56–20.60) < 0.001 12.29 (3.94–38.34) < 0.001 1.70 (0.21–13.43) 0.62
eGFR, per 10mL/min/1.73m2 1.04 (0.88–1.22) 0.69 1.06 (0.87–1.31) 0.56 0.91 (0.71–1.16) 0.45
QRS duration, per 10ms 0.93 (0.82–1.05) 0.23 0.94 (0.81–1.09) 0.41 0.89 (0.72–1.11) 0.30
Class III AAD at discharge 1.36 (0.55–3.36) 0.51 1.47 (0.48–4.46) 0.50 0.47 (0.06–3.71) 0.47
LV volumes and function
 LVEDV index, per 10mL/m2 1.00 (0.93–1.06) 0.91 0.93 (0.83–1.04) 0.18 0.98 (0.87–1.10) 0.70
 LVESV index, per 10mL/m2 0.99 (0.92–1.06) 0.71 0.90 (0.80–1.02) 0.086 0.97 (0.87–1.09) 0.64
 LVEF, per 10% 0.74 (0.54–1.01) 0.054 0.55 (0.36–0.83) 0.005 0.85 (0.51–1.41) 0.52
 LV mass index, per 10g/m2 0.88 (0.73–1.07) 0.20 0.89 (0.72–1.11) 0.31 0.75 (0.51–1.10) 0.14
RV volumes and function
 RVEDV index, per 10mL/m2 1.04 (0.94–1.16) 0.45 1.04 (0.91–1.18) 0.59 1.04 (0.87–1.24) 0.65
 RVESV index, per 10mL/m2 1.01 (0.90–1.14) 0.83 0.99 (0.85–1.15) 0.92 1.00 (0.82–1.23) 0.98
 RVEF, per 10% 1.01 (0.79–1.30) 0.92 0.94 (0.68–1.29) 0.68 0.94 (0.61–1.45) 0.78
T1 corrected, per 50ms 0.65 (0.45–0.93) 0.020 0.58 (0.37–0.92) 0.020 1.22 (0.66–2.26) 0.53
LGE
 LGE presence 2.71 (1.10–6.69) 0.031 ∞ < 0.001 0.59 (0.17–2.05) 0.41
 LGE extent
  Total LGE, per 10g 1.47 (1.10–1.97) 0.010 1.90 (1.35–2.67) < 0.001 0.87 (0.48–1.59) 0.66
  Core, per 10g 2.38 (1.34–4.22) 0.003 4.28 (2.15–8.51) < 0.001 0.74 (0.22–2.49) 0.63
  Border zone, per 10g 1.79 (1.03–3.10) 0.039 2.59 (1.38–4.86) 0.003 0.80 (0.26–2.48) 0.70
Abbreviations as in Table 1. When events only occurred in one subgroup, hazard ratios were infinite(∞) and 
p-values were derived from Kaplan-Meier analyses.
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Table 3. Specific LGe characteristics predicting monomorphic VT
Univariate analyses
amount of LGe Predictive value for monomorphic VT
Median (IQR) hazard ratio (95% CI) p
LGE location †
LGE in basal segments, g 2.0 (0.0–7.7) 3.82 (2.11–6.93)† < 0.001
LGE in nonbasal segments, g 1.1 (0.0–4.0) 2.17 (1.13–4.17)† 0.020
LGE according to % of maximal signal intensity
>70%, g 0.6 (0.0–1.8) 1.55 (1.29–1.85) < 0.001
60-70%, g 0.7 (0.0–1.6) 1.66 (1.28–2.13) < 0.001
50-60%, g 1.2 (0.0–2.4) 1.29 (1.11–1.50) 0.001
40-50%, g 1.8 (0.0–4.3) 1.21 (1.07–1.36) 0.003
30-40%, g 2.9 (0.0–7.0) 1.12 (1.03–1.21) 0.006
LGE transmurality areas ‡
76-100%, cm2 1.6 (0.0–7.0) 1.05 (1.01–1.10) 0.029
51-75%, cm2 1.6 (0.0–4.6) 1.22 (1.11–1.34) < 0.001
26-50%, cm2 3.4 (0.0–9.5) 1.09 (1.02–1.16) 0.007
1-25%, cm2 4.8 (0.0–12.1) 1.04 (0.99–1.08) 0.092
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Figure 3. LGe on CMR and any ventricular arrhythmia during follow-up.
LGE presence predicted any ventricular arrhythmia during follow-up. The risk for ventricular arrhythmia was 
only increased in patients with ≥7.2g LGE.
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DISCUSSIon
In this study we analyzed the impact of myocardial scar, assessed by LGE-CMR, on dif-
ferent types of ventricular arrhythmias in NIDCM. We found that LGE was an important 
predictor for monomorphic VT, but not for polymorphic VT/VF. The optimal cut-off value 
for the extent of LGE to predict monomorphic VT was 7.2g. Patients with LGE extent 
<7.2g were at very low risk for monomorphic VT. Specific LGE characteristics associated 
with a high risk for monomorphic VT were LGE extent in basal segments, extent with 
>60% of maximal signal intensity and area with 51-75% transmural scar. Of importance, 
patients without LGE remain at risk for potentially lethal polymorphic VT/VF, and the 
only predictor for polymorphic VT/VF was a history of OHCA-VF.
Myocardial scar and type of ventricular arrhythmia
The presence of LGE on CMR has been reported to predict combined arrhythmic 
endpoints.2-4,16 The present study is the first to analyze the predictive value of clinical 
and CMR parameters separately for monomorphic VT and polymorphic VT/VF. Patients 
presenting with sustained monomorphic VT had a substantially larger extent of LGE 
compared to patients without prior arrhythmias. Remarkably, the smallest LGE extent 
was observed in patients after OHCA-VF and accordingly, the predictive value of LGE 
for ventricular arrhythmias during follow-up was entirely explained by LGE predicting 
monomorphic VT, but not polymorphic VT/VF. This strong association between LGE and 
monomorphic VT is supported by studies on integration of CMR-derived data during VT 
ablation in patients with non-ischemic LV cardiomyopathy.5,7,8
The optimal cut-off for LGE extent to predict monomorphic VT was 7.2g. Patients with 
<7.2g LGE were at very low risk for monomorphic VT. Prior studies have identified 4–6.1% 
LGE as the optimal cut-off value for different combined endpoints (cardiovascular death 
and appropriate ICD therapy1; all-cause mortality and hospitalization for cardiovascular 
event;4 cardiac death, hospitalization for decompensated heart failure and appropriate 
ICD discharge16). To the best of our knowledge, none has analyzed cut-off values for 
prediction of arrhythmic endpoints.
When LGE extent was analyzed separately in basal or nonbasal segments, the basal 
LGE extent appeared to be a stronger predictor for monomorphic VT. This finding is 
consistent with VT ablation studies reporting predominantly basal substrates for mono-
morphic VT in non-ischemic LV cardiomyopathy.8 Similar to observations in post-infarct 
patients, basal scars and mitral/aortic annuli may serve as un-excitable barriers that can 
define parts of the re-entry circuit of monomorphic VT.
Other LGE features strongly associated with monomorphic VT were >60% of maximal 
signal intensity and 51-75% transmurality. This is in line with our prior findings during 
VT ablation procedures, demonstrating that the critical VT isthmus sites are typically 
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located close to the core-border zone transition (i.e., the 50% of maximal signal inten-
sity cut-off value) and to >75% transmural scar.17 These more specific LGE features may 
facilitate identification of NIDCM patients at risk for monomorphic VT.
Diffuse fibrosis and ventricular arrhythmias
The present study also analyzed post-contrast T1 values, which have been shown to cor-
relate with the amount of diffuse fibrosis in biopsy specimens.14 T1 values were similar 
between patients presenting with sustained monomorphic VT, OHCA-VF and no prior 
ventricular arrhythmias. In the latter group T1 values did not predict any type of ventricu-
lar arrhythmia during follow-up. Prior studies using endomyocardial biopsy specimens 
could also neither demonstrate a correlation between fibrosis content and history of 
ventricular arrhythmias,18 inducible sustained monomorphic VT,19 and LGE on CMR,20 nor 
between the amount of interstitial tissue and arrhythmic events during follow-up.21 Of in-
terest, some data suggest that the microscopic pattern of fibrosis, rather than the amount 
may be important for arrhythmias.22 Future studies are required to evaluate whether T1 
mapping may contribute to the identification of specific arrhythmogenic substrates.
Predicting polymorphic VT/VF
Although we could identify clinical and CMR characteristics with predictive value for 
monomorphic VT, the only predictor for polymorphic VT/VF was a history of OHCA-VF. 
Neither LV and RV volumes and function, nor LGE presence and extent were associ-
ated with polymorphic VT/VF. It therefore appears that polymorphic VT/VF cannot be 
predicted with the same methods/parameters that apply for monomorphic VT. More 
insights are required into the substrate and related mechanisms of polymorphic VT/VF 
in patients with NIDCM to identify predictors for these arrhythmias, which may include 
parameters that are beyond the scope of imaging techniques.
Limitations
Not all patients with NIDCM underwent CMR before ICD implantation, and although 
patient characteristics were similar to prior studies in patients with NIDCM undergoing 
CMR and ICD implantation,1,3 we cannot exclude a selection bias. T1 measurement is 
considered to be a marker for diffuse fibrosis, but is validated only to a limited extent 
by histology in patients with NIDCM.14 The LGE core, but not the border zone definition 
has been validated by histopathology in NIDCM.2 Also, core and border zone may not be 
comparable between patients after myocardial infarction and NIDCM due to differences 
in maximal LGE signal intensity. The present study did not allow differentiation between 
VTs based on scar-related re-entry or other mechanisms such as triggered activity. 
Follow-up was relatively long (median 45 months), but the sample size was limited and 
the multivariable models therefore had to be restricted to 2-3 variables.
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ConCLUSIonS
The present study provides evidence that different types of ventricular arrhythmias are 
due to different underlying substrates in patients with NIDCM. The presence and extent 
of LGE on CMR identifies patients who are at risk for monomorphic VT, but not those at 
risk for potentially fatal polymorphic VT/VF. Only patients with a significant amount of 
myocardial scar (i.e., ≥7.2g) appeared to be at high risk for monomorphic VT. In addition, 
specific LGE features (extent in basal segments, LGE with >60% of maximal signal intensity, 
LGE area with 51-75% transmurality) further indicate a predisposition for monomorphic 
VT. Although patients without LGE are at relatively low risk for ventricular arrhythmias 
during follow-up, they still remain at risk for potentially fatal polymorphic VT/VF.
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CLInICaL PeRSPeCTIVeS
Myocardial scar, assessed by LGE-CMR, has been shown to predict ap-
propriate ICD therapy and sudden cardiac death in patients with NIDCM. 
However, ventricular arrhythmias encompass monomorphic VT, polymor-
phic VT and VF which may be related to different underlying substrates. 
The present study is the first to evaluate the relation between myocardial 
scar and different types of arrhythmia in NIDCM. Importantly, it is dem-
onstrated that LGE predicts monomorphic VT, but not polymorphic VT/
VF. Specific LGE features (including mass ≥ 7.2g, basal location, higher 
signal intensity, and area with 51-75% transmurality) were associated with 
a high risk for monomorphic VT. Although patients without LGE were at 
relatively low risk for ventricular arrhythmias, they still remained at risk 
for polymorphic VT/VF. Despite the availability of advanced measures of 
LV and RV volumes and function and of LGE indices, the only predictor for 
polymorphic VT/VF was a history of out-of-hospital cardiac arrest.
These novel insights may have important implications for risk stratifi-
cation and therapeutic interventions. The risk for monomorphic VT in 
patients with NIDCM can be predicted by the presence, location and 
geometry of LGE on CMR, which may be useful for selection of patients 
that benefit from VT ablation at the time of ICD implantation. It is impor-
tant to recognize that patients without LGE remain at risk for potentially 
fatal polymorphic VT/VF. More insights are required into the substrate 
and mechanisms of the different ventricular arrhythmias in patients with 
NIDCM to also identify those at risk for polymorphic VT/VF.
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Age 55±14 60±9 0.17 52±13 0.45
Male gender 30 (51%) 15 (83%) 0.014 9 (90%) 0.035
Presenting arrhythmia
 OHCA 8 (14%) 1 (6%) 0.68 4 (40%) 0.064
 SMVT 1 (2%) 9 (50%) < 0.001 2 (20%) 0.053
Symptomatic heart failure 43 (73%) 10 (56%) 0.17 5 (50%) 0.16
History of AF / atrial flutter 9 (15%) 3 (17%) 1.00 1 (10%) 1.00
History of hypertension 13 (22%) 11 (61%) 0.002 3 (30%) 0.69
Diabetes mellitus 1 (2%) 5 (28%) 0.002 1 (10%) 0.27
eGFR, mL/min/1.73m2 73±22 67±20 0.31 75±36 0.90
QRS duration, ms 134±32 129±33 0.57 125±27 0.41
Class III AAD at discharge 8 (14%) 4 (22%) 0.46 1 (10%) 1.00
LV volumes and function
 LVEDV index, 10mL/m2 154 (123–176) 124 (100–165) 0.056 128 (116–195) 0.71
 LVESV index, 10mL/m2 113 (82–139) 72 (61–103) 0.008 74 (66–160) 0.38
 LVEF, % 27±11 37±13 0.001 33±13 0.18
 LV mass index, g/m2 75 (60–93) 68 (62–81) 0.77 67 (49–91) 0.41
RV volumes and function
 RVEDV index, mL/m2 77 (64–95) 81 (70–115) 0.33 98 (72–103) 0.19
 RVESV index, mL/m2 39 (28–59) 41 (31–58) 0.66 42 (33–54) 0.61
 RVEF, % 46±16 49±12 0.58 48±16 0.73
T1 corrected, ms 332±55 362±78 0.082 322±62 0.64
LGE
 LGE presence 33 (56%) 18 (100%) 0.001 5 (50%) 0.75
 LGE extent
  Total LGE, g 2.3 (0.0–10.2) 15.8 (9.7–24.3) < 0.001 6.9 (0.0–15.7) 0.60
  Core, g 1.0 (0.0–3.8) 9.4 (3.8–14.5) < 0.001 2.0 (0.0–9.3) 0.67
  Border zone, g 0.8 (0.0–6.6) 6.9 (4.7–10.7) < 0.001 2.6 (0.0–9.8) 0.72
Data are expressed as number (percentage), mean ± standard deviation or median (interquartile range).
AF indicates atrial fibrillation; eGFR, estimated glomerular filtration rate; LGE, late gadolinium enhance-
ment; LV, left ventricular; LVEDV, LV end-diastolic volume; LVEF, LV ejection fraction; LVESV, LV end-systolic 
volume; OHCA, out-of-hospital cardiac arrest; RV, right ventricular; SMVT, sustained monomorphic ven-
tricular tachycardia.
* vs. no arrhythmia
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Supplemental Table 2. extent of LGe adjusted for other predictors of any ventricular arrhythmia and 
monomorphic VT
Multivariate analyses
any ventricular arrhythmia Monomorphic VT
hazard ratio (95% CI) p hazard ratio (95% CI) p
Model 1
Total LGE, per 10g  1.42 (1.05–1.93) 0.023 1.87 (1.32–2.66) < 0.001
Male gender 3.24 (1.12–9.39) 0.030 2.46 (0.71–8.53) 0.16
Model 2
Total LGE, per 10g  1.36 (1.00–1.85) 0.049 1.63 (1.14–2.32) 0.007
History of hypertension 1.87 (0.84–4.14) 0.12 3.26 (1.18–8.96) 0.022
Model 3
Total LGE, per 10g  1.25 (0.90–1.74) 0.18 1.52 (1.03–2.25) 0.035
Diabetes mellitus 4.80 (1.44–16.01) 0.011 5.49 (1.43–21.18) 0.013
Model 4
Total LGE, per 10g  1.52 (1.12–2.05) 0.007 2.08 (1.42–3.03) < 0.001
LVEF, per 10%  0.72 (0.53–0.98) 0.034 0.55 (0.37–0.80) 0.002
Model 5
Total LGE, per 10g  1.46 (1.08–1.98) 0.014 1.97 (1.35–2.86) < 0.001
T1 corrected, per 50ms  0.65 (0.45–0.93) 0.018 0.57 (0.37–0.90) 0.016
LGE indicates late gadolinium enhancement; LVEF, LV ejection fraction.
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Supplemental Table 3. Predictors of any ventricular arrhythmia and monomorphic VT in primary 
prevention patients.
Univariate analyses
any ventricular arrhythmia Monomorphic VT
hazard ratio (95% CI) p hazard ratio (95% CI) P
Age, per 5 years  1.04 (0.84–1.28) 0.74 1.17 (0.85–1.60) 0.33
Male gender 9.87 (1.29–75.53) 0.028 5.11 (0.63–41.55) 0.13
Symptomatic heart failure 1.52 (0.34–6.78) 0.59 1.76 (0.22–14.34) 0.60
History of AF / atrial flutter 1.47 (0.46–4.69) 0.52 1.23 (0.25–6.14) 0.80
History of hypertension 4.40 (1.52–12.75) 0.006 ∞ < 0.001
Diabetes mellitus 18.69 (4.08–85.69) < 0.001 41.69 (6.79–256.14) < 0.001
eGFR, per 10mL/min/1.73m2  1.30 (1.00–1.68) 0.052 1.27 (0.90–1.80) 0.18
QRS duration, per 10ms  0.91 (0.76–1.09) 0.32 1.02 (0.82–1.28) 0.85
Class III AAD at discharge 1.36 (0.38 - 4.88) 0.64 0.71 (0.09 - 5.78) 0.75
LV volumes and function
 LVEDV index, per 10mL/m2  1.06 (0.99–1.13) 0.11 1.01 (0.90–1.13) 0.85
 LVESV index, per 10mL/m2  1.06 (0.99–1.14) 0.098 1.00 (0.90–1.13) 0.94
 LVEF, per 10%  1.23 (0.72–2.10) 0.44 0.81 (0.42–1.55) 0.53
 LV mass index, per 10 g/m2  1.10 (0.89–1.37) 0.37 1.06 (0.80–1.41) 0.67
RV volumes and function
 RVEDV index, per 10mL/m2  1.05 (0.91–1.21) 0.51 1.04 (0.85–1.25) 0.73
 RVESV index, per 10mL/m2  1.05 (0.92–1.20) 0.47 1.01 (0.83–1.23) 0.89
 RVEF, per 10%  1.23 (0.87–1.73) 0.24 1.03 (0.66–1.63) 0.89
 T1 corrected, per 50ms  0.79 (0.47–1.32) 0.37 0.78 (0.40–1.55) 0.48
LGE
 LGE presence 2.41 (0.67–8.66) 0.18 ∞ 0.024
 LGE extent
  Total LGE, per 10g  1.46 (0.97–2.22) 0.072 1.84 (1.12–3.03) 0.016
  Core, per 10g  2.14 (0.88–5.20) 0.094 3.43 (1.19–9.91) 0.023
  Border zone, per 10g  1.98 (0.95–4.13) 0.069 2.96 (1.22–7.17) 0.016
AF indicates atrial fibrillation; eGFR, estimated glomerular filtration rate; LGE, late gadolinium enhance-
ment; LV, left ventricular; LVEDV, LV end-diastolic volume; LVEF, LV ejection fraction; LVESV, LV end-systolic 
volume; RV right ventricular; RVEF, RV ejection fraction.
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Supplemental Table 4. Specific LGe characteristics predicting monomorphic VT – multivariable models.
Multivariable analyses
Monomorphic VT
hazard ratio (95% CI) p
Model 1: LGE in basal and nonbasal segments
 Basal segments, per 10g 3.95 (1.88–8.32) < 0.001
 Nonbasal segments, per 10g 0.93 (0.35–2.46) 0.88
Model 2: Signal intensity categories
 >60% of maximal SI, per g 1.36 (1.16–1.61) < 0.001
 30–60% of maximal SI, per g 0.97 (0.91–1.04) 0.40
Model 3: Transmurality categories (A)
 51–75% transmural LGE, per cm2 1.25 (1.12–1.40) < 0.001
 1–25% transmural LGE, per cm2 0.98 (0.93–1.03) 0.45
Model 4: Transmurality categories (B)
 51–75% transmural LGE, per cm2 1.31 (1.11–1.55) 0.001
 26–50% transmural LGE, per cm2 0.94 (0.84–1.06) 0.31
Model 5: Transmurality categories (C)
 51–75% transmural LGE, per cm2 1.22 (1.09–1.37) 0.001
 76–100% transmural LGE, per cm2 1.00 (0.93–1.07) 0.95
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Progressive activation delay after premature stimulation has been associated with ven-
tricular fibrillation in nonischemic cardiomyopathy (NICM). The purpose of this study 
was to (1) investigate prolongation of the paced QRS duration (QRSd) after premature 
stimulation as a marker of activation delay in NICM, (2) assess its relation to induced 
ventricular arrhythmias, and (3) analyze its underlying substrate by late gadolinium 
enhancement CMR (LGE-CMR) and endomyocardial biopsy.
Methods and results
Forty patients with NICM (age 57±14years, 83% male, LVEF 30±13%) were prospectively 
enrolled in the Leiden Nonischemic Cardiomyopathy Study and underwent a compre-
hensive evaluation including LGE-CMR, electrophysiological study (EPS) and endomyo-
cardial biopsy. Twenty patients without structural heart disease served as controls for 
EPS. After the 400 ms drive train and progressively premature stimulation, the maximum 
increase in QRSd was larger in NICM than in controls (35±18ms vs. 23±12ms, p=0.005) 
and the coupling interval window with QRSd prolongation was wider (47±23ms vs. 
31±14ms, p=0.005). The maximum paced QRSd exceeded the ventricular refractory 
period allowing for pacing before the QRS offset in 20/39 NICM patients vs. 1/20 controls 
(p<0.001). In NICM, QRSd prolongation was associated with polymorphic VT inducibility 
(16/39 patients), and was related to long thick strands of fibrosis in biopsies, but not to 
focal enhancement on LGE-CMR (all p>0.05).
Conclusions
QRSd is a simple parameter to quantify activation delay after premature stimulation 
and its prolongation is associated with the inducibility of polymorphic VT and with the 
pattern of myocardial fibrosis in biopsies.
Clinical Trial Registration—clinicaltrials.gov. Identifier: NCT01940081.
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InTRoDUCTIon
Implantable cardioverter defibrillator (ICD) therapy can terminate, but does not prevent 
potentially life-threatening ventricular arrhythmias. Although progress has been made 
to treat monomorphic ventricular tachycardia (VT), therapies that prevent polymorphic 
VT and ventricular fibrillation (VF) in nonischemic cardiomyopathy (NICM) are lack-
ing. Improved understanding and identification of the underlying substrate for these 
arrhythmias may allow personalized risk stratification and development of tailored 
treatment.
Activation delay following premature stimulation has been associated with a history 
of VF in patients with various non-coronary heart diseases based on intracardiac record-
ings from the right ventricle (RV).1 Total biventricular activation delay may be quantified 
by measuring paced QRS duration (QRSd) on surface ECGs, which is easy to apply and 
may better reflect activation delay in left dominant myocardial disease.
The purpose of this study was to (1) investigate prolongation of the paced QRSd fol-
lowing decremental premature stimulation as a marker of activation delay in NICM, (2) 
assess its relation to induced ventricular arrhythmias, and (3) analyze its association with 
the extent and distribution of fibrosis in endomyocardial biopsy specimens and on late 
gadolinium enhancement CMR (LGE-CMR).
MeThoDS
Patients
The Leiden Cardiomyopathy Study is a single-center, prospective cohort study designed 
to analyze the substrate and mechanisms of ventricular arrhythmias in NICM (Clinical-
Trials.gov Identifier: NCT01940081). From October 2011, patients 18-80 years old with 
NICM and documented sustained ventricular arrhythmia, suspected sustained ventricu-
lar arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or 
considered to be at intermediate or high risk for ventricular arrhythmias were enrolled. 
A high risk for ventricular arrhythmias was defined as a left ventricular ejection fraction 
(LVEF) ≤ 35%; an intermediate risk as LVEF ≤ 50% and late enhancement on LGE-CMR. 
Exclusion criteria were inability to understand the nature and risks of the study proce-
dures, pregnancy, inability to comply with the protocol due to hemodynamic instability, 
and other cardiomyopathies (e.g. prior myocardial infarction, sarcoidosis, infiltrative 
cardiac disease such as amyloidosis, Chagasic cardiomyopathy, arrhythmogenic right 
ventricular cardiomyopathy, hypertrophic cardiomyopathy, non-compaction cardiomy-
opathy and congenital heart disease).
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Patients underwent a comprehensive evaluation including transthoracic echocar-
diography, LGE-CMR, 24-hour Holter monitoring, exercise testing, blood sampling 
for NT-proBNP levels, an invasive electrophysiological study, endomyocardial biopsy, 
iodine-123 metaiodobenzylguanidine (MIBG) scan and genetic analysis of 55 cardio-
myopathy-related genes. Targeted next generation sequencing of these 55 genes, a list 
of which is provided in the Supplemental Methods, was performed analyzing 151 bp 
paired-end reads on an Illumina MiSeq sequencer, as previously described.2 The (likely) 
pathogenicity of single nucleotide polymorphisms and small indels was based on the 
nature and location of the variant, conservation of the affected amino acid residue(s) 
and the surrounding region, frequency of the variant in (healthy) population databases, 
its predicted pathogenicity according to multiple available prediction programs, the 
scientific literature and/or variant databases.
Premature ventricular contraction (PVC) or VT ablation and ICD implantation were 
performed if clinically indicated. The study protocol was approved by the local ethics 
committee and by the appropriate national ethics committee. All patients provided 
written informed consent.
The control group for electrophysiologic study measurements consisted of 20 patients 
referred for catheter ablation of atrioventricular nodal reentrant tachycardia or a con-
cealed bypass tract in the absence of structural heart disease, who underwent routine 
electrophysiological study according to our institutional protocol.
LGe-CMR acquisition
In patients who had not undergone LGE-CMR previously, CMR was performed on a 
1.5T Gyroscan ACS-NT/Intera MR system, or on a 3.0T Ingenia MR system (both Philips 
Medical Systems, Best, the Netherlands). A standardized protocol was followed, includ-
ing cine images in long-axis (two- and four-chamber) and short-axis views covering the 
complete LV. Approximately 15 minutes after bolus injection of gadolinium (Magnevist; 
Schering, Berlin, Germany; 0.15 mmol/kg) a look-locker sequence was acquired in short 
axis orientation at mid-ventricular level. T1-weighted LGE images were acquired with an 
inversion-recovery 3D turbo-field echo sequence with parallel imaging. The inversion 
time was optimized to null normal appearing myocardium. The heart was imaged in 
long-axis two- and four-chamber views (between 5-10 slices), and short-axis views (be-
tween 20-24 slices). Signal outside the field of view was suppressed using two saturation 
slabs to avoid fold-over artifacts.
In patients who had already undergone CMR previously, the scan was acquired on 
various systems, but always included cine acquisitions in long-axis (two- and four-
chamber) and short-axis views, covering the complete left ventricle (LV). LGE images 
were acquired in long-axis (two- and four-chamber) and short-axis views. CMR was not 
performed in patients with an implanted device.
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LGe-CMR analysis
All CMR analyses were performed using MASS software (research version 2012; LKEB; 
Leiden University Medical Center, the Netherlands). The LV and RV end-diastolic and 
end-systolic endocardial contours were traced on short-axis cine images to calculate 
the LV end-diastolic and end-systolic volumes, LVEF, LV mass, RV end-diastolic and end-
systolic volumes, and RV ejection fraction. The LV and RV volumes and the LV mass were 
indexed to body surface area.3 Myocardial scar was only considered to be present if LGE 
was visible in 2 orthogonal views. LGE was defined by signal intensity ≥35% of maximal 
myocardial signal intensity, and subdivided into core (≥50% of maximal signal intensity) 
and border zone (35-50% of maximal signal intensity).4
electrophysiological study
Anti-arrhythmic drugs were discontinued for at least 5 half-lives, if possible. Programmed 
electrical stimulation consisted of 3 drive trains of 8 beats (S1) (cycle lengths (CL) 600, 
500 and 400ms) with 1-3 ventricular extrastimuli and burst pacing at twice diastolic 
threshold from the RV apex and the RV outflow tract using the distal electrode pair of 
a quadripolar catheter. The first extrastimulus (S2) was applied at a coupling interval 
identical to the CL of the drive train, followed by a coupling interval (CI) of 350ms, which 
was then progressively decreased by steps of 10ms until the ventricular effective refrac-
tory period (VERP) was reached. Consecutive extrastimuli (S3 and S4) and burst pacing 
were applied from a coupling interval of 350ms down to 200ms. Polymorphic VT was 
defined by ≥5 consecutive ventricular beats at ≥ 120 bpm with continuously changing 
QRS morphology,5,6 and was regarded as sustained if lasting > 30s or requiring termina-
tion because of hemodynamic compromise. Sustained monomorphic VT was defined by 
similar beat-to-beat QRS morphology and duration >30s or the requirement for termina-
tion because of hemodynamic compromise. If no sustained ventricular arrhythmia was 
induced, stimulation was repeated with isoprenaline (2-10µg/min).
In the control group for electrophysiology study measurements, drive trains of 600 
and 400 ms with single extrastimuli were applied from the RV apex as part of the routine 
electrophysiological study protocol. All studies were recorded on an electrophysiology 
recording system for offline analysis, with a sweeping speed of 200 mm/second and 
bipolar electrograms filtered at 30-500 Hz (Prucka Cardiolab recording system, Houston, 
Texas).
electrophysiological study analysis
The paced QRSd was measured from the pacing artifact to the latest offset of the QRS 
in any lead (examples in Figure 1) using electronic calipers. For the 600ms and 400ms 
drive trains with single extrastimuli from the RV apex, QRSd restitution curves were 
constructed and the following parameters were derived:
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(1) CI at onset of QRSd prolongation (CIonset): the CI of the first premature extrastimulus 
that results in a ≥5 ms increase in QRSd compared to the previous step.
(2) CI window with QRSd prolongation: the interval between CIonset and the VERP.
(3) Maximal ∆QRSd: maximum increase in QRSd after premature stimulation.
(4) Critical QRSd prolongation: the QRSd that exceeds the length of the VERP, which 
allows to pace before the offset of the QRS (calculated as QRSd-VERP).
(5) Critical CI (CIcritical) window: the CI window at which the paced QRSd exceeds the 
length of the VERP.
Examples of QRS restitution curves and calculations of the derived parameters are 
displayed in Figure 1.
endomyocardial biopsy
After the electrophysiological study, endomyocardial biopsies were obtained – im-
mediately thereafter, two were stored in liquid nitrogen and one specimen was fixed 
in 4% formaldehyde and embedded in paraffin. Cross-sections were cut at 4 µm and 
stained with picro-Sirius Red to evaluate collagen content and collagen distribution 
patterns. Mayer’s haematoxylin was used to counterstain cell nuclei. Using a fluorescent 
microscope, high-resolution photomicrographs were taken with a digital camera (Nikon 
Eclipse, Nikon Europe, Badhoevedorp, the Netherlands) and analyzed using dedicated 
software (ImageJ 1.49c, National Institutes of Health, USA). All staining and subsequent 
analyses were performed by an independent investigator blinded to all clinical and 
procedural data. Fibrosis content was quantified by calculating the collagen area per-
centage. Distribution of fibrosis was categorized according to predefined patterns:
1) Interstitial: collagen strand thickness exceeds 10% of the width of adjacent cardio-
myocytes without interrupting myocardial fiber continuity.
2) Short thin strands: dispersed presence of two or more fibrotic areas smaller than the 
width of five cardiomyocytes that disrupt myocardial fiber continuity.
3) Long thick strands: one or more fibrotic areas exceeding the width of five cardiomyo-
cytes that disrupt the myocardial fiber continuity.
Underlying substrate of QRS prolongation
The relation between QRSd restitution curve parameters and the following parameters 
was analyzed: 1) CMR-derived LV and RV volumes and ejection fraction, 2) LGE on CMR, 
3) NT-proBNP levels, 4) collagen area percentages in biopsy specimens, 5) pattern of 
fibrosis in biopsy specimens and 6) the presence of a pathogenic or likely pathogenic 
mutation.





















































































































































































































































































































































































































































































































































































































































































































Categorical variables are displayed as number (percentage) and continuous variables 
are expressed as mean ± standard deviation or median (interquartile range, IQR). Cat-
egorical variables were compared using the χ2 test or the Fisher’s exact test. Continuous 
variables were compared using the Mann-Whitney U test because of the limited sample 
size. For paired variables the Wilcoxon signed-rank-test was used. The association 
between QRS restitution curve parameters and patient characteristics was analyzed 
by univariate linear regression analyses. For this purpose, NT-proBNP levels were log-
transformed because of the skewed distribution. All analyses were performed with SPSS 
version 20.0 (IBM, Somers, New York, USA). All tests are two-sided and probability values 
<0.05 were considered significant.
ReSULTS
Patients
Between October 2011 and August 2013, 40 patients (age 57 ± 14 years, 83% male) were 
enrolled in the Leiden Nonischemic Cardiomyopathy Study. Baseline characteristics are 
summarized in Table 1. Eight patients (20%) had documented sustained ventricular ar-
rhythmia, 6 (15%) had suspected sustained ventricular arrhythmia, and 26 (65%) were 
considered to be at intermediate or high risk for ventricular arrhythmia. Cine CMR was 
performed in 36 patients (90%), while the remaining 4 (10%) had an implanted device 
and underwent echocardiography. Based on combined CMR and echo data the LVEF 
was reduced in all patients and the LV end-diastolic volume index was increased in 34 
patients (85%) compared with published reference ranges normalized for gender, age 
and body surface area.7 LGE was observed in 26 of 34 (77%) patients with LGE images 
and the median LGE mass was 8.8 g (IQR, 1.1–19.3 g). CMR and biopsy data are sum-
marized in Table 2. Genetic analysis of 55 cardiomyopathy-related genes was performed 
in all but one patient and revealed a pathogenic or likely pathogenic mutation in 19 
(49%) – details are listed in supplemental Table 1.
QRSd prolongation in nICM patients and controls
Both in NICM and in controls, the QRSd increased after premature stimulation (examples 
in Figure 1). Differences between NICM patients and controls were more pronounced 
after the 400 ms drive train than after the 600 ms drive train (supplemental Figure 1 
and supplemental Table 2) and therefore, the 400 ms drive train was used for further 
analyses. After the 400 ms drive train, the onset of QRSd prolongation occurred at longer 
CI (CIonset) in NICM compared to controls (275±23 vs. 235±16 ms, p<0.001, Figure 2), the 
CI window with QRSd prolongation was wider (47±23 vs. 31±14 ms, p=0.005), and the 
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11maximum ∆ QRSd was larger (35±18 vs. 23±12 ms, p=0.005). Critical QRS prolongation 
(i.e., QRSd exceeding VERP, which allowed to apply an extrastimulus within the paced 
QRS complex) was observed in 20 of 39 patients with NICM (51%) compared with only 
one of 20 controls (5%, p<0.001) (Figure 1 panels G-I, Figure 2, example Figure 3). The 
critical CI window, with QRSd exceeding VERP, ranged from 10 to 130 ms in NICM, com-
pared with only one case with a critical CI window of 10 ms in controls (p<0.001, Figure 
Table 1. Baseline characteristics
n=40
Age, years 57 ± 14
Male 33 (83%)
BMI, kg/m² 27 ± 4
Diabetes mellitus 6 (15%)
Hypertension 10 (25%)
NYHA functional class
 I 7 (18%)
 II 20 (50%)
 III or IV 13 (33%)
History of AF / atrial flutter 16 (40%)
ECG
 Heart rate, bpm 73 ± 13
 PR interval, ms 182 ± 32
 QRS duration, ms 129 ± 34
eGFR, mL/min/1.73m2 86 ± 25
NT-proBNP, pg/mL 932 (499 - 1773)
Exercise test (n=29)
 Peak oxygen consumption, mL/kg/min 20 ± 6
 Peak oxygen consumption, % of predicted 80 ± 22
AAD during electrophysiology study
 Class I 0 (0%)
 Sotalol 1 (3%)
 Amiodarone 2 (5%)
Device at discharge
 CRT-defibrillator 20 (50%)
 Implantable cardioverter-defibrillator 13 (33%)
 None 7 (18%)
Genetic screening (n=39)
 Pathogenic or likely pathogenic mutation 19/39 (49%)
Variables are expressed as number (percentage), mean ± standard deviation, or median (interquartile 
range). AAD indicates anti-arrhythmic drugs; AF, atrial fibrillation; BMI, body mass index; CRT, cardiac resyn-
chronization therapy; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association
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2). Results were similar when excluding the 3 cardiomyopathy patients who were on 
class III anti-arrhythmic drugs.
QRSd prolongation and inducibility of polymorphic VT
The programmed electrical stimulation protocol could be successfully completed, or 
resulted in reproducible induction of sustained ventricular arrhythmias in 39 of 40 NICM 
patients (98%). Sustained monomorphic VT was induced in 11 of 39 patients (28%) and 
polymorphic VT ≥ 5 beats in 16 of 39 (41%) (Figure 3). The longest polymorphic VT was 
induced with triple extrastimuli in all 16 patients. None of the baseline characteristics 
were associated with polymorphic VT inducibility (Table 3).
Table 2. CMR and biopsy data
Parameter Value
CMR - cine images (n=36)
 LVEDV, mL 303 ± 90
 LVEDV index, mL/m2 147 ± 42
 LVESV, mL 221 ± 93
 LVESV index, mL/m2 107 ± 44
 LVEF, % 30 ± 13
 LV mass, g 143 ± 34
 LV mass index, g/m2 70 ± 16
 RVEDV, mL 189 ± 45
 RVEDV index, mL/m2 92 ± 19
 RVESV, mL 105 ± 39
 RVESV index, mL/m2 51 ± 18
 RVEF, % 46 ± 11
CMR - LGE images (n=34)
 LGE presence 26/34 (77%)
 LGE total, g 8.8 (1.1 - 19.3)
 Core mass, g 3.3 (0.4 - 8.7)
 Border zone mass, g 4.9 (0.6 - 13.4)
Endomyocardial biopsy (n=23)
 Collagen area percentage, % 33 (19 - 42)
 Collagen distribution type
  Interstitial 8/23 (35%)
  Short thin strands 7/23 (30%)
  Long thick strands 8/23 (35%)
Variables are expressed as number (percentage), mean ± standard deviation, or median (interquartile 
range). LGE denotes late gadolinium enhancement; LVEDV, LV end-diastolic volume; LVEF, LV ejection frac-
tion; LVESV, LV end-systolic volume; RVEDV, RV end-diastolic volume; RVEF, RV ejection fraction; RVESV, RV 
end-systolic volume.
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In contrast, four of five QRSd restitution curve parameters were associated with the 
inducibility of polymorphic VT (Figure 4 and supplemental Table 3). The CI at onset of 
QRS prolongation was similar in patients with vs. without inducible polymorphic VT (276 
































































































Figure 2. QRS duration prolongation in nonischemic cardiomyopathy and controls
The QRS duration restitution curve parameters based on 400 ms drive trains with single extrastimuli dif-
fered significantly between patients with cardiomyopathy and controls.
S1 S2 S3 S4 S1 
Figure 3. example of pacing within the QRS complex and induction of polymorphic VT
During application of triple extrastimuli after a 400 ms drive train, the QRS complex prolongs after prema-
ture stimulation. S3 and S4 are applied within the paced preceding QRS complexes, resulting in the induc-
tion of polymorphic VT.
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Table 3. Baseline characteristics and inducible polymorphic VT
PVT (n=16) no PVT (n=23) P
Age, years 60 ± 13 56 ± 13 0.40
Male 13 (81%) 19 (83%) 1.00
BMI, kg/m² 27 ± 4 28 ± 4 0.47
Diabetes mellitus 9 (56%) 7 (30%) 0.11
Hypertension 4 (25%) 6 (26%) 1.00
NYHA functional class III or IV 4 (25%) 9 (39%) 0.36
History of AF / atrial flutter 2 (13%) 4 (17%) 1.00
eGFR, mL/min/1.73m2 87 ± 24 86 ± 27 1.00
NT-proBNP, pg/mL 1058 (487 - 2232) 872 (498 - 1646) 0.64
ECG
 Heart rate 72 ± 15 73 ± 12 0.77
 PR interval 188 ± 33 181 ± 31 0.49
 QRS duration 126 ± 32 133 ± 36 0.69
Exercise test
 Peak oxygen consumption, mL/kg/min 19 ± 7 20 ± 5 0.65
 Peak oxygen consumption, % of predicted 81 ± 28 80 ± 16 0.91
Genetic screening
 Pathogenic or likely pathogenic mutation 8/16 (50%) 10/22 (46%) 0.78
MRI - cine images
 LVEDV index, mL/m2 136 ± 44 153 ± 41 0.27
 LVEF, % 35 ± 15 27 ± 12 0.19
 LV mass index, g/m2 67 ± 7 71 ± 19 0.51
 RVEDV index, mL/m2 96 ± 22 89 ± 18 0.63
 RVEF, % 41 ± 13 49 ± 10 0.057
MRI - LGE images
 LGE presence 11/13 (85%) 15/20 (75%) 0.68
 LGE total, g 15.0 (4.3 - 22.7) 8.2 (0.4 - 22.6) 0.32
 LGE core, g 5.5 (1.9 - 11.1) 2.9 (0.1 - 8.4) 0.41
 LGE BZ, g 7.7 (2.4 - 14.0) 4.3 (0.2 - 14.0) 0.39
Endomyocardial biopsy specimens
 Collagen area percentage, % 22 (10 - 39) 38 (23 - 51) 0.093
 Interstitial fibrosis 3/10 (30%) 4/12 (33%)
 Short thin strands 2/10 (20%) 5/12 (42%) 0.42
 Long thick strands 5/10 (50%) 3/12 (25%)
PVT denotes polymorphic ventricular tachycardia. Other abbreviations as in tables 1 and 2.
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(57 ± 25 ms vs. 39 ± 18 ms, p=0.015) and the maximum ∆ QRSd was larger (46 ± 17 ms 
vs 27 ± 14 ms, p=0.001). The critical QRS prolongation was significantly longer, allowing 
to pace further within the QRS (15 ± 37 ms vs -15 ± 36 ms, p=0.017) and the critical CI 
window tended to be wider, thereby allowing to pace within the QRS over a wider range 
of CIs (median 20 ms, IQR 0-75 ms vs. median 0 ms, IQR 0-20 ms, p=0.11).
CMR-derived data, nT-proBnP levels and genetics: relation to QRSd 
prolongation
Larger end-diastolic LV volume indexes were associated with a wider CI window with 
QRSd prolongation, and larger end-systolic LV volume indexes and lower LVEF were 
associated with a smaller maximal ∆ QRSd, but neither was associated with any of the 
other QRSd restitution curve parameters (Supplemental Table 4). The extent of LGE (total 
LGE, core and border zone), NT-proBNP levels and the presence of a (likely) pathogenic 
mutation were not associated with any QRSd restitution curve parameter (all p>0.05).
extent and distribution of fibrosis in biopsy specimens and association with 
QRSd prolongation
Endomyocardial biopsy was performed in 24 patients (60%; LV in 23 patients, RV 
side of septum in 1 patient); no biopsies were obtained in the remaining 16 patients 
(40%) because of a potential risk for complications or patient’s preference. One set of 
biopsies was excluded due to poor quality. In the remaining 23 patients, the median 
collagen area percentage was 33% (IQR, 19 – 42%) and the collagen distribution type 
was interstitial in 8 (35%), short thin strands in 7 (30%) and long thick strands in 8 (35%) 
















































































































































Figure 4. QRS duration prolongation and inducibility of polymorphic VT
Three QRS duration restitution curve parameters were associated with the inducibility of polymorphic VT 
in patients with cardiomyopathy.
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associated with a smaller maximal increase in QRSd but not with any other parameter of 
QRSd prolongation (Supplemental Table 4). However, long thick strands of fibrosis were 
associated with a wider CI window with QRSd prolongation, and with a wider critical CI 
window with the ability to pace within QRSd.
DISCUSSIon
The key findings of this study are: (1) In patients with NICM and in controls, the paced 
QRSd increased after premature stimulation, (2) in NICM, the QRSd started to increase 
earlier, at longer CI than in controls, the maximum increase in QRSd was larger and 
the paced QRSd frequently exceeded the VERP (i.e., critical QRS prolongation), which 
allowed to apply an extrastimulus within the paced QRS complex, (3) the CI window 
with QRSd prolongation, the maximal ∆QRSd, and critical QRS prolongation were associ-
ated with the inducibility of polymorphic VT in NICM, (4) not the density of fibrosis but 
the presence of long thick strands of fibrosis was associated with a wider CI window of 
progressive QRS prolongation and a wider critical CI window at which the QRSd exceeds 
VERP, which may indicate a substrate for polymorphic VT or VF, and (5) none of the QRSd 
Figure 5. examples of biopsy specimens
Typical photomicrographic examples demonstrat-
ing different patterns of fibrosis in endomyocardial 
biopsies as visualized by sirius red staining. (A) Typ-
ical example from a patient showing an interstitial 
fibrosis pattern. (B) Typical example from a patient 
with a fibrosis pattern that primarily consists of 
short thin fibrotic strands. (C) Typical example from 
a patient with a fibrosis pattern predominantly 
containing long thick fibrotic strands.
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restitution curve parameters was related to the presence or extent of LGE on CMR, NT-
pro BNP levels, nor the presence of (likely) pathogenic mutations.
Quantification of activation delay after premature stimulation
Activation delay after premature stimulation has previously been quantified and related 
to VF in humans with various cardiac diseases, in particular hypertrophic cardiomyopa-
thy, by applying stimulation protocols sequentially from 4 different RV catheters.1 Left 
ventricular activation could not be assessed as no catheters were placed in the LV. Of 
interest, both normal and abnormal electrogram responses were frequently observed 
at the different positions of the 4 RV catheters, suggesting that conduction delay may 
not be uniform and therefore, multiple recording sites may be required. In contrast, the 
paced QRSd is easily available, can be measured during a standard programmed electri-
cal stimulation protocol, does not require multiple intracardiac catheters and reflects 
both RV and LV activation.
activation delay and polymorphic VT
In the current study we could demonstrate that the CI window with QRSd prolongation, 
the maximum ∆ QRSd and critical QRS prolongation were associated with the induc-
ibility of polymorphic VT. In contrast, none of the baseline characteristics, including 
CMR-derived volumes, ejection fraction and LGE, NT-proBNP levels  and the presence of 
a (likely) pathogenic mutation, were associated with polymorphic VT inducibility.
A larger CI window with QRSd prolongation may increase the likelihood that a spon-
taneous PVC is discontinuously propagated, resulting in progressive activation delay, 
wave break and increased dispersion of repolarization. The maximal ∆ QRSd may be 
considered as a marker of the cumulative activation delay throughout the heart after 
the shortest-coupled (VERP + 10 ms) premature stimulus. Prolonged and pronounced 
activation delay may reflect non-uniform anisotropic conduction which, together with 
dispersion of repolarization, may predispose for polymorphic VT and VF.8
These findings are consistent with a prior study using extensive stimulation protocols 
and multiple RV catheters in patients with various non-coronary heart diseases (but 
only 5 patients with dilated cardiomyopathy), which demonstrated that the maximum 
increase in RV intracardiac electrogram duration was larger, but also that the S1S2 
coupling intervals at which the electrograms started to increase were longer in patients 
with a history of VF.1 In a retrospective study in consecutive patients with and without 
structural heart disease who underwent EPS for various reasons, activation delay, mea-
sured from the distal stimulation electrodes to proximal electrodes located at 35 mm 
distance, was substantially longer in patients with vs. without inducible VF.9 Finally, in 
a retrospective study conducted in borderline NICM patients with LVEF >50% and LV 
end-diastolic dimension < 65 mm, 15 patients resuscitated from polymorphic VT/VF had 
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longer paced QRSd after S3 (at CI 10 ms above VERP) compared to patients without 
documented ventricular arrhythmias.10
Substrate and mechanisms of activation delay and polymorphic VT
The QRSd restitution curve parameters that were associated with the inducibility of poly-
morphic VT did not correlate with CMR-derived volumes, ejection fraction or LGE, and 
were not related to larger fibrosis area percentages on biopsy, but tended to be related 
to long thick strands of fibrosis in biopsy. This is in line with two studies in explanted 
hearts from patients with end-stage heart failure, which suggested that activation delay 
after premature stimulation may be related to the presence of long fibrotic strands.11,12 In 
one of these studies, even large amounts of diffusely distributed, short-stranded fibrosis 
only marginally affected conduction velocity, whereas large fibrotic strands appeared 
to serve as inexcitable barriers with consecutive conduction delay, supporting that the 
geometry rather than the total amount of fibrosis creates a potential substrate for ar-
rhythmias.12 The authors elegantly demonstrated how such barriers may contribute to 
activation delay, namely by increased path length, transverse instead of longitudinal 
conduction, wave front curvature and reduced conduction velocity.12 In addition, ac-
tivation delay caused by long strands of fibrosis may promote wave break and thereby 
predispose for polymorphic VT/VF.13 Of interest, treatment with eplerenone, losartan, 
or both could reduce the development of age-related interstitial and patchy fibrosis in 
adult mice.14 Importantly, only the reduction of patchy fibrosis correlated with reduced 
inducibility of ventricular arrhythmias based on anisotropic reentry, further supporting 
the link between type of fibrosis and arrhythmogeneity.
Other potential mechanisms of activation delay after premature stimulation have 
been described in patients with various structural heart disease.15 In particular early 
applied extrastimuli that capture at an earlier and less repolarized level of the preceding 
beat correlated with delayed propagation. Mechanisms are not necessarily mutually ex-
clusive and the observed critical QRS prolongation may be dependent on the combina-
tion of different underlying structural and functional changes resulting in an increased 
vulnerability for polymorphic VT.
Clinical implications
Activation delay after premature stimulation, which was associated with ventricular 
arrhythmias in the present and in prior studies, can be easily quantified by any clinical 
electrophysiologist by measuring the QRSd after 400 ms drive trains with single extra-
stimuli. The protocol and calculation of the suggested parameters can be performed in 
a couple of minutes and can be obtained non-invasively in patients with pacemakers 
or implantable cardioverter-defibrillators. Whether QRSd restitution curve parameters 
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predict spontaneous ventricular arrhythmias requires further studies with larger sample 
sizes and long follow-up duration.
Limitations
The number of subjects is small. As this study focused on identifying electrophysiologi-
cal parameters associated with a predisposition towards polymorphic VT,  several factors 
such as dispersion of repolarization after premature stimulation not caused by activa-
tion delay,8 connexin 43 expression, distribution and co-localization with N-cadherin11 
were not analyzed. Also, the current study did not analyze the association between 
activation delay and spontaneous polymorphic VT/VF as such analyses require larger 
patient cohorts and long follow-up.
ConCLUSIon
Premature stimulation in patients with NICM causes progressive activation delay, which 
can be easily quantified by measuring the QRSd after a 400 ms drive train with single ex-
trastimuli. The CI window with QRSd prolongation was wider in patients with NICM than 
in controls, the maximum increase in QRSd was larger, and a pronounced critical QRS 
prolongation was demonstrated allowing for extrastimuli being applied within the QRS 
complex. These 3 phenomena, which are easily assessed during a 3-minute stimulation 
protocol, were associated with the inducibility of polymorphic VT. QRSd prolongation 
after premature stimulation tended to be related to long thick strands of fibrosis, but not 
to overall fibrosis area percentages in biopsy specimens, supporting the link between 
the geometry of fibrosis and arrhythmogeneity. Measuring the QRSd may be a simple 
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Supplemental Table 1. Genetic screening results












* 3 mutations: DSP, MYPN and MYH7
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Supplemental Table 2. Comparison of 600 ms and 400 ms drive trains between nICM and controls
nICM Controls p (Mann-Whitney)
Regular 12-lead eCG, 25 mm/second
 QRSd 129 ± 34 90 ± 12 < 0.001
ePS - drive train 600 ms from RV apex
 QRSd during drive train 195 ± 18 157 ± 12 < 0.001
 QRSd after extrastimulus 350 ms 191 ± 25 147 ± 14 < 0.001
 QRSd plateau 191 ± 25 148 ± 13 < 0.001
 CI at onset of QRSd prolongation 311 ± 17 262 ± 15 < 0.001
 Local VERP 259 ± 25 228 ± 26 < 0.001
 CI window with QRSd prolongation 54 ± 23 34 ± 20 0.003
 Maximal QRSd 229 ± 28 176 ± 15 < 0.001
 Maximal ∆ QRSd 38 ± 20 29 ± 12 0.21
 Critical QRSd prolongation -28 (-56 – -8) -51 (-77 – -28) 0.053
 Critical CI window 0 (0 – 0) 0 (0 – 0) 0.41
ePS - drive train 400 ms from RV apex
 QRSd during drive train 192 ± 23 153 ± 13 < 0.001
 QRSd after extrastimulus 350 ms 192 ± 26 150 ± 15 < 0.001
 QRSd plateau 191 ± 27 149 ± 15 < 0.001
 CI at onset of QRSd prolongation 275 ± 23 235 ± 16 < 0.001
 Local VERP 228 ± 23 204 ± 21 < 0.001
 CI window with QRSd prolongation 47 ± 23 31 ± 14 0.005
 Maximal QRSd 226 ± 31 172 ± 18 < 0.001
 Maximal ∆ QRSd 35 ± 18 23 ± 12 0.005
 Critical QRSd prolongation +1 (-37 – +26) -13 (-55 – -7) 0.017
 Critical CI window 10 (0 – 30) 0 (0 – 0) < 0.001
Variables are expressed as mean ± standard deviation or median (interquartile range).
CI indicates coupling interval; EPS, electrophysiology study; QRSd, QRS duration; RV, right ventricle; VERP, 
ventricular effective refractory period
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Supplemental Table 3. QRSd prolongation and inducibility of polymorphic VT
Polymorphic VT no Polymorphic VT p (Mann-Whitney)
Regular 12-lead eCG, 25 mm/second
 QRSd 126 ± 32 133 ± 36 0.69
RVa - Drive train 600 ms with 1 extrastimulus
 QRSd during drive train 193 ± 15 197 ± 20 0.63
 QRSd after extrastimulus 350 ms 188 ± 15 194 ± 32 0.85
 QRSd plateau 188 ± 15 194 ± 32 0.85
 CI at onset of QRSd prolongation 308 ± 18 314 ± 17 0.34
 Local VERP 252 ± 23 266 ± 25 0.11
 CI window with QRSd prolongation 60 ± 23 48 ± 23 0.14
 Maximal QRSd 234 ± 24 225 ± 31 0.23
 Maximal ∆ QRSd 45 ± 21 31 ± 17 0.058
 Critical QRSd prolongation -18 (-44 – +10) -38 (-73 – -11) 0.13
 Critical CI window 0 (0 – 20) 0 (0 – 0) 0.18
RVa - Drive train 400 ms with 1 extrastimulus
 QRSd during drive train 190 ± 17 193 ± 27 0.88
 QRSd after extrastimulus 350 ms 189 ± 19 194 ± 31 0.53
 QRSd plateau 188 ± 19 193 ± 32 0.68
 CI at onset of QRSd prolongation 276 ± 20 274 ± 26 0.92
 Local VERP 219 ± 19 235 ± 23 0.061
 CI window with QRSd prolongation 57 ± 25 39 ± 18 0.015
 Maximal QRSd 234 ± 26 220 ± 34 0.030
 Maximal ∆ QRSd 46 ± 17 27 ± 14 0.001
 Critical QRSd prolongation +13 (-17 – +49) -17 (-44 – +6) 0.017
 Critical CI window 20 (0 – 75) 0 (0 – 20) 0.11
Variables are expressed as mean ± standard deviation or median (interquartile range). Abbreviations as in 
supplemental Table 1.
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Summary, conclusions and future perspectives: Towards more effective, 
individualized substrate-based therapies for ventricular arrhythmias
In the general introduction of this thesis (chapter 1) it is stated that improved under-
standing of different types of ventricular arrhythmias, underlying substrates and mecha-
nisms is the key to more accurate risk stratification and development of more effective, 
individualized and substrate-based therapies.
Part I of this thesis focuses on image integration during VT ablation. The reported 
applications, potential advantages and limitations are reviewed in chapter 2. Imag-
ing modalities that have been applied include multidetector computed tomography 
(MDCT), late gadolinium enhancement magnetic resonance imaging (LGE-MRI), intra-
cardiac echocardiography (ICE) and nuclear imaging modalities. The majority of studies 
have focused on the integration of MDCT and LGE-MRI in post-myocardial infarction 
patients; MDCT because of its relatively high spatial resolution, and LGE-MRI as current 
non-invasive gold standard for visualization of fibrosis. To date, image integration has 
been used to uncover and delineate the arrhythmogenic substrate,1-10 to guide the 
procedural strategy,11,12 to avoid ablation in close proximity of coronary arteries,13,14 
to visualize epicardial fat tissue9,13 and to analyze ablation lesions.15,16 Although image 
integration has provided important insights into the substrate for VT, to date it has not 
been demonstrated that it is cost-effective, reduces total radiation exposure, shortens 
procedure and mapping time and, most importantly, improves the safety and acute 
and long-term outcome after VT ablation. Prospective randomized studies comparing 
imaging-guided VT ablation with standard VT ablation in the setting of different cardiac 
diseases are required to determine whether this promising technology translates into 
improved results.
Substrate mapping is indispensable during VT ablation, mainly due to the frequent 
inducibility of hemodynamic unstable VT. At the epicardium substrate mapping may 
be hampered by fat tissue, which attenuates bipolar electrogram amplitudes,13,17 and 
as a result, it may be difficult to differentiate between scar, myocardium and epicardial 
fat. Previous studies have demonstrated the feasibility and accuracy of integration of 
MRI-derived scar data with endocardial electroanatomical maps,2,7,10,16 and of MDCT-
derived epicardial fat with epicardial electroanatomical maps.13,17 In chapter 3, these 
image integration techniques are combined in a series of 10 patients with NICM who un-
derwent endocardial and epicardial VT ablation. It is demonstrated that bipolar voltage 
≤1.81mV and unipolar voltage ≤7.95mV are the optimal cutoff values to distinguish scar 
from viable myocardium in epicardial regions devoid of fat. However, both bipolar and 
unipolar voltages are reduced by epicardial fat. Specific electrogram morphologies were 
not affected by fat, but were present at only one quarter of all scar sites. An algorithm 
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was constructed to improve differentiation between scar, viable myocardium and fat. 
These findings provide important insights into epicardial substrate mapping in patients 
with NICM, which is essential for successful VT ablation.
Chapter 4 describes typical scar patterns and associated VT morphologies in a series 
of 19 consecutive patients with NICM who underwent VT ablation. In 17 of 19 patients, 
either a basal anteroseptal or inferolateral scar was observed. Both scar patterns were 
associated with specific VT 12-lead ECG morphologies. In the 9 patients with antero-
septal scar-related VT, the ablation target sites were mainly located in the aortic root 
and/or anteroseptal LV endocardium, and in only one case at the epicardium. Of the 
8 patients with inferolateral scar-related VT however, 5 had epicardial ablation target 
sites. The anteroseptal LV is usually difficult to reach during epicardial VT ablation due 
to the proximal coronary arteries, epicardial fat and the left atrial appendage.13,18 Epicar-
dial access to the inferolateral LV is typically not or only partly limited by epicardial fat, 
although the coronary arteries and the variable course of the phrenic nerve need to be 
considered. These findings are likely to be important for clinicians who consider epicar-
dial VT ablation in patients with NICM. After publication of this study, other investigators 
have replicated and extended our findings in a larger patient cohort, demonstrating 
that patients with predominant anteroseptal scar types are at higher risk for VT recur-
rence during follow-up.19
Chapter 5 analyzes the scar characteristics at critical isthmus sites of VTs in patients 
after myocardial infarction or with nonischemic cardiomyopathy (NICM), aiming to im-
prove our understanding of the substrate for VT, and to analyze the value of MRI-based 
areas of interest to guide VT ablation. Analysis of scar features at critical VT isthmus sites 
revealed that critical isthmus sites are characterized by relatively high scar transmural-
ity and signal intensity, compared to the average values for the entire scar, which was 
particularly evident for the central isthmus sites. The vast majority of critical isthmus 
sites were located within close proximity (i.e., 5 mm) of >75% transmural scar, and the 
transition between core and border zone. It is concluded that MRI-derived scar features 
may be used to guide VT ablation. Other investigations also suggest an association 
between scar transmurality and electrogram prolongation7,9,20,21 and VT isthmuses.21 The 
relation between scar transmurality and VT in NICM patients is further supported by 
the study described in chapter 10, which demonstrated that the area of 50-75% scar 
transmurality carried important prognostic information in patients with NICM undergo-
ing ICD implantation.
Overall, the integration of CT- and MRI-derived data has led to important insights into 
the substrate for sustained monomorphic VT. Practically, integration of MRI-derived data 
helps to identify and delineate the substrate, and to lead to areas that contain parts of 
the reentry circuit. Novel MRI techniques such as T1 mapping, which allows calculation 
of exact extracellular volumes, and wideband inversion pulses, which allows acquisi-
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tion of high-quality contrast-enhanced MRI images in patients with devices,22,23 may 
be applied to further enhance the added value of MRI during VT ablation procedures. 
Ultimately, randomized controlled trials need to be performed to assess the effect of MRI 
integration on procedural duration, complications and outcomes.
In part II of this thesis, the substrate, mechanisms and treatment for different types of 
ventricular arrhythmias are analyzed in patients with ischemic and nonischemic heart 
disease.
Chapter 6 focuses on the identification of VTs with an epicardial site of origin in pa-
tients with NICM. Although several investigators have previously reported that 12-lead 
ECG criteria allow differentiation between endocardial and epicardial VTs,24-26 the ECG 
criteria were only evaluated on electrophysiology recording systems with electronic 
calipers at a sweep speed of 100 mm/s. To guide pre-procedural planning, the ECG cri-
teria would however have to be applied to standard 25mm/s 12-lead ECGs of clinically 
documented VTs. The current study analyzed the value of ECG criteria for identification 
of VTs with an epicardial site of origin in 36 patients who underwent combined endocar-
dial and epicardial VT ablation. When applied to standard 25mm/s 12-lead ECGs, none of 
the criteria could accurately differentiate between endocardial or epicardial VTs. When 
applied to 100mm/s tracings, part of the ECG criteria could distinguish epicardial from 
endocardial VTs, but only in slow VTs and in patients on amiodarone. The latter may be 
explained by the fact that the majority of ECG criteria rely on accurate identification of 
the QRS onset, which may be difficult to define in fast VTs in patients off amiodarone. 
These data suggest that when applied to standard 12-lead ECGs, the ECG criteria do 
not allow identification of patients who are likely to benefit from a primary epicardial 
ablation approach. LGE-MRI-derived substrate features may be more reliable to guide 
the procedural strategy in patients undergoing VT ablation.11
If epicardial mapping and ablation are performed, post-procedural pericarditic chest 
pain and pericarditic ECG changes may occur. In chapter 7 we analyzed the effect of 
intrapericardial and systemic steroids on post-procedural pericarditic chest pain and 
ECG changes in a series of 85 patients who underwent epicardial mapping and ablation 
for VT. Over the years, the post-procedural management has evolved from no steroids, 
to systemic steroids, and finally to intrapericardial steroids. Pericarditic chest pain 
occurred in 59%, 43% and 21% of patients, respectively (overall p=0.017; no steroids 
vs intrapericardial steroids, p=0.006), and ECG changes in 41%, 30% and 37%, respec-
tively (overall p=0.72), suggesting that intrapericardial steroids may reduce pericarditic 
chest pain, but not ECG changes after epicardial mapping and ablation. Although not 
randomly allocated, therapies were applied unselectively in consecutive patients, and 
the observed effects were large, suggesting a true beneficial effect of intrapericardial 
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steroids on pericarditic chest pain after epicardial mapping and ablation. A randomized 
study would however be required to definitively prove its efficacy.
There is limited data on the outcome after VT ablation in patients with NICM, and in par-
ticular on the value of programmed electrical stimulation to assess the acute procedural 
outcome. Chapter 8 describes and analyzes the acute and long-term outcomes after VT 
ablation in a contemporary series of 45 patients with NICM. At the end of the procedure, 
a programmed electrical stimulation protocol was consistently applied and completed 
in all patients to assess the acute procedural outcome. Complete success was achieved 
in 38% of patients, partial success in another 38% and failure in 24%. Although 53% of 
patients had VT during an average of two years follow-up, the 6-month VT burden was 
reduced by ≥ 75% in 79% of patients. Non-complete success was the strongest predictor 
of VT recurrence, with recurrences in only 18% after complete success, compared with 
77% after partial success and 73% after procedural failure. Importantly, the inducibility 
of non-clinical, usually fast VTs after successful ablation of the clinical VT was associated 
with high recurrence rates, and should therefore not be regarded as a non-specific find-
ing. This does however not necessarily imply that fast, nonclinical VTs should always be 
targeted – persistent inducibility of fast VTs may also be a marker for a more complex or 
functionally determined arrhythmogenic substrate, which may be less amenable to VT 
ablation. Further studies are needed to assess whether targeting of these nonclinical, 
usually rapid VTs improves long-term outcomes after ablation. More generally, it is un-
clear whether and to what extent high VT recurrence rates are attributable to the timing 
of the procedure, not identified or not reachable substrates, insufficient lesion formation 
or lesion recovery, arrhythmogenic substrates that evolve over time, progressive heart 
failure, or other factors that are currently poorly understood. Future observational and 
experimental studies should aim to assess the effects of these and other factors (e.g., 
early referral, procedural strategy, ablation techniques, optimization of medical and 
device therapy) on procedural outcome.
Chapter 9 evaluates the impact of early reperfusion therapy on the inducibility and 
cycle length of VTs, and on the occurrence of VTs late after myocardial infarction. In a 
prior study in patients who were referred for treatment of VT, spontaneous and induced 
VTs were faster in reperfused patients, who typically had a patchy electroanatomic scar 
pattern, as opposed to a more confluent scar pattern in nonreperfused patients.27 The 
present study aimed to analyze the effects of reperfusion therapy on ventricular arrhyth-
mias in a large cohort of 506 post-infarction patients who underwent an electrophysiol-
ogy study before ICD implantation for primary or secondary prevention. Inducibility of 
VT was comparable between primary prevention patients with and without reperfusion 
therapy (56% and 58%, respectively), but higher in secondary prevention patients 
without reperfusion therapy compared to those who had underwent reperfusion 
therapy (79% versus 56%, respectively, p=0.001). The absence of reperfusion therapy 
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was independently associated with a slower CL of induced VTs. In primary prevention 
patients, nonreperfused patients had a more than twofold increased risk for appropriate 
ICD therapy during follow-up. Thus, the application of reperfusion therapies at the time 
of acute myocardial infarction is an important determinant of the occurrence and char-
acteristics of late ventricular arrhythmias. These findings improve our understanding of 
contemporary changes in arrhythmogenic substrates due to the widespread application 
of reperfusion therapies for acute myocardial infarction. Whether these changes are 
(partly) attributable to scar transmurality, which is associated with VT (chapter 5) and in 
general larger in nonreperfused patients, remains to be elucidated.
Not only in patients after myocardial infarction, but also in NICM patients accurate 
prediction of arrhythmic events is desirable, and would allow preventive treatment in 
those who are at risk. Prior studies have typically aimed to identify predictors for appro-
priate ICD therapy, sudden cardiac death, all-cause mortality or combined endpoints. 
Different types of ventricular arrhythmias may however have different underlying 
substrates and related predictors. Sustained monomorphic VT in NICM is considered 
to be the manifestation of a stable reentry circuit, whereas polymorphic VT and VF are 
thought to be related to one or more unstable reentry circuits or rotors. Chapter 10 
aimed to analyze the impact of myocardial scar on the occurrence and type of ventricular 
arrhythmia in patients with NICM, and to assess the predictive value of specific patterns 
of fibrosis for monomorphic VT. At the Maastricht en Leiden University Medical Centers, 
LGE-MRI was performed before ICD implantation in 87 patients with NICM. The pres-
ence, characteristics and extent of myocardial scar were assessed on LGE-MRI images. 
ICD recordings and 12-lead ECGs were reviewed to determine the occurrence and type 
of ventricular arrhythmia during follow-up. Importantly, the presence of myocardial scar 
predicted monomorphic VT, but not polymorphic VT/VF. The risk for monomorphic VT 
was particularly high when the LGE extent was ≥ 7.2 grams, whereas patients with < 
7.2 grams LGE were at low risk for monomorphic VT, but remained at risk for potentially 
fatal polymorphic VT/VF. Features that were associated with high risk for monomorphic 
VT were core extent, location in basal segments and area with 51-75% transmurality. 
Thus, the current study demonstrates that patients at risk for monomorphic VT can be 
identified by LGE-MRI, which may have important implications for risk stratification and 
therapeutic interventions in patients with NIDCM. If patients at risk for polymorphic VT/
VF can also be more accurately identified in the future, a randomized controlled trial 
should be performed to reassess the benefit of ICD implantation on all-cause mortality, 
quality of life and costs in patients who are considered at low risk for both monomorphic 
VT and polymorphic VT/VF.
Chapter 11 focuses on the substrate and mechanisms of polymorphic VT/VF in NICM. 
In order to improve our understanding of the substrate and mechanisms of ventricular 
arrhythmias in NICM, we designed and initialized the Leiden Nonischemic Cardiomy-
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opathy Study in 2011. In this prospective cohort study patients are comprehensively 
analyzed by LGE-MRI, echocardiography, 24-hour Holter monitoring, exercise testing, 
blood sampling, an invasive electrophysiological study, endomyocardial biopsy, an 
MIBG scan and genetic analysis of 55 cardiomyopathy-related genes. The first results 
of this study are presented in chapter 11, which focuses on the substrate and mecha-
nisms of polymorphic VT and VF. Prediction of these arrhythmias is challenged due to 
various potential causes, ranging from conduction and repolarization abnormalities to 
electrolyte imbalances.28-31 One phenomenon that has been related to VF in patients 
with NICM is progressive activation delay after premature stimulation.30 In the current 
study, we measured the paced QRS duration after premature stimulation as a simple 
marker of activation delay after premature stimulation in 40 patients with NICM and 
20 healthy controls. The QRS duration started to increase at longer coupling intervals 
in NICM compared with controls, and the maximum increase was larger. In patients 
with NICM, the local refractory period at the pacing site was frequently shorter than the 
maximal paced QRS duration, which allowed to pace and capture within the previous 
QRS complex, with the potential to initiate a second, different activation wave front. This 
phenomenon was related to the inducibility of polymorphic VT and was associated with 
long thick strands of fibrosis in biopsy specimens. This study suggest that progressive 
activation delay may be quantified by measuring the QRS duration during a standard 
electrophysiological study, and that activation delay correlates with electrical instability. 
A future research project within the Leiden Nonischemic Cardiomyopathy Study aims 
to analyze whether progressive activation delay after premature stimulation predicts 
spontaneous polymorphic VT and VF during follow-up.
ConCLUSIonS
In patients undergoing VT ablation, image integration improves preprocedural plan-
ning, substrate identification and delineation, and can guide to areas containing critical 
isthmus sites. In patients with prior myocardial infarction or NICM, the presence, extent 
and features of myocardial scar determine the occurrence and characteristics of mono-
morphic VT. Progressive activation delay after premature stimulation is associated with 
the inducibility of polymorphic VT in NICM.
The studies described in this thesis contribute to an improved understanding of the 
substrate and mechanisms of ventricular arrhythmias in ischemic and nonischemic 
heart disease, which is the most important prerequisite for the development of effective, 
individualized and substrate-based therapies for ventricular arrhythmias in the future.
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De onderzoeken die worden beschreven in dit proefschrift concentreren zich op struc-
turele afwijkingen en mechanismen die ten grondslag liggen aan hartritmestoornissen. 
In de verschillende studies werd gebruik gemaakt van driedimensionale reconstructies 
van het hart op basis van CT-scans, MRI-scans en katheter-mapping en er werden 
ritmestoornissen en reacties op elektrische stimulatie geanalyseerd. Dit alles om het 
begrip van kamerritmestoornissen te verbeteren, zodat in de toekomst effectievere 
behandelingen kunnen worden ontwikkeld. Hieronder volgt een samenvatting van de 
achtergrond, de verschillende onderzoeken en de conclusies van dit proefschrift.
Inleiding
Patiënten met structurele hartziekte hebben een verhoogd risico op plotse hartdood 
door kamerritmestoornissen zoals ventrikeltachycardieën (VT’s) en ventrikelfibrilleren 
(VF). In de afgelopen decennia zijn er belangrijke inzichten verkregen in het onderlig-
gende substraat en de mechanismen achter deze ritmestoornissen, maar er zijn nog veel 
aspecten onopgehelderd. Intussen is voor een pragmatische benadering gekozen door 
een inwendige defibrillator (implantable cardioverter difibrillator, ICD) te implanteren 
bij patiënten die VT of VF hebben overleefd of een verhoogd risico hebben op plotse 
hartdood. De ICD’s hebben op deze manier talloze levens gered en zijn niet meer weg 
te denken uit de huidige klinische praktijk. Het is echter belangrijk om te realiseren dat 
ICD’s levensbedreigende ritmestoornissen zoals VT en VF kunnen stoppen, maar niet 
voorkomen. Elektrische ICD shocks zijn potentieel traumatisch voor de patiënt en worden 
geassocieerd met een verhoogde mortaliteit. Behandelingen om recidiverende kamer-
ritmestoornissen te voorkomen, zoals anti-aritmische medicatie en katheterablatie van 
VT’s, zijn daarom des te belangrijker geworden in het tijdperk van de ICD’s. Momenteel 
wordt katheterablatie van VT’s door veel cardiologen, mede vanwege de aanzienlijke 
recidiefkansen, pas toegepast als medicijnen niet meer werken. Eerdere onderzoeken 
hebben laten zien dat ongeveer de helft van de patiënten in het eerste jaar na de ablatie 
minstens één recidief heeft, maar ook dat bij ongeveer tweederde van de patiënten het 
aantal ritmestoornissen met tenminste 75% is reduceerd. Een redelijk resultaat gezien 
de complexiteit van het ziektebeeld, maar er is nog veel winst te behalen.
In dit proefschrift wordt, zoals in hoofdstuk 1 gesteld, geprobeerd een bijdrage te 
leveren aan een beter begrip van het substraat en de mechanismen achter verschil-
lende typen kamerritmestoornissen bij patiënten met structurele hartziekte, zodat in 
de toekomst meer effectieve, geindividualiseerde en substraatgerichte behandelingen 
ontwikkeld kunnen worden.
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Deel I van dit proefschrift concentreert zich op integratie van beeldvormende technie-
ken tijdens VT-ablatie, met het doel om meer inzicht te krijgen in het substraat voor VT 
en de ablatiebehandeling te optimaliseren.
hoofdstuk 2 biedt een overzicht van de toepassingen, potentiele voordelen en de 
beperkingen van verschillende beeldvormende technieken. Eén van de belangrijkste 
hiervan is CT vanwege de hoge spatiële resolutie, waardoor onder andere de anatomie 
van het hart, het beloop van de kransslagaders en vet aan de buitenzijde van het hart 
uitstekend kunnen worden afgebeeld. Een andere belangrijke techniek is MRI vanwege 
de uitstekende weefselkarakterisatie, waardoor het substraat gedetailleerd in beeld kan 
worden gebracht.
In het geval van monomorfe VT’s (d.w.z. kamerritmestoornissen met een stabiele 
ECG-morfologie) bestaat het substraat over het algemeen uit een re-entry circuit (kort-
sluitingscircuit) door een litteken, wat bijvoorbeeld is ontstaan na een hartinfarct. Met 
elektroanatomische substraatmapping worden traag geleidende gebieden binnen het 
litteken, meestal de oorzaak van re-entry circuits, geïdentificeerd zodat deze middels 
ablatie kunnen worden uitgeschakeld. Epicardiaal (aan de buitenzijde van het hart) 
wordt substraatmapping bemoeilijkt door vet, wat net als litteken de gemeten voltages 
verlaagt. In hoofdstuk 3 worden zowel CT- als MRI-beelden met elektroanatomische 
maps geïntegreerd om een compleet inzicht te krijgen in laag gevolteerde en traag 
geleidende gebieden aan de buitenzijde van het hart (met elektroanatomische maps), 
het litteken (met MRI) en epicardiaal vet (met CT). Er wordt aangetoond dat een bipolair 
voltage ≤1.81 mV en een unipolair voltage ≤7.95 mV de beste afkapwaarden zijn om 
litteken van (relatief ) gezond myocard te onderscheiden in gebieden zonder vet. In 
gebieden met vet kunnen elektrogrammen en de epicardiale vetdikte gebaseerd op CT 
worden gebruikt.
In hoofstuk 4 worden met behulp van integratie van MRI twee typische substraatpa-
tronen beschreven in een serie van 19 patiënten met non-ischemische cardiomyopathie 
(d.w.z. hartziekte niet veroorzaakt door kransslagaderproblemen). Bij 17 van de 19 
patiënten werd ófwel een anteroseptaal, óf een inferolateraal substraat aangetoond 
en elk type was geassocieerd met specifieke typen ritmestoornissen en een beste be-
naderingswijze (van de binnenzijde of de buitenzijde van het hart). Na publicatie van 
deze studie zijn deze resultaten gerepliceerd door andere onderzoeksgroepen en is het 
belang voor de prognose aangetoond.
Zoals hierboven al genoemd bestaat het substraat in het geval van monomorfe VT’s 
over het algemeen uit een re-entry circuit (kortsluitingscircuit) door een litteken. In 
hoofdstuk 5 worden de eigenschappen van kritieke delen van deze re-entry circuits 
(en zodoende doelen voor ablatie) geanalyseerd met behulp van MRI-integratie tijdens 
VT-ablatie. De kritieke gebieden werden gekenmerkt door een hoge littekentransmu-
raliteit en een hoge signaalintensiteit op MRI. Het overgrote deel was gelokaliseerd op 
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hoogstens 5 mm van >75% transmuraal litteken en tevens op hoogstens 5 mm van de 
overgang tussen de kern en het randgebied van het litteken. Deze eigenschappen kun-
nen worden gebruikt om kritieke gebieden sneller te identificeren tijdens VT-ablaties.
Samenvattend heeft CT- en MRI-integratie tijdens VT-ablatie belangrijke inzichten 
opgeleverd. MRI-integratie kan helpen om het substraat te identificeren, de juiste 
benadering te kiezen en te leiden naar relevante gebieden. CT-integratie kan helpen 
om complicerende anatomische factoren zoals epicardiaal vet en kransslagaders te visu-
aliseren. Nieuwe beeldvormende technieken kunnen de toegevoegde waarde mogelijk 
verder verhogen. Uiteindelijk zullen gerandomiseerde trials uitgevoerd moeten worden 
om de effecten van CT- en MRI-integratie op de duur van de ingreep, complicaties en 
resultaten te bepalen.
In deel II van dit proefschrift worden het substraat, de mechanismen en de behande-
ling van verschillende typen kamerritmestoornissen geanalyseerd bij patiënten met 
ischemische en non-ischemische hartziekte (d.w.z. hartziekte respectievelijk wel en niet 
veroorzaakt door kransslagaderproblemen).
hoofdstuk 6 concentreert zich op de identificatie van VT’s met een epicardiale 
oorsprong bij patiënten met non-ischemische cardiomyopathie. Voor deze ritmestoor-
nissen kan een punctie onder het borstbeen nodig zijn om de ablatiekatheter in het 
hartzakje op te voeren zodat er aan de buitenzijde van het hart kan worden gebrand. 
In dit onderzoek werden eerder beschreven ECG criteria voor de identificatie van 
epicardiale VT’s toegepast op standaard ECG’s en op 100 mm/s ECG’s op elektrofysio-
logiesystemen bij 36 patiënten die een gecombineerd endo- en epicardiale VT-ablatie 
ondergingen. Uit de analyses bleek dat géén van de ECG criteria goed kon differentiëren 
tussen endocardiale en epicardiale VT’s wanneer deze werden toegepast op 100 mm/s 
ECG’s op electrofysiologiesystemen, maar wel als deze werden toegepast op standaard 
ECG’s. Er werd geconcludeerd dat de ECG criteria niet betrouwbaar zijn bij het bepalen 
van de beste benadering voor de ablatie indien deze worden toegepast op klinisch 
gedocumenteerde VT’s. Waarschijnlijk is MRI voor dit doeleinde een betrouwbaarder 
hulpmiddel.
Als besloten wordt tot epicardiale mapping en ablatie, dan kan dit ná de ingreep 
gecompliceerd worden door pijn op de borst en ECG-veranderingen die ook bij een 
spontane pericarditis (d.w.z. een ontsteking van het hartzakje) worden gezien. In 
hoofdstuk 7 wordt het effect van intrapericardiale (in het hartzakje) en systemische 
corticosteroïden op deze pijn en ECG-veranderingen geanalyseerd bij 85 patiënten die 
een epicardiale VT-ablatie ondergingen. Gedurende de afgelopen jaren evolueerde 
het beleid in het LUMC van géén steroïden, via systemische steroïden naar uiteindelijk 
intrapericardiale steroïden. In de laatste groep patiënten trad substantieel minder 
pericarditis-achtige pijn op de borst op dan in de twee eerdere groepen. Alhoewel het 
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hier niet om een gerandomiseerde studie gaat, werden de behandelingen niet-selectief 
toegepast in opeenvolgende patiënten en waren de effecten groot, wat suggereert dat 
er daadwerkelijk een gunstig effect is van intrapericardiale steroïden op pijn op de borst 
na de ingreep. Om dit definitief te bewijzen zou echter een gerandomiseerd onderzoek 
noodzakelijk zijn.
Er zijn slechts beperkte gegevens beschikbaar over de uitkomst na VT-ablatie bij 
patiënten met non-ischemische cardiomyopathie, met name wat betreft de waarde 
van het testen op induceerbaarheid van VT’s na ablatie. In hoofdstuk 8 beschrijven 
wij een groep van 45 patiënten met non-ischemische cardiomyopathie die VT-ablatie 
onderging. De sterkste voorspeller voor recidieven was de induceerbaarheid van VT’s 
na ablatie. Ook de induceerbaarheid van niet-klinische (meestal snelle) VT’s ná ablatie 
was geassocieerd met een hogerere recidiefkans. Dit betekent niet noodzakelijkerwijs 
dat deze meestal snelle, niet-klinische VT’s ook altijd benaderd moeten worden tijdens 
de ablatie – de induceerbaarheid van dit soort VT’s kan ook een marker zijn van een 
complexer of (deels) functioneel bepaald substraat, wat moeilijk met ablatie behandeld 
kan worden. In de toekomst moet daarom worden bepaald of het benaderen van dit 
soort VT’s de prognose na ablatie verbetert.
In het algemeen blijft het moeilijk de oorzaak voor een recidief na ablatie te ach-
terhalen. Zijn deze te wijten aan de timing van de ingreep, niet-geïdentificeerde of 
niet-bereikbare substraten, ontoereikende of herstellende ablatie-laesies, een evolue-
rend substraat, progressief hartfalen of andere factoren? Het is belangrijk dat er in de 
toekomst meer inzicht wordt verkregen op dit gebied.
hoofdstuk 9 richt zich op de invloed van reperfusietherapie (bijv. dotter- en 
stentbehandeling) ten tijde van een acuut hartinfarct op de latere induceerbaarheid, 
snelheid en het optreden van VT’s bij patiënten met ischemische hartziekte. Er werd 
een grote groep patiënten met een hartinfarct onderzocht die een elektrofysiologisch 
onderzoek hebben ondergaan vóór implantatie van een ICD. Het niet hebben gekregen 
van reperfusietherapie was een onafhankelijke voorspeller voor tragere geïnduceerde 
VT’s en voor het optreden van terechte ICD-therapie (pacing of shocks) tijdens follow-
up. Of deze relatie (deels) wordt verklaard door een grotere littekentransmuraliteit bij 
patiënten zonder reperfusietherapie, wat geassocieerd is met VT’s zoals ook beschreven 
in hoofstuk 5, is nog onopgehelderd.
Het accuraat kunnen voorspellen van ritmestoornissen wordt niet alleen nagestreefd 
bij patiënten met een eerder hartinfarct, maar ook bij patiënten met een non-ischemi-
sche cardiomyopathie, zodat preventieve behandelingen kunnen worden toegepast 
bij patiënten met een hoog risico. Eerdere studies hebben gecombineerde eindpunten 
gebruikt, maar verschillende typen ritmestoornissen hebben waarschijnlijk verschil-
lende onderliggende substraten en daarmee verschillende voorspellers. Monomorfe VT 
wordt normaliter veroorzaakt door een stabiel re-entry circuit, terwijl polymorfe VT en 
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VF (beide met een wisselende morfologie op het ECG) worden veroorzaakt door één of 
meer onstabiele circuits of rotors. In hoofdstuk 10 wordt de invloed van de aanwezig-
heid van litteken in het hart en haar karakteristieken op het optreden van verschillende 
typen ritmestoornissen geanalyseerd bij 87 patiënten met non-ischemische cardio-
myopathie die een MRI-scan en ICD-implantatie hebben ondergaan. De aanwezigheid 
van litteken voorspelde het optreden van monomorfe VT, maar niet van polymorfe VT 
en VF. Kenmerken van het litteken die voorspellend waren voor monomorfe VT waren 
uitgebreidheid van de kern, lokalisering in de basale segmenten en de grootte van 
het gebied met 51-75% transmuraliteit. Deze eigenschappen kunnen in de toekomst 
worden gebruikt om patiënten met een hoog risico op monomorfe VT te identificeren. 
Er werden geen voorspellers voor polymorfe VT of VF geïdentificeerd.
hoofdstuk 11 richt zich op het substraat en de mechanismen van polymorfe VT en VF 
bij patiënten met non-ischemische cardiomyopathie. Om de inzichten in het substraat en 
de mechanismen achter kamerritmestoornissen bij non-ischemische cardiomyopathie 
te verbeteren, startten wij in 2011 met de Leidse Non-ischemische Cardiomyopathie-
studie. In deze prospectieve cohortstudie worden patiënten uitgebreid geanalyseerd 
middels MRI, echocardiografie, 24-uurs Holters, inspanningstests, bloedonderzoek, een 
invasief elektrofysiologisch onderzoek, hartbiopsie, een MIBG-scan en genetische ana-
lyse van 55 relevante genen. De eerste resultaten van dit onderzoek worden gepresen-
teerd in hoofdstuk 11. In deze eerste studie werd bij 40 patiënten met non-ischemische 
cardiomyopathie en 20 controlepatiënten met een structureel normaal hart tijdens een 
elektrofysiologisch onderzoek de QRS-duur gemeten na elektrische stimulatie, als een 
eenvoudige marker voor vertraagde activatie en daarmee mogelijk een voorspeller voor 
polymorfe VT en VF. Verbreding van het QRS-complex na elektrische stimulatie bleek 
inderdaad duidelijk geassocieerd met de opwekbaarheid van polymorfe VT’s. Een nieuw 
onderzoeksproject binnen de Leidse Non-ischemische Cardiomyopathiestudie zal de 
voorspellende waarde van progressieve activatievertraging na elektrische stimulatie 
voor spontane polymorfe VT en VF tijdens follow-up analyseren.
ConCLUSIe
Bij patiënten die VT-ablatie ondergaan biedt integratie van beeldvormende technie-
ken toegevoegde waarde op het gebied van planning, substraatidentificatie en het 
leiden naar kritieke gebieden voor VT’s. Bij patiënten met een oud hartinfarct of een 
non-ischemische cardiomyopathie bepalen de aanwezigheid, de uitbreiding en de ken-
merken van litteken het toekomstige optreden en de karakteristieken van monomorfe 
VT’s. Progressieve activatievertraging na elektrische stimulatie is geassocieerd met de 
opwekbaarheid van polymorfe VT bij patiënten met non-ischemische cardiomyopathie.
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De studies beschreven in dit proefschrift dragen bij aan een beter begrip van het sub-
straat en de mechanismen van kamerritmestoornissen bij patiënten met ischemische en 
non-ischemische hartziekte. Dit is de meest belangrijke voorwaarde voor de ontwikke-
ling van meer effectieve, geïndividualiseerde en substraatgerichte behandelingen voor 
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